Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Previous issues

Page Path
HOME > Browse articles > Previous issues
50 Previous issues
Filter
Filter
Article category
Keywords
Authors
Volume 47(4); October 2015
Prev issue Next issue
Special Article
Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned
Dae Ho Lee, Vichien Srimuninnimit, Rebecca Cheng, Xin Wang, Mauro Orlando
Cancer Res Treat. 2015;47(4):549-554.   Published online April 29, 2015
DOI: https://doi.org/10.4143/crt.2014.362
AbstractAbstract PDFPubReaderePub
Advances in oncology research have led to identification of tumor-specific biomarkers, some of which are important predictive indicators and ideal targets for novel therapeutics. One such biomarker in non-small cell lung cancer (NSCLC) is the epidermal growth factor receptor (EGFR). Patients with NSCLC who harbor an activating EGFR mutation show a more favorable response to treatment with an EGFR inhibitor, such as gefitinib, erlotinib, or afatinib, than to chemotherapy. The prevalence of EGFR mutations in East Asian patients is higher than that in other populations, and in some clinical settings, patients have been treated with EGFR inhibitors based on clinicopathologic characteristics with no information on EGFR status. However, based on results from a series of studies in which East Asian patients with advanced non-squamous NSCLC were treated with EGFR inhibitors alone or in combination with standard chemotherapy, this may not be the best practice because EGFRmutation status was found to be a key predictor of outcome. Data from these studies highlight the necessity of EGFR testing in determining the most suitable treatment for patients with advanced or metastatic NSCLC.

Citations

Citations to this article as recorded by  
  • Epidermal Growth Factor Receptor Mutation Status and the Impact on Clinical Outcomes in Patients with Non-Small Cell Lung Cancer
    HM Huang, Y Wei, JJ Wang, FY Ran, Y Wen, QH Chen, BF Zhang
    Balkan Journal of Medical Genetics.2023; 25(2): 29.     CrossRef
  • EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
    Jiyoul Yang, Ok-Jun Lee, Seung-Myoung Son, Chang Gok Woo, Yusook Jeong, Yaewon Yang, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han
    Cancer Research and Treatment.2018; 50(3): 908.     CrossRef
  • Traditional Korean Medicine for Skin Toxic Side Effects from Afatinib in a Non-Small Cell Lung Cancer Patient: A Case Report
    So-hyun Shim, Hee-jeong Seo, Jin-yong Choi, Go-eun Bae, Hyung-bum Seo, So-yeon Kim, Chang-woo Han, Seong-ha Park, Young-ju Yun, In Lee, Jung-nam Kwon, Jin-woo Hong, Jun-yong Choi
    The Journal of Internal Korean Medicine.2018; 39(5): 973.     CrossRef
  • MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values
    Geun Dong Lee, Seung Eun Lee, Doo-Yi Oh, Dan-bi Yu, Hae Min Jeong, Jooseok Kim, Sungyoul Hong, Hun Soon Jung, Ensel Oh, Ji-Young Song, Mi-Sook Lee, Mingi Kim, Kyungsoo Jung, Jhingook Kim, Young Kee Shin, Yoon-La Choi, Hyeong Ryul Kim
    Journal of Thoracic Oncology.2017; 12(8): 1233.     CrossRef
  • Predicting EGFR mutation status in lung cancer:Proposal for a scoring model using imaging and demographic characteristics
    Ali Sabri, Madiha Batool, Zhaolin Xu, Drew Bethune, Mohamed Abdolell, Daria Manos
    European Radiology.2016; 26(11): 4141.     CrossRef
  • Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers
    Boram Lee, Taebum Lee, Se-Hoon Lee, Yoon-La Choi, Joungho Han
    Oncotarget.2016; 7(17): 23874.     CrossRef
  • The Difference of Clinical Characteristics Between Patients With Exon 19 Deletion and Those With L858R Mutation in Nonsmall Cell Lung Cancer
    Yaxiong Zhang, Dacheng He, Wenfeng Fang, Shiyang Kang, Gang Chen, Shaodong Hong, Jin Sheng, Jianhua Zhan, Nan Chen, Zhihuang Hu, Cong Xue, Yunpeng Yang, Yuxiang Ma, Tao Qin, Ting Zhou, Yan Huang, Li Zhang
    Medicine.2015; 94(44): e1949.     CrossRef
  • 12,318 View
  • 85 Download
  • 6 Web of Science
  • 7 Crossref
Close layer
Original Articles
Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute
Younak Choi, Bhumsuk Keam, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Dae Seog Heo
Cancer Res Treat. 2015;47(4):555-563.   Published online February 16, 2015
DOI: https://doi.org/10.4143/crt.2014.200
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to investigate and compare cancer treatment near the end-of-life (EOL) over a 10-year period. Materials and Methods Patients with advanced solid cancer at Seoul National University Hospital who received palliative chemotherapy and had died were enrolled. We categorized the consecutive patients according to two time periods: 2002 (n=57) and 2012 (n=206). Aggressiveness of cancer treatment near the EOL was evaluated.
Results
The median patient age was 62, and 65.4% of patients (n=172) were male. Time from the last chemotherapy to death (TCD) was found to have been significantly shortened, from 66.0 days to 34.0 days during 10 years (p < 0.001); 17% of patients received molecular targeted agents as the last chemotherapy regimen in 2012. The proportion of patients who received intensive care unit care within the last month increased from 1.8% in 2002 to 19.9% in 2012 (p < 0.001), and emergency room visits within the last month also increased from 22.8% to 74.8% (p < 0.001). Although hospice referral increased from 9.1% to 37.4% (p < 0.001), timing of referral was delayed from median 53 days to 8 days before death (p=0.004). Use of targeted agents as the last chemotherapy for over-two-regimen users was associated with shortened TCD (hazard ratio, 2.564; p=0.002). Conclusion Cancer treatment near the EOL became more aggressive over 10 years.

Citations

Citations to this article as recorded by  
  • Decreased aggressive care at the end of life among advanced cancer patients in the Republic of Korea: a nationwide study from 2012 to 2018
    Sara Kwon, Kyuwoong Kim, Bohyun Park, So-Jung Park, Hyun Jung Jho, Jin Young Choi
    BMC Palliative Care.2024;[Epub]     CrossRef
  • The impact of palliative care consultation on reducing antibiotic overuse in hospitalized patients with terminal cancer at the end of life: a propensity score-weighting study
    Jeong-Han Kim, Shin Hye Yoo, Bhumsuk Keam, Dae Seog Heo
    Journal of Antimicrobial Chemotherapy.2023; 78(1): 302.     CrossRef
  • Trends in appropriateness of end-of-life care in people with cancer, COPD or with dementia measured with population-level quality indicators
    Robrecht De Schreye, Luc Deliens, Lieven Annemans, Birgit Gielen, Tinne Smets, Joachim Cohen, Lihua Li
    PLOS ONE.2023; 18(2): e0273997.     CrossRef
  • Quality of End-of-Life Care during the COVID-19 Pandemic at a Comprehensive Cancer Center
    Yvonne Heung, Donna Zhukovsky, David Hui, Zhanni Lu, Clark Andersen, Eduardo Bruera
    Cancers.2023; 15(8): 2201.     CrossRef
  • Cancer care patterns in South Korea: Types of hospital where patients receive care and outcomes using national health insurance claims data
    Dong‐Woo Choi, Sun Jung Kim, Seungju Kim, Dong Wook Kim, Wonjeong Jeong, Kyu‐Tae Han
    Cancer Medicine.2023; 12(13): 14707.     CrossRef
  • Frequency of anticancer drug use at the end of life: a scoping review
    Endre Szigethy, Rosario Dorantes, Miguel Sugrañes, Meisser Madera, Ivan Sola, Gerard Urrútia, Xavier Bonfill
    Clinical and Translational Oncology.2023; 26(1): 178.     CrossRef
  • Preferred versus Actual Place of Care and Factors Associated with Home Discharge among Korean Patients with Advanced Cancer: A Retrospective Cohort Study
    In Young Hwang, Yohan Han, Min Sun Kim, Kyae Hyung Kim, Belong Cho, Wonho Choi, Yejin Kim, Shin Hye Yoo, Sun Young Lee
    Healthcare.2023; 11(13): 1939.     CrossRef
  • Effectiveness of Palliative Care before Death in Reducing Emergency Care Utilization for Patients with Terminal Cancer and Trends in the Utilization of Palliative Care from 2005–2018
    Yi-Shiun Tsai, Wen-Chen Tsai, Li-Ting Chiu, Pei-Tseng Kung
    Healthcare.2023; 11(21): 2907.     CrossRef
  • Potentially inappropriate end-of-life care and its association with relatives’ well-being: a systematic review
    Laurien Ham, Ellis Slotman, Carolien Burghout, Natasja JH Raijmakers, Lonneke V van de Poll-Franse, Lia van Zuylen, Heidi P Fransen
    Supportive Care in Cancer.2023;[Epub]     CrossRef
  • Disparities in healthcare expenditures according to economic status in cancer patients undergoing end-of-life care
    Kyu-Tae Han, Woorim Kim, Seungju Kim
    BMC Cancer.2022;[Epub]     CrossRef
  • Reasons for chemotherapy discontinuation and end-of-life in patients with gastrointestinal cancer: A multicenter prospective AGEO study
    Lola-Jade Palmieri, Olivier Dubreuil, Jean-Baptiste Bachet, Isabelle Trouilloud, Christophe Locher, Romain Coriat, Frederick Moryoussef, Bruno Landi, Géraldine Perkins, Vincent Hautefeuille, Solène Doat
    Clinics and Research in Hepatology and Gastroenterology.2021; 45(1): 101431.     CrossRef
  • Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients
    Kyung-In Joung, Jong Hwa Song, Kangho Suh, Seung-Mi Lee, Ji Hyun Jun, Taehwan Park, Dong Churl Suh
    BioDrugs.2021; 35(1): 61.     CrossRef
  • Difficulties Doctors Experience during Life-Sustaining Treatment Discussion after Enactment of the Life-Sustaining Treatment Decisions Act: A Cross-Sectional Study
    Shin Hye Yoo, Wonho Choi, Yejin Kim, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo
    Cancer Research and Treatment.2021; 53(2): 584.     CrossRef
  • Life-Sustaining Treatment States in Korean Cancer Patients after Enforcement of Act on Decisions on Life-Sustaining Treatment for Patients at the End of Life
    Young-Woong Won, Hwa Jung Kim, Jung Hye Kwon, Ha Yeon Lee, Sun Kyung Baek, Yu Jung Kim, Do Yeun Kim, Hyewon Ryu
    Cancer Research and Treatment.2021; 53(4): 908.     CrossRef
  • Healthcare Use during the Last Six Months of Life in Patients with Advanced Breast Cancer
    Renée. S. J. M. Schmitz, Sandra. M. E. Geurts, Khava. I. E. Ibragimova, Dominique. J. P. Tilli, Vivianne. C. G. Tjan-Heijnen, Maaike de Boer
    Cancers.2021; 13(21): 5271.     CrossRef
  • Impact of Palliative Care on Quality of End-of-Life Care Among Brazilian Patients With Advanced Cancers
    Talita Caroline de Oliveira Valentino, Carlos Eduardo Paiva, David Hui, Marco Antonio de Oliveira, Bianca Sakamoto Ribeiro Paiva
    Journal of Pain and Symptom Management.2020; 59(1): 39.     CrossRef
  • Aggressive End-of-Life Care and Symptom Relief Treatments in Terminally Ill Patients Who Had Discussed Withdrawal of Mechanical Ventilation: A Hospital-Based Observational Study
    Hsiao-Ting Chang, Ming-Hwai Lin, Chun-Ku Chen, Tzeng-Ji Chen, Shinn-Jang Hwang
    American Journal of Hospice and Palliative Medicine®.2020; 37(11): 897.     CrossRef
  • Chemotherapy and Tyrosine Kinase Inhibitors in the last month of life in patients with metastatic lung cancer: A patient file study in the Netherlands
    Adinda Mieras, Annemarie Becker‐Commissaris, H. Roeline W. Pasman, Anne‐Marie M. C. Dingemans, Edith V. Kok, Robin Cornelissen, Wouter Jacobs, Jan Willem Berg, Alle Welling, Brigitte A. H. A. Bogaarts, Lemke Pronk, Bregje D. Onwuteaka‐Philipsen
    European Journal of Cancer Care.2020;[Epub]     CrossRef
  • Modifiable Factors Associated with the Completion of Advance Treatment Directives in Hematologic Malignancy: A Patient–Caregiver Dyadic Analysis
    JinShil Kim, Jinny Park, Mee Ok Lee, Eun Young Park, Seongkum Heo, Jae Lan Shim
    Journal of Palliative Medicine.2020; 23(5): 611.     CrossRef
  • Changes of End of Life Practices for Cancer Patients and Their Association with Hospice Palliative Care Referral over 2009-2014: A Single Institution Study
    Hyun Jung Jho, Eun Jung Nam, Il Won Shin, Sun Young Kim
    Cancer Research and Treatment.2020; 52(2): 419.     CrossRef
  • Adverse events in deceased hospitalised cancer patients as a measure of quality and safety in end-of-life cancer care
    Ellinor Christin Haukland, Christian von Plessen, Carsten Nieder, Barthold Vonen
    BMC Palliative Care.2020;[Epub]     CrossRef
  • Implication of the Life-Sustaining Treatment Decisions Act on End-of-Life Care for Korean Terminal Patients
    Jung Sun Kim, Shin Hye Yoo, Wonho Choi, Yejin Kim, Jinui Hong, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo
    Cancer Research and Treatment.2020; 52(3): 917.     CrossRef
  • Status and cost analysis of antimicrobial treatment of terminally ill patients with hematological malignancy in an acute hospital
    Miyuki Chiba, Miyako Negishi, Sanae Miyagawa, Satoru Suzuki, Emiko Sasai, Kazunori Sugai, Shotaro Hagiwara
    Journal of Infection and Chemotherapy.2020; 26(12): 1288.     CrossRef
  • Factors associated with the aggressiveness of care at the end of life for patients with cancer dying in hospital: a nationwide retrospective cohort study in mainland Portugal
    Diogo Martins-Branco, Silvia Lopes, Rita Canario, Joao Freire, Madalena Feio, Jose Ferraz-Goncalves, Gabriela Sousa, Nuno Lunet, Barbara Gomes
    ESMO Open.2020; 5(6): e000953.     CrossRef
  • Duration of palliative care before death in international routine practice: a systematic review and meta-analysis
    Roberta I. Jordan, Matthew J. Allsop, Yousuf ElMokhallalati, Catriona E. Jackson, Helen L. Edwards, Emma J. Chapman, Luc Deliens, Michael I. Bennett
    BMC Medicine.2020;[Epub]     CrossRef
  • Attitudes of the General Public, Cancer Patients, Family Caregivers, and Physicians Toward Advance Care Planning: A Nationwide Survey Before the Enforcement of the Life-Sustaining Treatment Decision-Making Act
    Hye Yoon Park, Young Ae Kim, Jin-Ah Sim, Jihye Lee, Hyewon Ryu, Jung Lim Lee, Chi Hoon Maeng, Jung Hye Kwon, Yu Jung Kim, Eun Mi Nam, Hyun-Jeong Shim, Eun-Kee Song, Kyung Hae Jung, Eun Joo Kang, Jung Hun Kang, Young Ho Yun
    Journal of Pain and Symptom Management.2019; 57(4): 774.     CrossRef
  • Economic burden of lung cancer: A retrospective cohort study in South Korea, 2002-2015
    Soo Min Jeon, Jin-Won Kwon, Sun Ha Choi, Hae-Young Park, Seil Sohn
    PLOS ONE.2019; 14(2): e0212878.     CrossRef
  • The Korean–Advance Directive Model and Factors Associated With Its Completion Among Patients With Hematologic Disorders
    Mee Ok Lee, Jinny Park, Eun Young Park, Youngji Kim, Eunjoo Bang, Seongkum Heo, JinShil Kim
    Journal of Hospice & Palliative Nursing.2019; 21(4): E10.     CrossRef
  • Are physicians on the same page about do-not-resuscitate? To examine individual physicians’ influence on do-not-resuscitate decision-making: a retrospective and observational study
    Yen-Yuan Chen, Melany Su, Shu-Chien Huang, Tzong-Shinn Chu, Ming-Tsan Lin, Yu-Chun Chiu, Kuan-Han Lin
    BMC Medical Ethics.2019;[Epub]     CrossRef
  • Lung cancer and end-of-life care: a systematic review and thematic synthesis of aggressive inpatient care
    Olivier Bylicki, Morgane Didier, Frederic Riviere, Jacques Margery, Frederic Grassin, Christos Chouaid
    BMJ Supportive & Palliative Care.2019; 9(4): 413.     CrossRef
  • Correlates of life-support treatment preferences among low-income home-based cancer management recipients
    JinShil Kim, Seongkum Heo, Mi Yeong Kim, Eun Young Park, Eun Ju Seo, Mee Ok Lee, Bo Yoon Jeong, Jung-Ah Lee
    European Journal of Oncology Nursing.2019; 43: 101665.     CrossRef
  • Determinants of Last-line Treatment in Metastatic Breast Cancer
    Marika Cinausero, Lorenzo Gerratana, Elisa De Carlo, Donatella Iacono, Marta Bonotto, Valentina Fanotto, Vanessa Buoro, Debora Basile, Maria Grazia Vitale, Karim Rihawi, Gianpiero Fasola, Fabio Puglisi
    Clinical Breast Cancer.2018; 18(3): 205.     CrossRef
  • Impact of Targeted Therapy on the Quality of End-of-Life Care for Patients With Non–Small-Cell Lung Cancer: A Population-Based Study in Taiwan
    Hsin-Yun Tsai, Kuo-Piao Chung, Raymond Nien-Chen Kuo
    Journal of Pain and Symptom Management.2018; 55(3): 798.     CrossRef
  • Outpatient Palliative Care and Aggressiveness of End-of-Life Care in Patients with Metastatic Colorectal Cancer
    Si Won Lee, Hyun Jung Jho, Ji Yeon Baek, Eun Kyung Shim, Hyun Mi Kim, Ji Yeon Ku, Eun Jung Nam, Yoon-Jung Chang, Hye Jin Choi, Sun Young Kim
    American Journal of Hospice and Palliative Medicine®.2018; 35(1): 166.     CrossRef
  • Differences in do-not-resuscitate orders, hospice care utilization, and late referral to hospice care between cancer and non-cancer decedents in a tertiary Hospital in Taiwan between 2010 and 2015: a hospital-based observational study
    Tzu-Chien Shih, Hsiao-Ting Chang, Ming-Hwai Lin, Chun-Ku Chen, Tzeng-Ji Chen, Shinn-Jang Hwang
    BMC Palliative Care.2018;[Epub]     CrossRef
  • Factors Associated with Early Referral to Palliative Care in Outpatients with Advanced Cancer
    Deepa Wadhwa, Gordana Popovic, Ashley Pope, Nadia Swami, Lisa W. Le, Camilla Zimmermann
    Journal of Palliative Medicine.2018; 21(9): 1322.     CrossRef
  • Qualitative study of patients’ decision-making when accepting second-line treatment after failure of first-line chemotherapy
    Jean-Louis Pujol, Benoît Roch, Caroline Roth, Jean-Pierre Mérel, Yvonne Drewes
    PLOS ONE.2018; 13(5): e0197605.     CrossRef
  • The Disease Burden of Lung Cancer Attributable to Residential Radon Exposure in Korean Homes
    Jong-Hun Kim, Mina Ha
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer
    Shin Hye Yoo, Bhumsuk Keam, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo
    Cancer Research and Treatment.2018; 50(3): 720.     CrossRef
  • End-of-life care decisions using a Korean advance directive among cancer patient–caregiver dyads
    Shinmi Kim, Sujin Koh, Kwonoh Park, Jinshil Kim
    Palliative and Supportive Care.2017; 15(1): 77.     CrossRef
  • Long-term survival of out-of-hospital cardiac arrest patients with malignancy
    Saee Byel Kang, Kyung Su Kim, Gil Joon Suh, Woon Yong Kwon, Kyoung Min You, Min Ji Park, Jung-In Ko, Taegyun Kim
    The American Journal of Emergency Medicine.2017; 35(10): 1457.     CrossRef
  • Palliative care consultants’ ethical concerns with advanced cancer patients participating in phase 1 clinical trials. A case study
    Nunziata Comoretto, Ana Larumbe, Maria Arantzamendi, Carlos Centeno
    Progress in Palliative Care.2017; 25(5): 230.     CrossRef
  • Cases and Literature Review of Timing for Withdrawal of Palliative Chemotherapy
    Yun Jin Jeong, Do Yeun Kim
    The Korean Journal of Hospice and Palliative Care.2016; 19(1): 70.     CrossRef
  • Intensive care unit prognostic factors in critically ill patients with advanced solid tumors: a 3-year retrospective study
    Rui Xia, Donghao Wang
    BMC Cancer.2016;[Epub]     CrossRef
  • Herausforderungen der palliativen onkologischen Chirurgie
    Konrad K. Richter, U. Wedding
    Der Onkologe.2015; 21(11): 1074.     CrossRef
  • 12,490 View
  • 129 Download
  • 45 Web of Science
  • 45 Crossref
Close layer
Optimal Interval for Repeated Gastric Cancer Screening in Normal-Risk Healthy Korean Adults: A Retrospective Cohort Study
Jong-Myon Bae, Sang Yop Shin, Eun Hee Kim
Cancer Res Treat. 2015;47(4):564-568.   Published online January 30, 2015
DOI: https://doi.org/10.4143/crt.2014.098
AbstractAbstract PDFPubReaderePub
Purpose
This retrospective cohort study was conducted to estimate the optimal interval for gastric cancer screening in Korean adults with initial negative screening results.
Materials and Methods
This study consisted of voluntary Korean screenees aged 40 to 69 years who underwent subsequent screening gastroscopies after testing negative in the baseline screening performed between January 2007 and December 2011. A new case was defined as the presence of gastric cancer cells in biopsy specimens obtained upon gastroscopy. The follow-up periods were calculated during the months between the date of baseline screening gastroscopy and positive findings upon subsequent screenings, stratified by sex and age group. The mean sojourn time (MST) for determining the screening interval was estimated using the prevalence/incidence ratio.
Results
Of the 293,520 voluntary screenees for the gastric cancer screening program, 91,850 (31.29%) underwent subsequent screening gastroscopies between January 2007 and December 2011. The MSTs in men and women were 21.67 months (95% confidence intervals [CI], 17.64 to 26.88 months) and 15.14 months (95% CI, 9.44 to 25.85 months), respectively.
Conclusion
These findings suggest that the optimal interval for subsequent gastric screening in both men and women is 24 months, supporting the 2-year interval recommended by the nationwide gastric cancer screening program.

Citations

Citations to this article as recorded by  
  • Current therapeutic options for gastric adenocarcinoma
    C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
    Saudi Journal of Biological Sciences.2021; 28(9): 5371.     CrossRef
  • Potential of non-invasive breath tests for preselecting individuals for invasive gastric cancer screening endoscopy
    Agne Krilaviciute, Christian Stock, Marcis Leja, Hermann Brenner
    Journal of Breath Research.2018; 12(3): 036009.     CrossRef
  • Endoscopic Screening in Asian Countries Is Associated With Reduced Gastric Cancer Mortality: A Meta-analysis and Systematic Review
    Xing Zhang, Meng Li, Shuntai Chen, Jiaqi Hu, Qiujun Guo, Rui Liu, Honggang Zheng, Zhichao Jin, Yuan Yuan, Yupeng Xi, Baojin Hua
    Gastroenterology.2018; 155(2): 347.     CrossRef
  • Comparison of gastric cancer survival after R0 resection in the US and China
    Ping Li, Chang‐Ming Huang, Chao‐Hui Zheng, Ashley Russo, Priyanka Kasbekar, Murray F. Brennan, Daniel G. Coit, Vivian E. Strong
    Journal of Surgical Oncology.2018; 118(6): 975.     CrossRef
  • Does the interval of screening endoscopy affect survival in gastric cancer patients?
    Jieun Kim, Su Mi Kim, Man Ho Ha, Jeong Eun Seo, Min-Gew Choi, Jun Ho Lee, Tae Sung Sohn, Sung Kim, Sin-Ho Jung, Jae Moon Bae
    Medicine.2016; 95(49): e5490.     CrossRef
  • Questionnaire-Based Survey on Diagnostic and Therapeutic Endoscopies and H. pylori Eradication for Elderly Patients in East Asian Countries
    Juntaro Matsuzaki, Ryoma Hayashi, Tetsuo Arakawa, Fumiaki Ueno, Yoshikazu Kinoshita, Takashi Joh, Shin''ichi Takahashi, Yuji Naito, Shin Fukudo, Francis K.L. Chan, Ki-Baik Hahm, Udom Kachintorn, Kwong Ming Fock, Ari Fahrial Syam, Abdul Aziz Rani, Jose D.
    Digestion.2016; 93(1): 93.     CrossRef
  • DNA Methylation as Surrogate Marker For Gastric Cancer
    Jung-Hwan Oh, Sung-Hoon Jung, Seung-Jin Hong, Mun-Gan Rhyu
    Journal of Cancer Prevention.2015; 20(3): 172.     CrossRef
  • 12,005 View
  • 117 Download
  • 5 Web of Science
  • 7 Crossref
Close layer
Population-based Incidence and Survival for Primary Central Nervous System Lymphoma in Korea, 1999-2009
Sang-Hoon Shin, Kyu-Won Jung, Johyun Ha, Seung Hoon Lee, Young-Joo Won, Heon Yoo
Cancer Res Treat. 2015;47(4):569-574.   Published online February 12, 2015
DOI: https://doi.org/10.4143/crt.2014.085
AbstractAbstract PDFPubReaderePub
Purpose
Primary central nervous system lymphoma (PCNSL) is an uncommon brain tumor accounting for 2%-5% of all primary brain tumors. Few population-based analyses of survival for patients with PCNSL have been conducted, particularly in Asian countries. Materials and Methods Using the Korea National Cancer Incidence Database, 1,062 cases of PCNSL newly diagnosed from 1999 to 2009 were analyzed. The crude rate, age-standardized rate (ASR), and annual percent change were calculated. To estimate the observed survival, we restricted the data to between 1999 and 2007 and followed the cases until December 2010. The overall survival was estimated using the Kaplan-Meier method, and piecewise Poisson regression model.
Results
The ASR for PCNSL between 1999 and 2009 was 0.17 per 100,000, and the annual percent change from 1999 to 2009 was 8.8% (p < 0.001). The ASR of males was higher than that of females, and the older groups (60s or over) showed the largest increase in incidence rates. For all ages, the five-year survival from PCNSL was 29.9% between 1999 and 2007. Survival from PCNSL is known to show strong association with age at diagnosis. Conclusion These results are similar to those of previous studies. Our findings may be helpful to clinicians and patients in determining long-term prognoses for PCNSL.

Citations

Citations to this article as recorded by  
  • All-cause and tumor-specific mortality trends in elderly primary central nervous system lymphoma (PCNSL) patients: a surveillance, epidemiology, and end results (SEER) analysis
    Taylor FURST, Haydn HOFFMAN, Lawrence S. CHIN
    Journal of Neurosurgical Sciences.2024;[Epub]     CrossRef
  • Intrathecal IgM synthesis as a diagnostic marker in patients with suspected CNS lymphoma
    Raphael Reinecke, Kolja Jahnke, Martha Foltyn‐Dumitru, Karsten Lachner, Moritz Armbrust, Katharina J. Weber, Pia S. Zeiner, Marcus Czabanka, Uta Brunnberg, Sylvia Hartmann, Joachim P. Steinbach, Michael W. Ronellenfitsch
    Journal of Neurochemistry.2024; 168(6): 1157.     CrossRef
  • Targeting the tumor microenvironment in primary central nervous system lymphoma: Implications for prognosis
    Han Shi, Xuefei Sun, Yuchen Wu, Qu Cui, Shengjun Sun, Nan Ji, Yuanbo Liu
    Journal of Clinical Neuroscience.2024; 124: 36.     CrossRef
  • Long term outcomes in older patients with primary central nervous system lymphoma: an analysis of the Texas Cancer Registry
    Ethan A. Burns, Cesar Gentille Sanchez, Sunil Mathur, Carlo Guerrero, Ibrahim N. Muhsen, Humaira Sarfraz, Chih-Chi Andrew Hu, Chih-Hang Anthony Tang, Shilpan S. Shah, Ivo W. Tremont, Bin Teh, Siddhartha Ganguly, Sai Ravi Kiran Pingali
    Annals of Hematology.2023; 102(5): 1111.     CrossRef
  • Exosomal miR-200c and miR-141 as cerebrospinal fluid biopsy biomarkers for the response to chemotherapy in primary central nervous system lymphoma
    Yao Hu, Qingyun Zhang, Zhiyuan Wu, Kun Chen, Xiao Xu, Weizhe Ma, Bobin Chen, Limin Jin, Ming Guan
    Discover Oncology.2023;[Epub]     CrossRef
  • Primary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis
    Inka Puhakka, Hanne Kuitunen, Pekka Jäkälä, Eila Sonkajärvi, Taina Turpeenniemi-Hujanen, Aino Rönkä, Tuomas Selander, Miika Korhonen, Outi Kuittinen
    BMC Cancer.2022;[Epub]     CrossRef
  • Use of rituximab, temozolomide, and radiation in recurrent and refractory primary central nervous system lymphoma in the Philippines: a retrospective analysis
    Julette Marie F Batara, Almira Doreen Abigail O Apor, Christianne V Mojica, Mark Willy L Mondia
    Neuro-Oncology Advances.2022;[Epub]     CrossRef
  • The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper
    Justine R Smith, Alexandra L Farrall, Janet L Davis, Joke H de Boer, Anthony J Hall, Manabu Mochizuki, H Nida Sen, Hiroshi Takase, Ninette H ten Dam-van Loon, Valérie Touitou, Daniel V Vasconcelos-Santos, David J Wilson, Steven Yeh, Mark H B Radford
    BMJ Open.2022; 12(7): e060701.     CrossRef
  • Changing Incidence and Survival of Primary Central Nervous System Lymphoma in Australia: A 33-Year National Population-Based Study
    Alexandra L. Farrall, Justine R. Smith
    Cancers.2021; 13(3): 403.     CrossRef
  • Eye involvement in primary central nervous system lymphoma
    Alexandra L. Farrall, Justine R. Smith
    Survey of Ophthalmology.2020; 65(5): 548.     CrossRef
  • Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study
    Chava Perry, Sharon Ben Barouch, Neta Goldschmidt, Nadav Sarid, Yair Herishanu, Lev Shvidel, Osnat Bairey, Noa Lavi, Netanel Horowitz, Avraham Avigdor, Eyal Lebel, Orit Sofer, Ron Ram, Irit Avivi
    American Journal of Hematology.2019; 94(9): 992.     CrossRef
  • Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989–2015
    M van der Meulen, A G Dinmohamed, O Visser, J K Doorduijn, J E C Bromberg
    Leukemia.2017; 31(8): 1822.     CrossRef
  • Role of radiation therapy in primary central nervous system lymphoma
    Hyeon Kang Koh, Il Han Kim, Tae Min Kim, Do Hoon Lim, Dongryul Oh, Jae Ho Cho, Woo-Chul Kim, Jin Hee Kim, Woong-Ki Chung, Bae-Kwon Jeong, Ki Mun Kang, Semie Hong, Chang-Ok Suh, In Ah Kim
    Journal of Neuro-Oncology.2017; 135(3): 629.     CrossRef
  • 12,378 View
  • 115 Download
  • 14 Web of Science
  • 13 Crossref
Close layer
Incidence and Treatment Pattern of Extremity Soft Tissue Sarcoma in Korea, 2009-2011: A Nationwide Study Based on the Health Insurance Review and Assessment Service Database
Seungcheol Kang, Han-Soo Kim, Eun-Seok Choi, Ilkyu Han
Cancer Res Treat. 2015;47(4):575-582.   Published online January 2, 2015
DOI: https://doi.org/10.4143/crt.2014.047
AbstractAbstract PDFPubReaderePub
Purpose
We conducted a nationwide study to assess the incidence and treatment patterns of extremity soft tissue sarcoma (STS) in South Korea.
Materials and Methods
The nationwide incidence and treatment patterns of extremity STS were assessed using two nationwide databases, the Korea National Cancer Incidence (KNCI) database and the Health Insurance Review and Assessment Service (HIRA) database.
Results
A total of 1,236 patients were newly diagnosed with extremity STS during the 3-year study period, from 2009 to 2011. The annual incidence of extremity STS in the Korean population was approximately 0.9 per 100,000 people with a male bias that increased with age and was especially pronounced amongst individuals aged > 80 years. Approximately 7% of patients did not receive any treatment, and surgical excision was performed for 85% of those who were treated.
Conclusion
This is the first nationwide study of the incidence and treatment patterns of extremity STS in Korea using two national databases (KNCI and HIRA), which include the entire Korean population. The results of this study may be useful for future planning and management of STS, at the national level.

Citations

Citations to this article as recorded by  
  • Evaluation for Skin Cancer and Precancer in Patients With Vitiligo Treated With Long-term Narrowband UV-B Phototherapy
    Jung Min Bae, Hyun Jeong Ju, Ro Woo Lee, Sang Ho Oh, Jeong Hyun Shin, Hee Young Kang, Ji Hun Park, Hee Jung Kim, Ki-Heon Jeong, Hee Jung Lee, SangHoon Lee, Dong Hyun Kim, Dong-Youn Lee, You Chan Kim, Gwang Seong Choi, Ki-Ho Kim, Chul Jong Park, Chong Won
    JAMA Dermatology.2020; 156(5): 529.     CrossRef
  • Incidence of soft tissue sarcoma in Taiwan: A nationwide population-based study (2007–2013)
    Giun-Yi Hung, Jiun-Lin Horng, Paul Chih-Hsueh Chen, Li-Yih Lin, Jinn-Yang Chen, Pei-Hung Chuang, Ta-Chung Chao, Chueh-Chuan Yen
    Cancer Epidemiology.2019; 60: 185.     CrossRef
  • Molecular changes in solitary fibrous tumor progression
    Hyung Kyu Park, Dan Bi Yu, Minjung Sung, Ensel Oh, Mingi Kim, Ji-Young Song, Mi-Sook Lee, Kyungsoo Jung, Ka-Won Noh, Sungbin An, Kyoung Song, Do-Hyun Nam, Yu Jin Kim, Yoon-La Choi
    Journal of Molecular Medicine.2019; 97(10): 1413.     CrossRef
  • Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea
    Hyo Song Kim, Chung Mo Nam, Suk-Yong Jang, Sun Kyu Choi, Minkyung Han, Seonmin Kim, Maria Victoria Moneta, Sae Young Lee, Jae Min Cho, Diego Novick, Sun Young Rha
    Cancer Research and Treatment.2019; 51(4): 1380.     CrossRef
  • Breast reconstruction statistics in Korea from the Big Data Hub of the Health Insurance Review and Assessment Service
    Jae-Won Kim, Jun-Ho Lee, Tae-Gon Kim, Yong-Ha Kim, Kyu Jin Chung
    Archives of Plastic Surgery.2018; 45(05): 441.     CrossRef
  • Clinical research using medical big data
    Geum Joon Cho
    Anesthesia and Pain Medicine.2017; 12(1): 9.     CrossRef
  • 12,077 View
  • 127 Download
  • 9 Web of Science
  • 6 Crossref
Close layer
The Economic Burden of Breast Cancer in Korea from 2007-2010
Young Ae Kim, In-Hwan Oh, Seok-Jun Yoon, Hyun-Jin Kim, Hye-Young Seo, Eun-Jung Kim, Yo Han Lee, Jae Hun Jung
Cancer Res Treat. 2015;47(4):583-590.   Published online February 13, 2015
DOI: https://doi.org/10.4143/crt.2014.143
AbstractAbstract PDFPubReaderePub
Purpose
This study estimates the socioeconomic cost and burden for breast cancer patients in Korea between 2007 and 2010. Materials and Methods This study used a prevalence-based approach to estimate the cost of breast cancer. Breast cancer patients were defined as those who were hospitalized or have visited an outpatient clinic during the period from 2007 to 2010. The socioeconomic costs of breast cancer were subdivided into two costs: direct and indirect.
Results
From 2007 to 2010, the prevalence of treated breast cancer increased from 7.9% to 20.4%. The total socioeconomic costs incurred by breast cancer increased by approximately 40.7% from US $668.49 million in 2007 to US $940.75 million in 2010. The direct medical care costs for 2010 were 1.4 times greater (US $399.22 million) than for 2007 (US $278.71 million). The direct non-medical costs rose from US $50.69 million in 2007 to US $75.83 million in 2010, a 49.6% increase. Regarding the economic burden of breast cancer, the total indirect costs were US $339.09 million in 2007 and increased by 37.3% to US $465.70 million in 2010. In the sensitivity analysis, with the annual discount rate for each year ranging from 0%-5%, the costs increased 1.1-1.2 times. Conclusion Due to the growing incidence of breast cancer, the annual prevalence and related costs are increasing. We must strive to reduce the socioeconomic burden of breast cancer through preventive measures and early screening.

Citations

Citations to this article as recorded by  
  • Cost of illness of breast cancer in low- and middle-income countries: a systematic review
    Siew Wei Yeong, Sit Wai Lee, Siew Chin Ong
    Health Economics Review.2024;[Epub]     CrossRef
  • Therapy-related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy
    Ji Won Lee, Hoonji Oh, Ji Young You, Eun-Shin Lee, Jung Hyun Lee, Sung Eun Song, Nam Kwon Lee, Seung Pil Jung, Jung Seok An, Kyu Ran Cho, Cheol Yong Kim, Kyong Hwa Park
    European Journal of Cancer.2023; 191: 112952.     CrossRef
  • Economic burden of breast cancer: a case of Southern Iran
    Faride Sadat Jalali, Khosro Keshavarz, Mozhgan Seif, Majid Akrami, Abdosaleh Jafari, Ramin Ravangard
    Cost Effectiveness and Resource Allocation.2023;[Epub]     CrossRef
  • Economic burden of breast cancer in northern Serbia
    Marko Milovic, Tatjana Tamas, Veljko Crnobrnja, Milica Paut Kusturica
    Frontiers in Public Health.2023;[Epub]     CrossRef
  • Measuring Trends in the Socioeconomic Burden of Disease in Korea, 2007-2015
    Tae Eung Kim, Ru-Gyeom Lee, So-Youn Park, In-Hwan Oh
    Journal of Preventive Medicine and Public Health.2022; 55(1): 19.     CrossRef
  • The direct cost incurred by patients and caregivers in diagnosing and managing prostate cancer in Ghana
    Ebenezer Wiafe, Kofi Boamah Mensah, Kwaku Addai Arhin Appiah, Frasia Oosthuizen, Varsha Bangalee
    BMC Health Services Research.2022;[Epub]     CrossRef
  • Cost analysis of breast cancer: a comparison between private and public hospitals in Iran
    Abolhasan Afkar, Habib Jalilian, Abolghasem Pourreza, Habibeh Mir, Abdolhosein Emami Sigaroudi, Somayeh Heydari
    BMC Health Services Research.2021;[Epub]     CrossRef
  • The Economic Burden Associated with the Management of Different Stages of Breast Cancer: A Retrospective Cost of Illness Analysis in Saudi Arabia
    Ahmed Alghamdi, Bander Balkhi, Shahad Alqahtani, Hamoud Almotairi
    Healthcare.2021; 9(7): 907.     CrossRef
  • Direct Medical Costs for Stage-Specific Breast Cancer: A Retrospective Analysis
    Qais Alefan, Alaa Saadeh, Rami J Yaghan
    Breast Cancer Management.2020;[Epub]     CrossRef
  • Socioeconomic Burden of Cancer in Korea from 2011 to 2015
    Young Ae Kim, Ye-Rin Lee, Jeongjoo Park, In-Hwan Oh, Hoseob Kim, Seok-Jun Yoon, Keeho Park
    Cancer Research and Treatment.2020; 52(3): 896.     CrossRef
  • Structural and Molecular Docking Analytical Studies of the Predicted Ligand Binding Sites of Cadherin-1 in Cancer Prognostics


    Olalekan Olanrewaju Bakare, Adewale Oluwaseun Fadaka, Marshall Keyster, Ashley Pretorius
    Advances and Applications in Bioinformatics and Chemistry.2020; Volume 13: 1.     CrossRef
  • Influencing Factors of Transportation Costs regarding Healthcare Service Utilization in Korea
    Su Yeon Jang, Jeong Yeon Seon, In-Hwan Oh
    Journal of Korean Medical Science.2020;[Epub]     CrossRef
  • Measuring the Economic Burden of Disease and Injury in Korea, 2015
    Ye-Rin Lee, Bogeum Cho, Min-Woo Jo, Minsu Ock, Donghoon Lee, Doungkyu Lee, Moon Jung Kim, In-Hwan Oh
    Journal of Korean Medical Science.2019;[Epub]     CrossRef
  • Complementary medicine use and costs in patients with breast cancer who experienced treatment-related side effects: A cross-sectional survey in Korea
    Sola Han, Bo-Hyoung Jang, Hae Sun Suh, Deok-Sang Hwang
    Complementary Therapies in Medicine.2019; 44: 210.     CrossRef
  • Financial barriers related to breast cancer screening and treatment: A cross-sectional survey of women in Kenya
    Sujha Subramanian, Robai Gakunga, Madeleine Jones, Asaph Kinyanjui, Emily Ochieng’, Nancy Gikaara, Maluni, David Wata, Anne Korir, Zipporah Ali
    Journal of Cancer Policy.2019; 22: 100206.     CrossRef
  • The economic burden of rotavirus infection in South Korea from 2009 to 2012
    Kyung Suk Lee, Ye-Rin Lee, So-Youn Park, In-Hwan Oh, Donald R. Olson
    PLOS ONE.2018; 13(3): e0194120.     CrossRef
  • Household Costs of Breast Cancer Morbidity: An Empirical Assessment from Pakistan
    Hafiz Zahid Mahmood, Imran Hameed Khaliq, Zafar Iqbal Bhatti, Kimberly J. Wilson, Khalid Masood Gondal, Summaira Malik, Shakila Zaman
    SSRN Electronic Journal .2018;[Epub]     CrossRef
  • Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma
    Kiyong Na, Jung-Yun Lee, Ji-Youn Sung, Gun Min Kim, Ja Seung Koo, Hyun-Soo Kim
    Virchows Archiv.2018; 473(2): 165.     CrossRef
  • Breast Cancer Detection Using Infrared Thermal Imaging and a Deep Learning Model
    Sebastien Jean Mambou, Petra Maresova, Ondrej Krejcar, Ali Selamat, Kamil Kuca
    Sensors.2018; 18(9): 2799.     CrossRef
  • The effect of tamoxifen therapy on the endometrium and ovarian cyst formation in patients with breast cancer
    Seul Lee, Yun Hwa Kim, Seung Chul Kim, Jong Kil Joo, Dong Suh Seo, Ki Hyung Kim, Kyu Sup Lee
    Obstetrics & Gynecology Science.2018; 61(5): 615.     CrossRef
  • The human circadian clock from health to economics
    Bala S. C. Koritala, Selim Çakmaklı
    PsyCh Journal.2018; 7(4): 176.     CrossRef
  • Economic Burden for Lung Cancer Survivors in Urban China
    Xin Zhang, Shuai Liu, Yang Liu, Jian Du, Wenqi Fu, Xiaowen Zhao, Weidong Huang, Xianming Zhao, Guoxiang Liu, Zhengzhong Mao, Teh-wei Hu
    International Journal of Environmental Research and Public Health.2017; 14(3): 308.     CrossRef
  • Strategies for Appropriate Patient-centered Care to Decrease the Nationwide Cost of Cancers in Korea
    Jong-Myon Bae
    Journal of Preventive Medicine and Public Health.2017; 50(4): 217.     CrossRef
  • Productivity losses and public finance burden attributable to breast cancer in Poland, 2010–2014
    Błażej Łyszczarz, Ewelina Nojszewska
    BMC Cancer.2017;[Epub]     CrossRef
  • The Economic Burden of Otitis Media in Korea, 2012: A Nationally Representative Cross-Sectional Study
    Young-Eun Kim, Ye-Rin Lee, So-Youn Park, Kyung Suk Lee, In-Hwan Oh
    BioMed Research International.2016; 2016: 1.     CrossRef
  • The Burden of Cancer in Korea during 2012: Findings from a Prevalence-Based Approach
    Young-hoon Gong, Seok-Jun Yoon, Min-Woo Jo, Arim Kim, Young Ae Kim, Jihyun Yoon, Hyeyoung Seo, Dongwoo Kim
    Journal of Korean Medical Science.2016; 31(Suppl 2): S168.     CrossRef
  • 13,952 View
  • 188 Download
  • 26 Web of Science
  • 26 Crossref
Close layer
Oncologist Perspectives on Rare Cancer Care: A Nationwide Survey
Dong Wook Shin, Juhee Cho, Hyung Kook Yang, So Young Kim, Su Hyun Lee, Beomseok Suh, Hee-Young Shin, Hyun Joo Lee, Dae Ghon Kim, Jong Hyock Park
Cancer Res Treat. 2015;47(4):591-599.   Published online January 5, 2015
DOI: https://doi.org/10.4143/crt.2014.086
AbstractAbstract PDFPubReaderePub
Purpose
In response to the challenges and difficulties imposed by rare cancers, multi-stakeholder initiatives dedicated to improving rare cancer care was launched, and several recommendations were made by professional societies. However, these primarily reflect the view of the advocates and supporters, and may not represent the views of the “average” clinician or researcher. In this study, we sought to investigate perceived difficulties with regard to rare cancer care and potential solutions endorsed by oncologists.
Materials and Methods
A representative sample of 420 oncologists recruited in 13 cancer centers participated in a nationwide survey.
Results
Oncologists faced various difficulties in treatment of patients with rare cancers, including the lack of clinical practice guidelines (65.7%) and personal experience (65.2%), lack of approved treatment options (39.8%), and reimbursement issues (44.5%). They were generally supportive of recent recommendations by multi-stakeholder initiatives as well as professional societies for development of clear clinical practice guidelines (66.0%), flexible reimbursement guidelines (52.9%), and a national rare cancer registry (47.4%). However, there was only moderate endorsement for referrals to high-volume centers (35.5%) and encouragement of off-label treatments (21.0%).
Conclusion
Insights into the general attitudes of oncologists gained through our nationwide survey of representative samples would be helpful in development of clinical practices and public health policies in rare cancer treatment and research.

Citations

Citations to this article as recorded by  
  • Choreographed expansion of services results in decreased patient burden without compromise of outcomes: An assessment of the Ontario experience
    Kathryn Rzadki, Wafa Baqri, Olga Yermakhanova, Steven Habbous, Sunit Das
    Neuro-Oncology Practice.2024; 11(2): 178.     CrossRef
  • Primary Small Cell Carcinoma of the Kidney: Disease Characteristics and Treatment Outcomes
    Thomas F. Monaghan, Kyle P. Michelson, Nicholas R. Suss, Christina W. Agudelo, Syed N. Rahman, Dennis J. Robins, Viktor X. Flores, Brian K. McNeil, Jeffrey P. Weiss, Andrew G. Winer
    Medicines.2021; 8(1): 6.     CrossRef
  • Rare cancers in India: A road less travelled
    HS Darling, Sameer Rastogi
    Indian Journal of Cancer.2020; 57(2): 139.     CrossRef
  • Cancer Patients’ Utilization of Tertiary Hospitals in Seoul Before and After the Benefit Expansion Policy
    Sanghyun Cho, Youngs Chang, Yoon Kim
    Journal of Preventive Medicine and Public Health.2019; 52(1): 41.     CrossRef
  • Physicians’ attitudes towards the media and peer-review selection of the ‘best cancer doctor’: comparison of two different selection methods
    Dong Wook Shin, Juhee Cho, Hyung Kook Yang, So Young Kim, Soohyeon Lee, Eun Joo Nam, Joo Seop Chung, Jeong-Soo Im, Keeho Park, Jong Hyock Park
    BMJ Open.2018; 8(5): e019067.     CrossRef
  • Rare cancers—Rarity as a cost and value argument
    J.-Matthias Graf von der Schulenburg, Frédéric Pauer
    Journal of Cancer Policy.2017; 11: 54.     CrossRef
  • Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study
    Gemma Gatta, Riccardo Capocaccia, Laura Botta, Sandra Mallone, Roberta De Angelis, Eva Ardanaz, Harry Comber, Nadya Dimitrova, Maarit K Leinonen, Sabine Siesling, Jan M van der Zwan, Liesbet Van Eycken, Otto Visser, Maja P Žakelj, Lesley A Anderson, Franc
    The Lancet Oncology.2017; 18(8): 1022.     CrossRef
  • 10,890 View
  • 97 Download
  • 5 Web of Science
  • 7 Crossref
Close layer
Oncologists’ Experience with Patients with Second Primary Cancer and the Attitudes toward Second Primary Cancer Screening: A Nationwide Survey
Dong Wook Shin, Juhee Cho, Hyung Kook Yang, So Young Kim, Boram Park, BeLong Cho, Hyung Jin Kim, Young Jun Lee, Deog-Yeon Jo, Jong Hyock Park
Cancer Res Treat. 2015;47(4):600-606.   Published online February 12, 2015
DOI: https://doi.org/10.4143/crt.2014.162
AbstractAbstract PDFPubReaderePub
Purpose
Screening for second primary cancer (SPC) is one of the key components to survivorship care. We aim to evaluate the oncologists’ experience with SPCs and assess the current practice, perceived barriers, and recommendations related to SPC screening. Materials and Methods A nationwide survey was conducted with a representative sample of 496 Korean oncologists. A questionnaire based on the findings from our previous qualitative study was administered. Results More than three-fourths of oncologists (76.3%), who participated in the study, had experience with SPC patients. Over half of them (51.9%) stated that it was an embarrassing experience. While the current management practice for SPC varies, most oncologists (80.2%) agreed on the necessity in proactively providing information on SPC screening. A short consultation time (52.3%), lack of guidelines and evidence on SPC screening (47.7%), and patients’ lack of knowledge about SPCs (45.1%) or SPC screening (41.4%) were most frequently reported as barriers to providing appropriate care for managing SPC. Oncologists recommended the development of specific screening programs or guidelines in accordance to the type of primary cancer (65.9%), the development of an internal system for SPC screening within the hospital (59.7%) or systematic connection with the national cancer screening program (44.3%), and education of oncologists (41.4%) as well as patients (48.9%) regarding SPC screening. Conclusion Many oncologists reported the occurrence of SPC as an embarrassing experience. Given the variations in current practice and the lack of consensus, further studies are warranted to develop the optimal clinical strategy to provide SPC screening for cancer survivors.

Citations

Citations to this article as recorded by  
  • Cardiovascular risk and undertreatment of dyslipidemia in lung cancer survivors: A nationwide population-based study
    In Young Cho, Kyungdo Han, Dong Wook Shin, Sang Hyun Park, Dong Woog Yoon, Sujeong Shin, Su-Min Jeong, Jong Ho Cho
    Current Problems in Cancer.2021; 45(1): 100615.     CrossRef
  • Developing an instrument to assess cancer patient preparedness for transition to survivorship care in Korea
    Jung‐won Lim
    Asian Social Work and Policy Review.2020; 14(3): 172.     CrossRef
  • Second Primary Cancer after Treating Gastrointestinal Cancer
    Jeong Youp Park
    The Korean Journal of Gastroenterology.2019; 74(4): 193.     CrossRef
  • A national survey of lung cancer specialists’ views on low-dose CT screening for lung cancer in Korea
    Dong Wook Shin, Sohyun Chun, Young Il Kim, Seung Joon Kim, Jung Soo Kim, SeMin Chong, Young Sik Park, Sang-Yun Song, Jin Han Lee, Hee Kyung Ahn, Eun Young Kim, Sei Hoon Yang, Myoung Kyu Lee, Deog Gon Cho, Tae Won Jang, Ji Woong Son, Jeong-Seon Ryu, Moon-J
    PLOS ONE.2018; 13(2): e0192626.     CrossRef
  • The Dyadic Effects of Family Cohesion and Communication on Health-Related Quality of Life: The Moderating Role of Sex
    Jung-won Lim, En-jung Shon
    Cancer Nursing.2018; 41(2): 156.     CrossRef
  • Physicians’ attitudes towards the media and peer-review selection of the ‘best cancer doctor’: comparison of two different selection methods
    Dong Wook Shin, Juhee Cho, Hyung Kook Yang, So Young Kim, Soohyeon Lee, Eun Joo Nam, Joo Seop Chung, Jeong-Soo Im, Keeho Park, Jong Hyock Park
    BMJ Open.2018; 8(5): e019067.     CrossRef
  • 10,088 View
  • 91 Download
  • 5 Web of Science
  • 6 Crossref
Close layer
Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
Do-Youn Oh, Se-Hoon Lee, Sae-Won Han, Mi-Jung Kim, Tae-Min Kim, Tae-You Kim, Dae Seog Heo, Miyuki Yuasa, Yasuo Yanagihara, Yung-Jue Bang
Cancer Res Treat. 2015;47(4):607-615.   Published online February 26, 2015
DOI: https://doi.org/10.4143/crt.2014.249
AbstractAbstract PDFPubReaderePub
Purpose
OPB-31121 is an oral STAT3 inhibitor with a good preclinical antitumor activity. This phase I dose-escalation study of OPB-31121 was conducted to determine maximum-tolerated dose (MTD), safety, pharmacokinetics, and preliminary antitumor efficacy in patients with advanced solid tumors. Materials and Methods Patients received OPB-31121 once daily for 28 days of each cycle followed by 2 weeks rest. A standard 3+3 design was used for dose-escalation. Safety and response were evaluated by the National Cancer Institute–Common Terminology Criteria for Adverse Events (NCICTCAE) ver. 3.0 and Response Evaluation Criteria in Solid Tumor (RECIST) ver. 1.0, respectively.
Results
Twenty-five patients were treated with OPB-31121 at five dose levels: 100 mg (n=4), 200 mg (n=3), 400 mg (n=3), 600 mg (n=7), and 800 mg (n=8). Seven patients discontinued treatment during cycle 1 for various reasons other than study drug-related adverse events. Among 18 patients who were evaluable for dose-limiting toxicity (DLT), three DLTs were observed: one DLT (grade 3 vomiting) at 600 mg and two DLTs (grade 3 vomiting, grade 3 diarrhea) at 800 mg. The MTD was determined as 800 mg/day. Common adverse events were gastrointestinal adverse event including nausea (84%), vomiting (80%), and diarrhea (72%). Pharmacokinetics did not demonstrate dose-proportionality of OPB-31121. Eight patients had stable disease and 10 patients had disease progression. Two patients (1 colon cancer, 1 rectal cancer) showed tumor shrinkage. One gastric cancer patient continued treatment up to cycle 13 before disease progression. Conclusion This study demonstrates feasibility of STAT3 inhibition in patients with advanced solid tumor. OPB-31121, at the MTD of 800 mg/day, was safe and relatively well tolerated, and has a preliminary antitumor activity.

Citations

Citations to this article as recorded by  
  • Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery
    Yamei Hu, Zigang Dong, Kangdong Liu
    Journal of Experimental & Clinical Cancer Research.2024;[Epub]     CrossRef
  • Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets
    Greta Pessino, Claudia Scotti, Maristella Maggi
    Cancers.2024; 16(5): 901.     CrossRef
  • Impact of STAT-signaling pathway on cancer-associated fibroblasts in colorectal cancer and its role in immunosuppression
    Damián Sánchez-Ramírez, Mónica G Mendoza-Rodríguez, Omar R Alemán, Fernando A Candanedo-González, Miriam Rodríguez-Sosa, Juan José Montesinos-Montesinos, Mauricio Salcedo, Ismael Brito-Toledo, Felipe Vaca-Paniagua, Luis I Terrazas
    World Journal of Gastrointestinal Oncology.2024; 16(5): 1705.     CrossRef
  • Targeted Treatment against Cancer Stem Cells in Colorectal Cancer
    Julia Martínez-Pérez, Carlos Torrado, María A. Domínguez-Cejudo, Manuel Valladares-Ayerbes
    International Journal of Molecular Sciences.2024; 25(11): 6220.     CrossRef
  • Interleukin-6 serves as a critical factor in various cancer progression and therapy
    Asma’a H. Mohamed, Abdulrahman T. Ahmed, Waleed Al Abdulmonem, Dmitry Olegovich Bokov, Alaa Shafie, Hussein Riyadh Abdul Kareem Al-Hetty, Chou-Yi Hsu, Mohammed Alissa, Shahid Nazir, Mohammad Chand Jamali, Mustafa Mudhafar
    Medical Oncology.2024;[Epub]     CrossRef
  • Targeting cytokine and chemokine signaling pathways for cancer therapy
    Ming Yi, Tianye Li, Mengke Niu, Haoxiang Zhang, Yuze Wu, Kongming Wu, Zhijun Dai
    Signal Transduction and Targeted Therapy.2024;[Epub]     CrossRef
  • Recent advances in targeted drug delivery systems for multiple myeloma
    Ashruti Pant, Aayushi Laliwala, Sarah A. Holstein, Aaron M. Mohs
    Journal of Controlled Release.2024; 376: 215.     CrossRef
  • A strategic review of STAT3 signaling inhibition by phytochemicals for cancer prevention and treatment: Advances and insights
    Suryaa Manoharan, Ekambaram Perumal
    Fitoterapia.2024; 179: 106265.     CrossRef
  • Expression of STAT3, IL27p28 and IL12p35 is deregulated and linked to autoimmune markers in chronic spontaneous urticaria
    Sahar Rastgoo, Mojgan Mohammadi, Marcus Maurer, Mahdi Atabaki, Jalil Tavakkol-Afshari, Maryam Khoshkhui
    Clinical and Experimental Dermatology.2024;[Epub]     CrossRef
  • The STAT family: Key transcription factors mediating crosstalk between cancer stem cells and tumor immune microenvironment
    Mengxuan Zhu, Suyao Li, Xin Cao, Khalid Rashid, Tianshu Liu
    Seminars in Cancer Biology.2023; 88: 18.     CrossRef
  • Dual inhibition of MYC and SLC39A10 by a novel natural product STAT3 inhibitor derived from Chaetomium globosum suppresses tumor growth and metastasis in gastric cancer
    Xiaoqing Guan, Jing Yang, Weiyi Wang, Bing Zhao, Shiyu Hu, Dehua Yu, Li Yuan, Yunfu Shi, Jingli Xu, Jinyun Dong, Jinxin Wang, Xiang-Dong Cheng, Jiang-Jiang Qin
    Pharmacological Research.2023; 189: 106703.     CrossRef
  • JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens
    Qian Hu, Qihui Bian, Dingchao Rong, Leiyun Wang, Jianan Song, Hsuan-Shun Huang, Jun Zeng, Jie Mei, Peng-Yuan Wang
    Frontiers in Bioengineering and Biotechnology.2023;[Epub]     CrossRef
  • Brevilin A is a potent anti-metastatic CRC agent that targets the VEGF-IL6-STAT3 axis in the HSCs-CRC interplay
    Xueying Fan, Mingjing Meng, Baoting Li, Hui Chen, Jincheng Tan, Keyang Xu, Shilin Xiao, Hiu-Yee Kwan, Zhongqiu Liu, Tao Su
    Journal of Translational Medicine.2023;[Epub]     CrossRef
  • Application of Nano-Antibodies for Cancer Immunotherapy
    Sunanda Singh, Samara P. Singh, Ashutosh S. Parihar
    Current Tissue Microenvironment Reports.2023; 4(2): 17.     CrossRef
  • Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies
    Yan-Ruide Li, Ying Fang, Zibai Lyu, Yichen Zhu, Lili Yang
    Journal of Translational Medicine.2023;[Epub]     CrossRef
  • C188-9, a specific inhibitor of STAT3 signaling, prevents thermal burn-induced skeletal muscle wasting in mice
    Yuko Ono, Masafumi Saito, Kazuho Sakamoto, Yuko Maejima, Shingen Misaka, Kenju Shimomura, Nobuto Nakanishi, Shigeaki Inoue, Joji Kotani
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Signaling Pathways and Targeted Therapies for Stem Cells in Prostate Cancer
    Madhuvanthi Giridharan, Vasu Rupani, Satarupa Banerjee
    ACS Pharmacology & Translational Science.2022; 5(4): 193.     CrossRef
  • Insights into the role of STAT3 in intrahepatic cholangiocarcinoma (Review)
    Ranzhiqiang Yang, Yinghui Song, Kashif Shakoor, Weimin Yi, Chuang Peng, Sulai Liu
    Molecular Medicine Reports.2022;[Epub]     CrossRef
  • Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer
    Shumin Ouyang, Huaxuan Li, Linlin Lou, Qiuyao Huang, Zhenhua Zhang, Jianshan Mo, Min Li, Jiaye Lu, Kai Zhu, Yunjie Chu, Wen Ding, Jianzheng Zhu, Ziyou Lin, Lin Zhong, Junjian Wang, Peibin Yue, James Turkson, Peiqing Liu, Yuanxiang Wang, Xiaolei Zhang
    Redox Biology.2022; 52: 102317.     CrossRef
  • Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers
    Yanhong Ni, Jun T. Low, John Silke, Lorraine A. O’Reilly
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • A Broad-Based Characterization of a Cell-Penetrating, Single Domain Camelid Bi-Specific Antibody Monomer That Targets STAT3 and KRAS Dependent Cancers
    Sunanda Singh, Genoveva Murillo, Justin Richner, Samara P. Singh, Erica Berleth, Vijay Kumar, Rajendra Mehta, Vijay Ramiya, Ashutosh S. Parihar
    International Journal of Molecular Sciences.2022; 23(14): 7565.     CrossRef
  • Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy
    Elham Patrad, Solmaz Khalighfard, Taghi Amiriani, Vahid Khori, Ali Mohammad Alizadeh
    Cellular Oncology.2022; 45(6): 1073.     CrossRef
  • STAT3 and Its Targeting Inhibitors in Oral Squamous Cell Carcinoma
    Mingjing Jiang, Bo Li
    Cells.2022; 11(19): 3131.     CrossRef
  • The Role of IL-6 in Cancer Cell Invasiveness and Metastasis—Overview and Therapeutic Opportunities
    Magdalena Rašková, Lukáš Lacina, Zdeněk Kejík, Anna Venhauerová, Markéta Skaličková, Michal Kolář, Milan Jakubek, Daniel Rosel, Karel Smetana, Jan Brábek
    Cells.2022; 11(22): 3698.     CrossRef
  • An update on investigational therapies that target STAT3 for the treatment of cancer
    Matteo Santoni, Francesca Miccini, Alessia Cimadamore, Francesco Piva, Francesco Massari, Liang Cheng, Antonio Lopez-Beltran, Rodolfo Montironi, Nicola Battelli
    Expert Opinion on Investigational Drugs.2021; 30(3): 245.     CrossRef
  • RETRACTED: GATA4 Regulates Inflammation-Driven Pancreatic Ductal Adenocarcinoma Progression
    Weiliang Jiang, Congying Chen, Li Huang, Jie Shen, Lijuan Yang
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • Phytochemicals Targeting JAK–STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models
    Sun Young Moon, Kwang Dong Kim, Jiyun Yoo, Jeong-Hyung Lee, Cheol Hwangbo
    Molecules.2021; 26(9): 2824.     CrossRef
  • Development and Validation of an IL6/JAK/STAT3-Related Gene Signature to Predict Overall Survival in Clear Cell Renal Cell Carcinoma
    Chuanchuan Zhan, Chao Xu, Jiajun Chen, Chong Shen, Jinkun Li, Zichu Wang, Xiangrong Ying, Zhengang Luo, Yu Ren, Gangfeng Wu, Haojie Zhang, Manfei Qian
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • Emerging role of signal transducer and activator of transcription 3 (STAT3) in pituitary adenomas
    Cyndy Liu, Tae Nakano-Tateno, Motoyasu Satou, Constance Chik, Toru Tateno
    Endocrine Journal.2021; 68(10): 1143.     CrossRef
  • The JAK/STAT signaling pathway: from bench to clinic
    Xiaoyi Hu, Jing li, Maorong Fu, Xia Zhao, Wei Wang
    Signal Transduction and Targeted Therapy.2021;[Epub]     CrossRef
  • Interleukin-6 and colorectal cancer development
    I.А. Hromakova, P.P. Sorochan, N.E. Prokhach, I.S. Hromakova
    Український радіологічний та онкологічний журнал.2021; 29(4): 89.     CrossRef
  • Ailanthone suppresses the activity of human colorectal cancer cells through the STAT3 signaling pathway
    Haixiang Ding, Xiuchong Yu, Zhilong Yan
    International Journal of Molecular Medicine.2021;[Epub]     CrossRef
  • Radiation induces an inflammatory response that results in STAT3-dependent changes in cellular plasticity and radioresistance of breast cancer stem-like cells
    Kimberly M. Arnold, Lynn M. Opdenaker, Nicole J. Flynn, Daniel Kwesi Appeah, Jennifer Sims-Mourtada
    International Journal of Radiation Biology.2020; 96(4): 434.     CrossRef
  • Quinazoline Ligands Induce Cancer Cell Death through Selective STAT3 Inhibition and G-Quadruplex Stabilization
    Jan Jamroskovic, Mara Doimo, Karam Chand, Ikenna Obi, Rajendra Kumar, Kristoffer Brännström, Mattias Hedenström, Rabindra Nath Das, Almaz Akhunzianov, Marco Deiana, Kazutoshi Kasho, Sebastian Sulis Sato, Parham L. Pourbozorgi, James E. Mason, Paolo Medini
    Journal of the American Chemical Society.2020; 142(6): 2876.     CrossRef
  • Phosphotyrosine isosteres: past, present and future
    Robert A. Cerulli, Joshua A. Kritzer
    Organic & Biomolecular Chemistry.2020; 18(4): 583.     CrossRef
  • Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1
    Hai Zhang, Yu-ping Tan, Lin Zhao, Lun Wang, Nai-jie Fu, Song-ping Zheng, Xiao-fei Shen
    Cell Death & Disease.2020;[Epub]     CrossRef
  • JAK/STAT signaling in hepatocellular carcinoma
    Justin Jit Hin Tang, Dexter Kai Hao Thng, Jhin Jieh Lim, Tan Boon Toh
    Hepatic Oncology.2020;[Epub]     CrossRef
  • JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
    Azucena Salas, Cristian Hernandez-Rocha, Marjolijn Duijvestein, William Faubion, Dermot McGovern, Severine Vermeire, Stefania Vetrano, Niels Vande Casteele
    Nature Reviews Gastroenterology & Hepatology.2020; 17(6): 323.     CrossRef
  • Targeting STAT3 in cancer and autoimmune diseases
    Tohid Gharibi, Zohreh Babaloo, Arezoo Hosseini, Meghdad Abdollahpour-alitappeh, Vida Hashemi, Faroogh Marofi, Kazem Nejati, Behzad Baradaran
    European Journal of Pharmacology.2020; 878: 173107.     CrossRef
  • Betacellulin drives therapy resistance in glioblastoma
    Qiwen Fan, Zhenyi An, Robyn A Wong, Xujun Luo, Edbert D Lu, Albert Baldwin, Manasi K Mayekar, Franziska Haderk, Kevan M Shokat, Trever G Bivona, William A Weiss
    Neuro-Oncology.2020; 22(4): 457.     CrossRef
  • A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction
    Soo Kyung Park, Woong Sub Byun, Seungbeom Lee, Young Taek Han, Yoo-Seong Jeong, Kyungkuk Jang, Suk-Jae Chung, Jeeyeon Lee, Young-Ger Suh, Sang Kook Lee
    Biochemical Pharmacology.2020; 178: 114053.     CrossRef
  • STAT3 Pathway in Gastric Cancer: Signaling, Therapeutic Targeting and Future Prospects
    Milad Ashrafizadeh, Ali Zarrabi, Sima Orouei, Vahideh Zarrin, Ebrahim Rahmani Moghadam, Amirhossein Zabolian, Shima Mohammadi, Kiavash Hushmandi, Yashar Gharehaghajlou, Pooyan Makvandi, Masoud Najafi, Reza Mohammadinejad
    Biology.2020; 9(6): 126.     CrossRef
  • Towards the Inhibition of Protein–Protein Interactions (PPIs) in STAT3: Insights into a New Class of Benzothiadiazole Derivatives
    Matteo Mori, Ettore Gilardoni, Luca Regazzoni, Alessandro Pedretti, Diego Colombo, Gary Parkinson, Akira Asai, Fiorella Meneghetti, Stefania Villa, Arianna Gelain
    Molecules.2020; 25(15): 3509.     CrossRef
  • STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy
    Ping-Lian Yang, Lu-Xin Liu, En-Min Li, Li-Yan Xu
    Cancers.2020; 12(9): 2459.     CrossRef
  • Progress in Understanding the IL-6/STAT3 Pathway in Colorectal Cancer


    Yan Lin, Ziqin He, Jiazhou Ye, Ziyu Liu, Xiaomin She, Xing Gao, Rong Liang
    OncoTargets and Therapy.2020; Volume 13: 13023.     CrossRef
  • Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes
    Chen-Hao Zhang, Ming Li, You-Pei Lin, Qiang Gao
    Current Gene Therapy.2020; 20(2): 84.     CrossRef
  • Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma
    Yung-Hsing Huang, Mohammad Reza Vakili, Ommoleila Molavi, Yuen Morrissey, Chengsheng Wu, Igor Paiva, Amir Hasan Soleimani, Forugh Sanaee, Afsaneh Lavasanifar, Raymond Lai
    Cancers.2019; 11(2): 248.     CrossRef
  • Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
    Changhoon Yoo, Jihoon Kang, Ho Yeong Lim, Jee Hyun Kim, Myung-Ah Lee, Kyung-Hun Lee, Tae-You Kim, Baek-Yeol Ryoo
    Cancer Research and Treatment.2019; 51(2): 510.     CrossRef
  • IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2
    Xiaodong Chen, Feng Chen, Yu Ren, Guobin Weng, Lijun Xu, Xiang Xue, Peter C. Keng, Soo Ok Lee, Yuhchyau Chen
    Journal of Cancer Research and Clinical Oncology.2019; 145(6): 1471.     CrossRef
  • Proton pump inhibitor: The dual role in gastric cancer
    Moon Kyung Joo, Jong-Jae Park, Hoon Jai Chun
    World Journal of Gastroenterology.2019; 25(17): 2058.     CrossRef
  • Transcriptional Reprogramming and Novel Therapeutic Approaches for Targeting Prostate Cancer Stem Cells
    Gianluca Civenni, Domenico Albino, Dheeraj Shinde, Ramiro Vázquez, Jessica Merulla, Aleksandra Kokanovic, Sarah N. Mapelli, Giuseppina M. Carbone, Carlo V. Catapano
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
    Jiang-Jiang Qin, Li Yan, Jia Zhang, Wei-Dong Zhang
    Journal of Experimental & Clinical Cancer Research.2019;[Epub]     CrossRef
  • JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors
    Emily A. Irey, Chelsea M. Lassiter, Nicholas J. Brady, Pavlina Chuntova, Ying Wang, Todd P. Knutson, Christine Henzler, Thomas S. Chaffee, Rachel I. Vogel, Andrew C. Nelson, Michael A. Farrar, Kathryn L. Schwertfeger
    Proceedings of the National Academy of Sciences.2019; 116(25): 12442.     CrossRef
  • Elevated HOX gene expression in acute myeloid leukemia is associated with NPM1 mutations and poor survival
    Ádám Nagy, Ágnes Ősz, Jan Budczies, Szilvia Krizsán, Gergely Szombath, Judit Demeter, Csaba Bödör, Balázs Győrffy
    Journal of Advanced Research.2019; 20: 105.     CrossRef
  • Antitumor activity of novel pyrazole-based small molecular inhibitors of the STAT3 pathway in patient derived high grade glioma cells
    Liang Zhang, Timothy E. Peterson, Victor M. Lu, Ian F. Parney, David J. Daniels, Ilya Ulasov
    PLOS ONE.2019; 14(7): e0220569.     CrossRef
  • Inhibition of Stat3 Signaling Pathway by Natural Product Pectolinarigenin Attenuates Breast Cancer Metastasis
    Yali Li, Cailing Gan, Yange Zhang, Yan Yu, Chen Fan, Yuanle Deng, Qianyu Zhang, Xi Yu, Yiwen Zhang, Liqun Wang, Fang He, Yongmei Xie, Tinghong Ye, Wenya Yin
    Frontiers in Pharmacology.2019;[Epub]     CrossRef
  • Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status
    Tadashi Ashizawa, Akira Iizuka, Chie Maeda, Emiko Tanaka, Ryota Kondou, Haruo Miyata, Takashi Sugino, Takuya Kawata, Shoichi Deguchi, Koichi Mitsuya, Nakamasa Hayashi, Akira Asai, Mamoru Ito, Ken Yamaguchi, Yasuto Akiyama
    Immunology Letters.2019; 216: 43.     CrossRef
  • Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents
    Arianna Gelain, Matteo Mori, Fiorella Meneghetti, Stefania Villa
    Current Medicinal Chemistry.2019; 26(27): 5165.     CrossRef
  • The effects of signal transducer and activator of transcription three mutations on human platelets
    Floor E. Aleva, Frank L. van de Veerdonk, Yang Li, Rahajeng N. Tunjungputri, Sami Simons, Philip G. De Groot, Mihai M. Netea, Yvonne F. Heijdra, Quirijn de Mast, André J.A.M. van der Ven
    Platelets.2018; 29(6): 602.     CrossRef
  • Mechanisms Linking Obesity and Thyroid Cancer Development and Progression in Mouse Models
    Won Gu Kim, Sheue-yann Cheng
    Hormones and Cancer.2018; 9(2): 108.     CrossRef
  • Targeting the IL-6/JAK/STAT3 signalling axis in cancer
    Daniel E. Johnson, Rachel A. O'Keefe, Jennifer R. Grandis
    Nature Reviews Clinical Oncology.2018; 15(4): 234.     CrossRef
  • Arsenic trioxide attenuates STAT-3 activity and epithelial-mesenchymal transition through induction of SHP-1 in gastric cancer cells
    Sung Ho Kim, Hyo Soon Yoo, Moon Kyung Joo, Taehyun Kim, Jong-Jae Park, Beom Jae Lee, Hoon Jai Chun, Sang Woo Lee, Young-Tae Bak
    BMC Cancer.2018;[Epub]     CrossRef
  • Linker Variation and Structure–Activity Relationship Analyses of Carboxylic Acid-based Small Molecule STAT3 Inhibitors
    Francisco Lopez-Tapia, Christine Brotherton-Pleiss, Peibin Yue, Heide Murakami, Ana Carolina Costa Araujo, Bruna Reis dos Santos, Erin Ichinotsubo, Anna Rabkin, Raj Shah, Megan Lantz, Suzie Chen, Marcus A. Tius, James Turkson
    ACS Medicinal Chemistry Letters.2018; 9(3): 250.     CrossRef
  • Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy
    Mario M. Soldevilla, Fernando Pastor
    Molecular Therapy.2018; 26(3): 675.     CrossRef
  • Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?
    Jenny D. Beebe, Jing-Yuan Liu, Jian-Ting Zhang
    Pharmacology & Therapeutics.2018; 191: 74.     CrossRef
  • Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs
    Massimo Gadina, Catrina Johnson, Daniella Schwartz, Michael Bonelli, Sarfaraz Hasni, Yuka Kanno, Paul Changelian, Arian Laurence, John J O’Shea
    Journal of Leukocyte Biology.2018; 104(3): 499.     CrossRef
  • Targeting JAK-STAT signal transduction in IBD
    Christoffer Soendergaard, Fredrik Holmberg Bergenheim, Jakob Tveiten Bjerrum, Ole Haagen Nielsen
    Pharmacology & Therapeutics.2018; 192: 100.     CrossRef
  • “Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
    Emira Bousoik, Hamidreza Montazeri Aliabadi
    Frontiers in Oncology.2018;[Epub]     CrossRef
  • Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance
    Megha Budhwani, Roberta Mazzieri, Riccardo Dolcetti
    Frontiers in Oncology.2018;[Epub]     CrossRef
  • STAT3 in Breast Cancer Onset and Progression: A Matter of Time and Context
    Ilenia Segatto, Gustavo Baldassarre, Barbara Belletti
    International Journal of Molecular Sciences.2018; 19(9): 2818.     CrossRef
  • Suppression of STAT3 signaling promotes cellular reprogramming into insulin-producing cells induced by defined transcription factors
    Masaki Miura, Takeshi Miyatsuka, Takehiro Katahira, Shugo Sasaki, Luka Suzuki, Miwa Himuro, Yuya Nishida, Yoshio Fujitani, Taka-aki Matsuoka, Hirotaka Watada
    EBioMedicine.2018; 36: 358.     CrossRef
  • Aptamer-iRNAs as Therapeutics for Cancer Treatment
    Mario M. Soldevilla, Daniel Meraviglia-Crivelli de Caso, Ashwathi P. Menon, Fernando Pastor
    Pharmaceuticals.2018; 11(4): 108.     CrossRef
  • A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
    Anthony Tolcher, Keith Flaherty, Geoffrey I. Shapiro, Jordan Berlin, Thomas Witzig, Thomas Habermann, Andrea Bullock, Edwin Rock, Agnes Elekes, Chester Lin, Dusan Kostic, Naoto Ohi, Drew Rasco, Kyriakos P. Papadopoulos, Amita Patnaik, Lon Smith, Gregory M
    The Oncologist.2018; 23(6): 658.     CrossRef
  • Impact of STAT3 phosphorylation in glioblastoma stem cells radiosensitization and patient outcome
    Konstantin Masliantsev, Baptiste Pinel, Anaïs Balbous, Pierre-Olivier Guichet, Gaëlle Tachon, Serge Milin, Julie Godet, Mathilde Duchesne, Antoine Berger, Christos Petropoulos, Michel Wager, Lucie Karayan-Tapon
    Oncotarget.2018; 9(3): 3968.     CrossRef
  • Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking
    Wenying Yu, Chenglong Li, Wenda Zhang, Yuanzheng Xia, Shanshan Li, Jia-yuh Lin, Keqin Yu, Mu Liu, Lei Yang, Jianguang Luo, Yijun Chen, Hongbin Sun, Lingyi Kong
    Journal of Medicinal Chemistry.2017; 60(7): 2718.     CrossRef
  • Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic
    Fenil Shah, Derek Logsdon, Richard A. Messmann, Jill C. Fehrenbacher, Melissa L. Fishel, Mark R. Kelley
    npj Precision Oncology.2017;[Epub]     CrossRef
  • Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells
    Davide Genini, Lara Brambilla, Erik Laurini, Jessica Merulla, Gianluca Civenni, Shusil Pandit, Rocco D'Antuono, Laurent Perez, David E. Levy, Sabrina Pricl, Giuseppina M. Carbone, Carlo V. Catapano
    Proceedings of the National Academy of Sciences.2017;[Epub]     CrossRef
  • Identification of novel small molecules that inhibit STAT3-dependent transcription and function
    Iryna Kolosenko, Yasmin Yu, Sander Busker, Matheus Dyczynski, Jianping Liu, Martin Haraldsson, Caroline Palm Apergi, Thomas Helleday, Katja Pokrovskaja Tamm, Brent D. G. Page, Dan Grander, Aamir Ahmad
    PLOS ONE.2017; 12(6): e0178844.     CrossRef
  • Antineoplastic effects of CPPTL via the ROS/JNK pathway in acute myeloid leukemia
    Hui-Er Gao, Yue Sun, Ya-Hui Ding, Jing Long, Xiao-Lei Liu, Ming Yang, Qing Ji, Ying-Hui Li, Yue Chen, Quan Zhang, Ying-Dai Gao
    Oncotarget.2017; 8(24): 38990.     CrossRef
  • Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation
    Verena Leidgens, Judith Proske, Lisa Rauer, Sylvia Moeckel, Kathrin Renner, Ulrich Bogdahn, Markus J. Riemenschneider, Martin Proescholdt, Arabel Vollmann-Zwerenz, Peter Hau, Corinna Seliger
    Oncotarget.2017; 8(5): 8250.     CrossRef
  • Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug
    Yu Dong, Takuya Furuta, Hemragul Sabit, Tomohiro Kitabayashi, Shabierjiang Jiapaer, Masahiko Kobayashi, Yasushi Ino, Tomoki Todo, Lei Teng, Atsushi Hirao, Shi-Guang Zhao, Mitsutoshi Nakada
    Oncotarget.2017; 8(67): 111728.     CrossRef
  • Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism
    Chengguang Zhao, Huameng Li, Huey-Jen Lin, Shulin Yang, Jiayuh Lin, Guang Liang
    Trends in Pharmacological Sciences.2016; 37(1): 47.     CrossRef
  • Targeting transcription factor STAT3 for cancer prevention and therapy
    Edna Zhi Pei Chai, Muthu K. Shanmugam, Frank Arfuso, Arunasalam Dharmarajan, Chao Wang, Alan Prem Kumar, Ramar Perumal Samy, Lina H.K. Lim, Lingzhi Wang, Boon Cher Goh, Kwang Seok Ahn, Kam Man Hui, Gautam Sethi
    Pharmacology & Therapeutics.2016; 162: 86.     CrossRef
  • Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma
    Chiara Lazzari, Alberto Verlicchi, Anastasios Gkountakos, Sara Pilotto, Mariacarmela Santarpia, Imane Chaib, Jose Luis Ramirez Serrano, Santiago Viteri, Daniela Morales-Espinosa, Claudio Dazzi, Filippo de Marinis, Peng Cao, Niki Karachaliou, Rafael Rosell
    Pulmonary Therapy.2016; 2(1): 1.     CrossRef
  • Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer
    Zilma Escobar, Anders Bjartell, Giacomo Canesin, Susan Evans-Axelsson, Olov Sterner, Rebecka Hellsten, Martin H Johansson
    Journal of Medicinal Chemistry.2016; 59(10): 4551.     CrossRef
  • A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer
    Andres Rojas, Pingyu Zhang, Ying Wang, Wai Chin Foo, Nina M. Muñoz, Lianchun Xiao, Jing Wang, Gregory J. Gores, Mien-Chie Hung, Boris Blechacz
    Neoplasia.2016; 18(6): 371.     CrossRef
  • Novel STAT 3 inhibitors for treating gastric cancer
    Catherine Cafferkey, Ian Chau
    Expert Opinion on Investigational Drugs.2016; 25(9): 1023.     CrossRef
  • ‘Acute myeloid leukemia: a comprehensive review and 2016 update’
    I De Kouchkovsky, M Abdul-Hay
    Blood Cancer Journal.2016; 6(7): e441.     CrossRef
  • Recent updates of precision therapy for gastric cancer: Towards optimal tailored management
    Moon Kyung Joo, Jong-Jae Park, Hoon Jai Chun
    World Journal of Gastroenterology.2016; 22(19): 4638.     CrossRef
  • Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease
    Malgorzata Szelag, Anna Piaszyk-Borychowska, Martyna Plens-Galaska, Joanna Wesoly, Hans A.R. Bluyssen
    Oncotarget.2016; 7(30): 48788.     CrossRef
  • Cell-cell and cell-matrix adhesion in survival and metastasis: Stat3 versus Akt
    Maximilian Niit, Victoria Hoskin, Esther Carefoot, Mulu Geletu, Rozanne Arulanandam, Bruce Elliott, Leda Raptis
    Biomolecular Concepts.2015; 6(5-6): 383.     CrossRef
  • Phase 1 and pharmacological trial of OPB‐31121, a signal transducer and activator of transcription‐3 inhibitor, in patients with advanced hepatocellular carcinoma
    Takuji Okusaka, Hideki Ueno, Masafumi Ikeda, Shuichi Mitsunaga, Masato Ozaka, Hiroshi Ishii, Osamu Yokosuka, Yoshihiko Ooka, Ryo Yoshimoto, Yasuo Yanagihara, Kiwamu Okita
    Hepatology Research.2015; 45(13): 1283.     CrossRef
  • STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells
    Heng Yang, Takahiro Yamazaki, Federico Pietrocola, Heng Zhou, Laurence Zitvogel, Yuting Ma, Guido Kroemer
    Cancer Research.2015; 75(18): 3812.     CrossRef
  • 18,239 View
  • 250 Download
  • 90 Web of Science
  • 93 Crossref
Close layer
Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial
Dae Ho Lee, Jung Shin Lee, Jie Wang, Te-Chun Hsia, Xin Wang, Jongseok Kim, Mauro Orlando
Cancer Res Treat. 2015;47(4):616-629.   Published online November 24, 2014
DOI: https://doi.org/10.4143/crt.2014.051
AbstractAbstract PDFPubReaderePub
Purpose
This subgroup analysis of a phase II trial was conducted to assess possible ethnicity-based trends in efficacy and safety in East Asian (EA) and non-EA populations with nonsquamous non-small cell lung cancer (NSCLC).
Materials and Methods
Never-smoker patients (n=240) with locally advanced or metastatic nonsquamous NSCLC included 133 EA patients randomized to pemetrexed supplemented with dexamethasone, folic acid, and vitamin B12 plus erlotinib (pemetrexed-erlotinib) (n=41), erlotinib (n=49), or pemetrexed (n=43), and 107 non-EA patients randomized to pemetrexed-erlotinib (n=37), erlotinib (n=33), or pemetrexed (n=37). The primary endpoint, progression-free survival (PFS), was analyzed using a multivariate Cox model.
Results
Consistent with the results of the overall study, a statistically significant difference in PFS among the three arms was noted in the EA population favoring pemetrexed-erlotinib (overall p=0.003) as compared with either single-agent arm (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.29 to 0.79; p=0.004 vs. erlotinib; HR, 0.40; 95% CI, 0.23 to 0.70; p=0.001 vs. pemetrexed). The EA patients treated with pemetrexed-erlotinib achieved a longer median PFS (7.4 months) compared with erlotinib (4.5 months) and pemetrexed (4.0 months). The PFS results also numerically favored pemetrexed-erlotinib in the non-EA population (overall p=0.210) (HR, 0.62; 95% CI, 0.37 to 1.05; p=0.078 vs. erlotinib; HR, 0.75; 95% CI, 0.42 to 1.32; p=0.320 vs. pemetrexed) (median PFS: pemetrexed-erlotinib, 6.7 months; erlotinib, 3.0 months; pemetrexed, 4.4 months).
Conclusion
The PFS results from this subset analysis in both EA and non-EA populations are consistent with the results in the overall population. The PFS advantage for pemetrexed-erlotinib is significant compared with the single agents in EA patients.

Citations

Citations to this article as recorded by  
  • Association of Hypokalemia Incidence and Better Treatment Response in NSCLC Patients: A Meta-Analysis and Systematic Review on Anti-EGFR Targeted Therapy Clinical Trials
    Jiawei Zhou, Jianling Bai, Yuanping Yue, Xin Chen, Theis Lange, Dongfang You, Yang Zhao
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Non-Smoking-Associated Lung Cancer: A distinct Entity in Terms of Tumor Biology, Patient Characteristics and Impact of Hereditary Cancer Predisposition
    Elisabeth Smolle, Martin Pichler
    Cancers.2019; 11(2): 204.     CrossRef
  • Pemetrexed versus Gefitinib as Second-line Treatment for Advanced Non-small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials
    Huiyu Wang, Zunjing Zhang, Feng Liu, Miaoying Zhou, Handi Lv
    Pteridines.2019; 30(1): 171.     CrossRef
  • A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer
    James Chih-Hsin Yang, Tony Mok, Baohui Han, Mauro Orlando, Tarun Puri, Keunchil Park
    Clinical Lung Cancer.2018; 19(1): 27.     CrossRef
  • Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer
    Tianhong Li, Bilal Piperdi, William V. Walsh, Mimi Kim, Laurel A. Beckett, Rasim Gucalp, Missak Haigentz, Venu G. Bathini, Huiyu Wen, Kaili Zhou, Patricia B. Pasquinelli, Srikanth Gajavelli, Meera Sreedhara, Xianhong Xie, Primo N. Lara, David R. Gandara,
    Clinical Lung Cancer.2017; 18(1): 60.     CrossRef
  • Erlotinib intercalating pemetrexed/cisplatin versus erlotinib alone in Chinese patients with brain metastases from lung adenocarcinoma: a prospective, non-randomised, concurrent controlled trial (NCT01578668)
    Haihong Yang, Qiuhua Deng, Yuan Qiu, Jun Huang, Yubao Guan, Fengnan Wang, Xin Xu, Xinyun Yang
    ESMO Open.2017; 2: e000112.     CrossRef
  • Gene mutation discovery research of non-smoking lung cancer patients due to indoor radon exposure
    Jung Ran Choi, Seong Yong Park, O Kyu Noh, Young Wha Koh, Dae Ryong Kang
    Annals of Occupational and Environmental Medicine.2016;[Epub]     CrossRef
  • Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned
    Dae Ho Lee, Vichien Srimuninnimit, Rebecca Cheng, Xin Wang, Mauro Orlando
    Cancer Research and Treatment.2015; 47(4): 549.     CrossRef
  • 12,496 View
  • 136 Download
  • 8 Crossref
Close layer
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
Sehhoon Park, Bhumsuk Keam, Se Hyun Kim, Ki Hwan Kim, Yu Jung Kim, Jin-Soo Kim, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Jong Seok Lee, Dae Seog Heo
Cancer Res Treat. 2015;47(4):630-637.   Published online February 16, 2015
DOI: https://doi.org/10.4143/crt.2014.244
AbstractAbstract PDFPubReaderePub
Purpose
Platinum-based doublet chemotherapy is the treatment of choice for patients with non-small cell lung cancer (NSCLC); however, the role of a platinum-based doublet as second-line therapy after failure of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for NSCLC patients has not yet been elucidated. The purpose of this study was to compare the clinical efficacy of pemetrexed versus a platinum-based doublet as second-line therapy after failure of EGFR TKI used as first-line therapy for NSCLC patients with EGFR mutations. Materials and Methods We designed a multicenter retrospective cohort study of 314 NSCLC patients with EGFR mutations who received an EGFR TKI as first-line palliative chemotherapy. Our analysis included 83 patients who failed EGFR TKI therapy and received second-line cytotoxic chemotherapy.
Results
Forty-six patients were treated using a platinum-based doublet and 37 patients were treated using singlet pemetrexed. The overall response rates of patients receiving a platinum-based doublet and patients receiving pemetrexed were17.4% and 32.4%, respectively (p=0.111). The median progression-free survival (PFS) of patients receiving pemetrexed was significantly longer than that of patients receiving a platinum-based doublet (4.2 months vs. 2.7 months, respectively; p=0.008). The hazard ratio was 0.54 (95% confidence interval, 0.34 to 0.86; p=0.009). Conclusion Our retrospective analysis found that second-line pemetrexed singlet therapy provided significantly prolonged PFS compared to second-line platinum-based doublet chemotherapy for NSCLC patients with EGFRmutations who failed first-line EGFR TKI. Conduct of prospective studies for confirmation of our results is warranted.

Citations

Citations to this article as recorded by  
  • Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer
    Gee-Chen Chang, Jin-Yuan Shih, Chong-Jen Yu, Heng-Sheng Chao, Cheng-Ta Yang, Chien-Chung Lin, Jen-Yu Hung, Sheng-Yen Hsiao, Chin-Chou Wang, Chih-Feng Chian, Te-Chun Hsia, Yuh-Min Chen, Chien-Feng Li
    PLOS ONE.2024; 19(5): e0303046.     CrossRef
  • Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
    Miso Kim, Soyeon Kim, Jeemin Yim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Dae Seog Heo
    Cancer Research and Treatment.2023; 55(4): 1134.     CrossRef
  • A meta-analysis of the safety and effectiveness of pemetrexed compared with gefitinib for pre-treated advanced or metastatic NSCLC
    Xiaoxin Lu, Shengshu Li, Weizong Chen, Dongyang Zheng, Yuzhu Li, Fang Li
    Medicine.2020; 99(29): e21170.     CrossRef
  • A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line
    Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, Ki Hyeong Lee, Keon Uk Park, Ki Hwan Kim, Eun Kyung Cho, Yoon Hee Choi, Hye Ryun Kim, Hoon-Gu Kim, Heui June Ahn, Ha Yeon Lee, Hwan Jung Yun, Jin-Hyoung Kang, Jaeheon Jeong, Moon Young Choi, Sin-Ho Jung, Jong-Mu Sun,
    Cancer Research and Treatment.2019; 51(2): 718.     CrossRef
  • Overexpression of PTEN may increase the effect of pemetrexed on A549 cells via inhibition of the PI3K/AKT/mTOR pathway and carbohydrate metabolism
    Bo Li, Junkai Zhang, Ya Su, Yiling Hou, Zhenguo Wang, Lin Zhao, Shengkai Sun, Hao Fu
    Molecular Medicine Reports.2019;[Epub]     CrossRef
  • Pemetrexed versus Gefitinib as Second-line Treatment for Advanced Non-small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials
    Huiyu Wang, Zunjing Zhang, Feng Liu, Miaoying Zhou, Handi Lv
    Pteridines.2019; 30(1): 171.     CrossRef
  • Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis
    Kathleen M. Aguilar, Katherine B. Winfree, Catherine E. Muehlenbein, Yajun Emily Zhu, Thomas Wilson, Stewart Wetmore, Eric S. Nadler
    Advances in Therapy.2018; 35(11): 1905.     CrossRef
  • The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
    Hyungjin Kim, Chang Min Park, Bhumsuk Keam, Sang Joon Park, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Jin Mo Goo, Fan Yang
    PLOS ONE.2017; 12(11): e0187500.     CrossRef
  • Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature
    Caicun Zhou, Luan Di Yao
    Journal of Thoracic Oncology.2016; 11(2): 174.     CrossRef
  • Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer
    Federico Cappuzzo, Alessandro Morabito, Nicola Normanno, Paolo Bidoli, Alessandro Del Conte, Laura Giannetta, Agnese Montanino, Francesca Mazzoni, Roberta Buosi, Marco Angelo Burgio, Giulio Cerea, Rita Chiari, Diego Cortinovis, Giovanna Finocchiaro, Luisa
    Lung Cancer.2016; 99: 31.     CrossRef
  • Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options
    Jordi Remon, Benjamin Besse
    ESMO Open.2016; 1(4): e000081.     CrossRef
  • Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs
    Su Jin Lee, Jong-Mu Sun, Se Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
    Lung Cancer.2015; 90(2): 261.     CrossRef
  • 14,691 View
  • 163 Download
  • 22 Web of Science
  • 12 Crossref
Close layer
The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
Ik-Chan Song, Hyo-Jin Lee, Young-Jun Yang, Yoon-Seok Choi, Hye-Won Ryu, Myung-Won Lee, Ji Young Moon, Deog-Yeon Jo, Samyong Kim, Hwan-Jung Yun
Cancer Res Treat. 2015;47(4):638-644.   Published online March 2, 2015
DOI: https://doi.org/10.4143/crt.2014.316
AbstractAbstract PDFPubReaderePub
Purpose
There is no regimen that is strongly recommended for more than second-line treatment. We investigated the efficacy and safety of platinum/vinorelbine as more than second-line treatment. Materials and Methods We selected patients with advanced non-small cell lung cancer (NSCLC) who received treatment with platinum/vinorelbine at Chungnam National University Hospital from August 2001 to December 2013. The primary end point was the response rate, and secondary end points were progression-free survival (PFS), overall survival (OS), and toxicity.
Results
Thirty-five patients were enrolled. Response rate was 22.9% (complete response, 0 patients [0%]; partial response, eight patients [22.9%]; stable disease, 10 patients [28.6%]; progressive disease, 14 patients [40.0%]). A significantly higher response rate was observed for patients who had responded to previous chemotherapy than for those who did not (34.8% [8/23] vs. 0% [0/12], p=0.020). The median PFS was 4 months (range, 1 to 21 months). Patients with adenocarcinoma and non-smokers had a significantly longer PFS than patients with non-adenocarcinoma and smokers (5 months vs. 2 months, p=0.007; 4.5 months vs. 2 months, p=0.046, respectively). The median OS was 10 months (range, 1 to 41 months). Patients with good performance status and non-smokers had a significantly longer OS than patients with poor performance status and smokers (14 months vs. 4 months, p=0.02; 18.5 months vs. 6 months, p=0.049, respectively). The main serious adverse event (grade 3 or 4) was neutropenia (15 events, 13.3%) in a total of 113 cycles. Conclusion Platinum/vinorelbine was effective as more than second-line chemotherapy, and the toxicity was tolerable, in patients with advanced NSCLC.
  • 11,888 View
  • 60 Download
Close layer
Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer
Jae Myoung Noh, Yong Chan Ahn, Hyebin Lee, Hongryull Pyo, BoKyong Kim, Dongryul Oh, Hyojung Park, Eonju Lee, Keunchil Park, Jin Seok Ahn, Myung-Ju Ahn, Jong-Mu Sun
Cancer Res Treat. 2015;47(4):645-652.   Published online February 12, 2015
DOI: https://doi.org/10.4143/crt.2014.144
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted to evaluate the treatment outcomes following definitive bimodality concurrent chemoradiotherapy (CCRT) in patients with inoperable N2-positive stage IIIA (N2- IIIA) non-small cell lung cancer (NSCLC). Materials and Methods From May 1997 to December 2012, 65 out of 633 patients with N2-IIIA NSCLC received bimodality therapy. The treatment modality was selected during/after neoadjuvant CCRT in 21 patients or primarily at diagnosis in 44 through a multidisciplinary consensus meeting. The median age was 65 years (range, 36 to 76 years). Sixty patients (92.3%) had clinically evident N2 disease, while 22 (33.8%) had multi-station N2 involvement. The median radiation therapy dose was 66 Gy in 33 fractions, while the dose was elevated to 72 Gy in 13 patients who had a treatment break due to delayed decision regarding resectability. The most frequent chemotherapy regimen was weekly paclitaxel or docetaxel plus cisplatin or carboplatin (54, 83.1%).
Results
During the median follow-up of 18.8 months (range, 1.6 to 173.1 months), 34 patients (52.3%) experienced disease progression, with distant metastasis being the most common first treatment failure pattern (23, 34.8%). The median and 2-year rates of progression-free survival were 18.8 months and 45.9%, respectively. The median and 2-year rates of overall survival were 28.6 months and 50.1%, respectively. Conclusion Definitive bimodality therapy in patients with N2-IIIA NSCLC demonstrated favorable outcomes, while trimodality therapy could be considered for candidates for less than pneumonectomy.

Citations

Citations to this article as recorded by  
  • Toxicity of Proton Therapy versus Photon Therapy on Salvage Re-Irradiation for Non-Small Cell Lung Cancer
    Kyungmi Yang, Yang-Gun Suh, Hyunju Shin, Hongryull Pyo, Sung Ho Moon, Yong Chan Ahn, Dongryul Oh, Eunah Chung, Kwanghyun Jo, Jae Myoung Noh
    Life.2022; 12(2): 292.     CrossRef
  • Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer
    Hyunju Shin, Jae Myoung Noh, Hongryull Pyo, Yong Chan Ahn, Dongryul Oh
    Radiation Oncology Journal.2021; 39(1): 24.     CrossRef
  • Experiences of patients with lung cancer receiving concurrent chemo-radiotherapy
    Choi Eunsook, Park Sunhee
    Clinical Journal of Nursing Care and Practice.2021; 5(1): 015.     CrossRef
  • Prognostic significance of tumor poliovirus receptor and CTLA4 expression in patients with surgically resected non-small-cell lung cancer
    Hui You, Yi-Zhong Zhang, Huan-Ling Lai, Dan Li, Yu-Quan Liu, Run-Ze Li, Imran Khan, Wendy Wen-Lun Hsiao, Fu-Gang Duan, Xing-Xing Fan, Xiao-Jun Yao, Ya-Bing Cao, Qi-Biao Wu, Elaine Lai-Han Leung, Mei-Fang Wang
    Journal of Cancer Research and Clinical Oncology.2020; 146(6): 1441.     CrossRef
  • Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study
    Liwen Xiong, Rong Li, Jiayuan Sun, Yuqing Lou, Weiyan Zhang, Hao Bai, Huiming Wang, Jie Shen, Bo Jing, Chunlei Shi, Hua Zhong, Aiqin Gu, Liyan Jiang, Jianxing Shi, Wentao Fang, Heng Zhao, Jie Zhang, Junyuan Wang, Junyi Ye, Baohui Han
    The Oncologist.2019; 24(2): 157.     CrossRef
  • Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer
    Junghee Lee, Hong Kwan Kim, Byung Jo Park, Jong Ho Cho, Yong Soo Choi, Jae Ill Zo, Young Mog Shim, Hongryull Pyo, Yong Chan Ahn, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jhingook Kim
    Lung Cancer.2018; 115: 89.     CrossRef
  • 13,555 View
  • 89 Download
  • 5 Web of Science
  • 6 Crossref
Close layer
Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation–Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma
Chi Hong Kim, Seung Hoon Kim, Sonya Youngju Park, Jinyoung Yoo, Sung Kyoung Kim, Hoon Kyo Kim
Cancer Res Treat. 2015;47(4):653-660.   Published online January 30, 2015
DOI: https://doi.org/10.4143/crt.2014.118
AbstractAbstract PDFPubReaderePub
Purpose
Mutation-specific antibodies have recently been developed for identification of epidermal growth factor receptor (EGFR) mutations by immunohistochemistry (IHC). This study was designed to investigate whether the type of specimen (biopsy vs. resection) would make a difference in determining mutation status by IHC, and to evaluate whether biopsies are suitable for detection of mutant EGFR protein.
Materials and Methods
IHC was performed using mutation-specific antibodies for E746-A750 deletion (DEL) and L858R point mutation (L858R) in biopsies and tissue microarrays of resected tumors from 154 patients with pulmonary adenocarcinoma. Results were then compared with DNA sequencing data.
Results
Molecular-based assays detected EGFR mutations in 62 patients (40.3%), including 14 (9.1%) with DEL, and 31 (20.1%) with L858R. IHC with two mutation-specific antibodies showed a homogeneous staining pattern, and correctly identified EGFRmutation status in 89% (137/154). Overall (biopsy/resection) sensitivity, specificity, positive predictive value, and negative predictive value were 75.6% (78.3%/72.7%), 94.5% (90.9%/96.3%), 85% (78.3%/88.9%), and 90.4% (90.9%/89.7%), respectively.
Conclusion
Our data showed that IHC using EGFR mutation–specific antibodies is useful for detection of EGFRmutations with high specificity and good sensitivity not only for resection specimens but also for biopsy materials. Therefore, IHC using EGFRmutation–specific antibodies may preclude a second biopsy procedure to obtain additional tissues for identification of EGFR mutations by molecular assays in biopsies from advanced cancer, particularly when tumor cells in the samples are limited.

Citations

Citations to this article as recorded by  
  • SH3 domain‑binding glutamic acid‑rich protein‑like 3 is associated with hyperglycemia and a poor outcome in Epstein‑Barr virus‑negative gastric carcinoma
    Houqiang Li, Lanqing Zheng, Xia Zhang, Xunbin Yu, Guodong Zhong, Xiaoyan Chen, Xin Chen, Linying Chen
    Oncology Letters.2024;[Epub]     CrossRef
  • MEK Is a Potential Indirect Target in Subtypes of Head and Neck Cancers
    Bianka Gurbi, Diána Brauswetter, Kinga Pénzes, Attila Varga, Tibor Krenács, Kornél Dános, Ede Birtalan, László Tamás, Miklós Csala
    International Journal of Molecular Sciences.2023; 24(3): 2782.     CrossRef
  • Effects of EGFR gene mutation on stage 3A lung adenocarcinomas in the clinical decision-making process for mediastinal invasive staging
    İsmail Ağababaoğlu, Özgür Ömer Yıldız, Hasan Ersöz, Gökçen Şimşek, Yavuz Selim Sanisoğlu, Nurettin Karaoğlanoğlu
    Medical Science and Discovery.2022; 9(1): 44.     CrossRef
  • Dual NGS Comparative Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Samples of Non-Small Cell Lung Carcinoma (NSCLC)
    Laura Buburuzan, Maria-Anca Zamfir (Irofei), Carmen Maria Ardeleanu, Alin Horatiu Muresan, Florina Vasilescu, Ariana Hudita, Marieta Costache, Bianca Galateanu, Alexandra Puscasu, Alexandru Filippi, Natalia Motas
    Cancers.2022; 14(24): 6084.     CrossRef
  • Role of EGFR and HER-2/NEU Expression in Gall Bladder Carcinoma (GBC)
    Chhanda Das, Madhumita Mukhopadhyay, Srijana Subba, Ashis Kumar Saha, Biswanath Mukhopadhyay
    Journal of Laboratory Physicians.2021; 13(01): 029.     CrossRef
  • Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review
    Jasmina Obradovic, Jovana Todosijevic, Vladimir Jurisic
    Molecular Biology Reports.2021; 48(4): 3593.     CrossRef
  • RETRACTED ARTICLE: AKT3-mediated IWS1 phosphorylation promotes the proliferation of EGFR-mutant lung adenocarcinomas through cell cycle-regulated U2AF2 RNA splicing
    Georgios I. Laliotis, Evangelia Chavdoula, Maria D. Paraskevopoulou, Abdul Kaba, Alessandro La Ferlita, Satishkumar Singh, Vollter Anastas, Keith A. Nair, Arturo Orlacchio, Vasiliki Taraslia, Ioannis Vlachos, Marina Capece, Artemis Hatzigeorgiou, Dario Pa
    Nature Communications.2021;[Epub]     CrossRef
  • Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung
    Moupali Ghosh, Madhumita Mukhopadhyay, Chhanda Das, Surojit Chatterjee, Bidisha Ghosh Naskar
    Journal of Cancer Research and Therapeutics.2021; 17(6): 1389.     CrossRef
  • Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets
    Arutha Kulasinghe, Joanna Kapeleris, Carolina Cooper, Majid Ebrahimi Warkiani, Kenneth O’Byrne, Chamindie Punyadeera
    Cancers.2019; 11(3): 380.     CrossRef
  • Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma
    Dhoha Dhieb, Imen Belguith, Laura Capelli, Elisa Chiadini, Matteo Canale, Sara Bravaccini, Ilhem Yangui, Ons Boudawara, Rachid Jlidi, Tahya Boudawara, Daniele Calistri, Leila Ammar Keskes, Paola Ulivi
    Cells.2019; 8(6): 514.     CrossRef
  • Intratumour heterogeneity of p53 expression; causes and consequences
    Yuezhen Xue, Boris San Luis, David P Lane
    The Journal of Pathology.2019; 249(3): 274.     CrossRef
  • Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non–Small-cell Lung Cancer
    Edward Kim, Rebecca Feldman, Ignacio I. Wistuba
    Clinical Lung Cancer.2018; 19(2): 105.     CrossRef
  • Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?
    Véronique Hofman, Sandra Lassalle, Coraline Bence, Elodie Long-Mira, Sacha Nahon-Estève, Simon Heeke, Virginie Lespinet-Fabre, Catherine Butori, Marius Ilié, Paul Hofman
    Cancers.2018; 10(3): 70.     CrossRef
  • EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry
    Zohra Mraihi, Jihen Ben Amar, Hend Bouacha, Soumaya Rammeh, Lamia Hila
    BMC Pulmonary Medicine.2018;[Epub]     CrossRef
  • Immunohistochemistry for EGFR Mutation Detection in Non–Small-Cell Lung Cancer
    Nina Turnšek Hitij, Izidor Kern, Aleksander Sadikov, Lea Knez, Karmen Stanič, Matjaž Zwitter, Tanja Cufer
    Clinical Lung Cancer.2017; 18(3): e187.     CrossRef
  • Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer
    Aeri Kim, Min Hye Jang, Soo Jung Lee, Young Kyung Bae
    Journal of Breast Cancer.2017; 20(2): 150.     CrossRef
  • Detection of epidermal growth factor receptor mutations in lung adenocarcinoma cytological specimens by immunocytochemistry
    Masami Yoshida, Tadasuke Nagatomo, Takafumi Ohnishi, Mayumi Kawashima, Akira Naitoh, Eiichi Morii
    Molecular and Clinical Oncology.2017;[Epub]     CrossRef
  • Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods
    Hua-Lin Kao, Yi-Chen Yeh, Chin-Hsuan Lin, Wei-Fang Hsu, Wen-Yu Hsieh, Hsiang-Ling Ho, Teh-Ying Chou
    Lung Cancer.2016; 101: 40.     CrossRef
  • LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients
    Yu Jin Kim, Sungyoul Hong, Minjung Sung, Min Jeong Park, Kyungsoo Jung, Ka-Won Noh, Doo-Yi Oh, Mi-Sook Lee, Ensel Oh, Young Kee Shin, Yoon-La Choi
    Oncotarget.2016; 7(50): 82876.     CrossRef
  • 14,444 View
  • 117 Download
  • 23 Web of Science
  • 19 Crossref
Close layer
Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer
Seong-Hoon Yoon, Yoo-Duk Choi, In-Jae Oh, Kyu-Sik Kim, Hayoung Choi, Jinsun Chang, Hong-Joon Shin, Cheol-Kyu Park, Young-Chul Kim
Cancer Res Treat. 2015;47(4):661-669.   Published online February 23, 2015
DOI: https://doi.org/10.4143/crt.2014.282
AbstractAbstract PDFPubReaderePub
Purpose
Direct sequencing (DS) is the standard method for detection of epidermal growth factor receptor (EGFR) gene mutation in non-small cell lung cancer (NSCLC); however, low detection sensitivity is a problem. The aim of this study is to demonstrate higher detection rate of EGFR gene mutation with peptide nucleic acid (PNA) clamping compared with DS. Materials and Methods This is a single arm, prospective study for patients with stage IIIB/IV or relapsed NSCLC. Using tumor DNA from 138 patients, both DS and PNA clamping for EGFR gene in exon 18, 19, 20, and 21 were performed. Discrepant results between the two methods were verified using Cobas and a mutant enrichment based next generation sequencing (NGS). Patients with activating mutations were treated with EGFR tyrosine kinase inhibitor (EGFR-TKI, gefitinib, or erlotinib) as first line treatment.
Results
Of 138 paired test sets, 24 (17.4%) and 45 (32.6%) cases with activating mutations were detected by DS and PNA clamping, respectively. The difference of detection rate between the two methods was 15.2% (95% confidence interval, 8.7% to 17.8%; p < 0.001). Between the two methods, 25 cases showed discrepant results (n=23, PNA+/DS–; n=2, PNA–/DS+). Mutations were confirmed by Cobas or NGS in 22 of 23 PNA+/DS– cases. The response rates to EGFR-TKI were 72.2% in the PNA+/DS+ group and 85.0% in the PNA+/DS– group. Conclusion PNA clamping showed a significantly higher detection rate of EGFR gene mutation compared with DS. Higher sensitivity of PNA clamping was not compromised by the loss of predictive power of response to EGFR-TKI.

Citations

Citations to this article as recorded by  
  • Highly Sensitive Enrichment of Low-Frequency Variants by Hairpin Competition Amplification
    Zhaocheng Liu, Rui Zhang, Xixi Jiang, Li Ji, Ping Sun, Yong Ji, Yu Zhang, Yan Ding, Koukou Li, Zhening Pu, Fengsheng Zhou, Jian Zou
    Analytical Chemistry.2023; 95(32): 12015.     CrossRef
  • Peptide Nucleic Acids: Recent Developments in the Synthesis and Backbone Modifications
    Gurpreet Singh, Vikramdeep Monga
    Bioorganic Chemistry.2023; 141: 106860.     CrossRef
  • Genetic Alterations and Risk Factors for Recurrence in Patients with Non-Small Cell Lung Cancer Who Underwent Complete Surgical Resection
    Hwa Park, Yoo Choi, Ju-Sik Yun, Sang-Yun Song, Kook-Joo Na, Joon Yoon, Chang-Seok Yoon, Hyung-Joo Oh, Young-Chul Kim, In-Jae Oh
    Cancers.2023; 15(23): 5679.     CrossRef
  • Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
    Hayoung Choi, Jae‐Kyeong Lee, Hyung‐Joo Oh, Min‐Seok Kim, Bo Gun Kho, Cheol Kyu Park, In‐Jae Oh, Young‐Chul Kim
    Thoracic Cancer.2021; 12(10): 1598.     CrossRef
  • Bronchial brushing cytology is comparable to bronchial biopsy for epidermal growth factor receptor mutation test in non-small cell lung cancer
    Joo-Yeon Koo, Nah-Ihm Kim, Taebum Lee, Yoo-Duk Choi
    Cytojournal.2020; 17: 16.     CrossRef
  • Potential applications of peptide nucleic acid in biomedical domain
    Kshitij RB Singh, Parikipandla Sridevi, Ravindra Pratap Singh
    Engineering Reports.2020;[Epub]     CrossRef
  • Prognostic value of quantitative measurement of EGFR mutation using peptide nucleic acid clamping in advanced EGFR mutant non‐small cell lung cancer patients
    Insu Kim, Jung Seop Eom, Eun Jung Jo, Jeongha Mok.Ki Uk, Kwangha Lee, Ki Uk Kim, Hye‐Kyung Park, Min Ki Lee, Mi‐Hyun Kim
    Thoracic Cancer.2019; 10(7): 1561.     CrossRef
  • Sensitive detection of low-abundance in-frame deletions in EGFR exon 19 using novel wild-type blockers in real-time PCR
    Xiao-Dong Ren, Ding-Yuan Liu, Hai-Qin Guo, Liu Wang, Na Zhao, Ning Su, Kun Wei, Sai Ren, Xue-Mei Qu, Xiao-Tian Dai, Qing Huang
    Scientific Reports.2019;[Epub]     CrossRef
  • Peptide Nucleic Acid Clamping and Direct Sequencing in the Detection of Oncogenic Alterations in Lung Cancer: Systematic Review and Meta-Analysis
    Jae-Uk Song, Jonghoo Lee
    Yonsei Medical Journal.2018; 59(2): 211.     CrossRef
  • Comparative analysis of Adam33 mutations in murine lung cancer cell lines by droplet digital PCR, real-time PCR and Insight Onco™ NGS
    Soo-Jin Kim, Eunhee Kim, Kyung-Taek Rim
    Molecular & Cellular Toxicology.2018; 14(2): 221.     CrossRef
  • Feasibility of re‐biopsy and EGFR mutation analysis in patients with non‐small cell lung cancer
    Tae‐Ok Kim, In‐Jae Oh, Bo Gun Kho, Ha Young Park, Jin Sun Chang, Cheol‐Kyu Park, Hong‐Joon Shin, Jung‐Hwan Lim, Yong‐Soo Kwon, Yu‐Il Kim, Sung‐Chul Lim, Young‐Chul Kim, Yoo‐Duk Choi
    Thoracic Cancer.2018; 9(7): 856.     CrossRef
  • Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma
    In-Jae Oh, Jae Young Hur, Cheol-Kyu Park, Young-Chul Kim, Seung Joon Kim, Min Ki Lee, Hee Joung Kim, Kye Young Lee, Jae Cheol Lee, Chang-Min Choi
    Clinical Lung Cancer.2018; 19(5): e775.     CrossRef
  • Genetic Biomarkers and Their Applications to Prevent Occupational Diseases: A Literature Review
    Kyung-Taek Rim
    Toxicology and Environmental Health Sciences.2018; 10(3): 147.     CrossRef
  • Molecular masquerading of rare EGFR L858M/L861R mutations as common L858R/L861Q mutations by PNA clamping assay
    Ji Hyung Hong, Seung-Hyun Jung, Min Sung Kim, Sug Hyung Lee, Yeun-Jun Chung
    Pathology.2017; 49(4): 453.     CrossRef
  • Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer
    Aeri Kim, Min Hye Jang, Soo Jung Lee, Young Kyung Bae
    Journal of Breast Cancer.2017; 20(2): 150.     CrossRef
  • Peptide nucleic acids: Advanced tools for biomedical applications
    Anjali Gupta, Anuradha Mishra, Nidhi Puri
    Journal of Biotechnology.2017; 259: 148.     CrossRef
  • Non-invasive quantification of cell-free DNA mutations in plasma during lung tumor progression in mice
    Soo-Jin Kim, Eunhee Kim, Kyung-Taek Rim
    Cancer Biomarkers.2017; 20(4): 477.     CrossRef
  • Peptide Nucleic Acid-Based Biosensors for Cancer Diagnosis
    Roberta D’Agata, Maria Giuffrida, Giuseppe Spoto
    Molecules.2017; 22(11): 1951.     CrossRef
  • Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing
    Mi-Young Park, Min Hee Jung, Eun Young Eo, Seokjoong Kim, Sang Hoon Lee, Yeon Joo Lee, Jong Sun Park, Young Jae Cho, Jin Haeng Chung, Cheol Hyeon Kim, Ho Il Yoon, Jae Ho Lee, Choon-Taek Lee
    Oncotarget.2017; 8(22): 36331.     CrossRef
  • Application of Peptide Nucleic Acid-based Assays Toward Detection of Somatic Mosaicism
    Christopher S Hong, Chunzhang Yang, Zhengping Zhuang
    Molecular Therapy - Nucleic Acids.2016; 5: e314.     CrossRef
  • Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
    Ha Young Park, Hyung Joo Oh, Ki‐Hyun Kim, Tae‐Ok Kim, Cheol‐Kyu Park, Hong‐Jun Shin, Jung‐Hwan Lim, Yong‐Soo Kwon, In‐Jae Oh, Yu‐Il Kim, Sung‐Chul Lim, Young‐Chul Kim, Yoo‐Duk Choi
    Thoracic Cancer.2016; 7(6): 639.     CrossRef
  • Association between GWAS-identified lung adenocarcinoma susceptibility loci andEGFRmutations in never-smoking Asian women, and comparison with findings from Western populations
    Wei Jie Seow, Keitaro Matsuo, Chao Agnes Hsiung, Kouya Shiraishi, Minsun Song, Hee Nam Kim, Maria Pik Wong, Yun-Chul Hong, H. Dean Hosgood, Zhaoming Wang, I-Shou Chang, Jiu-Cun Wang, Nilanjan Chatterjee, Margaret Tucker, Hu Wei, Tetsuya Mitsudomi, Wei Zhe
    Human Molecular Genetics.2016; : ddw414.     CrossRef
  • 12,513 View
  • 173 Download
  • 20 Web of Science
  • 22 Crossref
Close layer
Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer
Yun-Gyoo Lee, Eunyoung Lee, Inho Kim, Keun-Wook Lee, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Dae Seog Heo
Cancer Res Treat. 2015;47(4):670-675.   Published online January 2, 2015
DOI: https://doi.org/10.4143/crt.2014.045
AbstractAbstract PDFPubReaderePub
Purpose
Cisplatin-associated arterial and venous thromboembolic events (TEEs) are becoming an increasing concern. In patients with small-cell lung cancer (SCLC) who are treated using cisplatin-based chemotherapy, we assume that the overall risk of TEEs is high. However, cisplatin-associated vascular toxicity in patients with SCLC has been overlooked to date. The aim of this study was to determine the incidence of TEEs in patients with SCLC and to analyze the predictors for TEE occurrence. Materials and Methods We retrospectively analyzed 277 patients who received chemotherapy for SCLC between 2006 and 2012. As the influence of chemotherapy on TEE occurrence developed after its initiation, a time-dependent Cox regression analysis was used to estimate the significant predictors for TEE. Results Among the 277 patients, 30 patients (11%) developed a TEE. The 3-month, 6-month, and 1-year cumulative incidences of TEEs were 5.0%, 9.1%, and 10.2%, respectively. Of 30 total TEEs, 22 (73%) occurred between the time of initiation and 4 weeks after the last dose of platinum-based chemotherapy. Approximately 218 patients (79%) received cisplatin-based chemotherapy. In multivariate analysis, cisplatin-based chemotherapy was an independent risk factor for TEE occurrence (hazard ratio [HR], 4.36; p=0.05). Variables including smoking status (common HR, 2.14; p=0.01) and comorbidity index (common HR, 1.60; p=0.05) also showed significant association with TEE occurrence. Conclusion The 1-year cumulative incidence of TEE is 10.2% in Asian patients with SCLC. Cisplatinbased chemotherapy in SCLC might be a strong predictor for the risk of TEE.

Citations

Citations to this article as recorded by  
  • Lung cancer, comorbidities, and medication: the infernal trio
    Hélène Pluchart, Sébastien Chanoine, Denis Moro-Sibilot, Christos Chouaid, Gil Frey, Julie Villa, Bruno Degano, Matteo Giaj Levra, Pierrick Bedouch, Anne-Claire Toffart
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Acute brachial artery occlusion following cisplatin-based chemotherapy: case report
    Abenezer Melaku Tafese, Amanuel Yegnanew Adela, Assefa Getachew Kebede, Aklilu Sinte Tegegn, Elsabeth Tizazu Asare, Munir Awol
    SAGE Open Medical Case Reports.2024;[Epub]     CrossRef
  • Stratification of Risk Factors of Lung Cancer-Associated Venous Thromboembolism and Determining the Critical Point for Preemptive Intervention: A Systematic Review With Meta-analysis
    Theresa Nwagha, Martins Nweke
    Clinical Medicine Insights: Oncology.2023;[Epub]     CrossRef
  • Seratrodast platinum(iv) hybrids efficiently inhibit cancer-related thrombosis and metastasis phenotype in vitro and in vivo
    Xue-Qing Song, Yi-Xin Ding, Yu-Hang Zhang, Qing Xu, Xiaofeng Xie, Yali Song, Longfei Li
    Inorganic Chemistry Frontiers.2023; 10(22): 6596.     CrossRef
  • Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
    Hundo Cho, Jin-Hyuk Choi, Seok Yun Kang, Hyun Woo Lee, Yong Won Choi, Tae-Hwan Kim, Mi Sun Ahn, Chul-Ho Kim, Yoo Seob Shin, Jeon Yeob Jang, Young-Taek Oh, Jaesung Heo, Seung Soo Sheen
    The Korean Journal of Internal Medicine.2022; 37(3): 653.     CrossRef
  • Analysis of thromboembolic events in patients with non-small cell lung cancer who received adjuvant chemotherapy: single-center real-world data
    Tae-Hwan Kim, Yong Won Choi, Hyun Woo Lee, Seok Yun Kang, Heejun Son, Jin-Hyuk Choi, Mi Sun Ahn, Seung-Soo Sheen
    Scientific Reports.2022;[Epub]     CrossRef
  • Embolic Stroke Due to a Mural Thrombus in the Ascending Aorta Following Cisplatin-based Chemotherapy
    Yukiko Ochiai, Marie Tsunogae, Masayuki Ueda
    Internal Medicine.2021; 60(6): 945.     CrossRef
  • Effect of thromboprophylaxis on the incidence of venous thromboembolism in surgical patients with colorectal cancer: a meta-analysis
    Yu-Dong Li, Hai-Dong Li, Shu-Xin Zhang
    International Angiology.2020;[Epub]     CrossRef
  • Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients
    Ruth Maria Schorling, Christian Pfrepper, Thomas Golombek, Chiara Alessandra Cella, Nerea Muñoz-Unceta, Roland Siegemund, Christoph Engel, Sirak Petros, Florian Lordick, Maren Knödler
    Oncology Research and Treatment.2020; 43(9): 414.     CrossRef
  • Aortic Mural Thrombus in the Non-atherosclerotic Aorta of Patients with Multiple Hypercoagulable Factors
    Takeshi Yagyu, Maiko Naito, Masahiro Kumada, Tsutomu Nakagawa
    Internal Medicine.2019; 58(3): 381.     CrossRef
  • Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models
    Silvia Riondino, Patrizia Ferroni, Fabio Massimo Zanzotto, Mario Roselli, Fiorella Guadagni
    Cancers.2019; 11(1): 95.     CrossRef
  • Altered fibrin clot properties in advanced lung cancer: strong impact of cigarette smoking
    Michał Ząbczyk, Grzegorz Królczyk, Grzegorz Czyżewicz, Krzysztof Plens, Shannon Prior, Saulius Butenas, Anetta Undas
    Medical Oncology.2019;[Epub]     CrossRef
  • New data for venous thromboembolism in patients with small cell lung cancer: A review
    Evangelos Dimakakos, Konstantinos Livanios, Ioannis Gkiozos, Adriani Charpidou, Eleutheria Ntalakou, llias Kainis, Konstantinos Syrigos
    Phlebology: The Journal of Venous Disease.2018; 33(8): 517.     CrossRef
  • Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography
    Hyungseop Kim, Woo-Baek Chung, Kyoung Im Cho, Bong-Joon Kim, Jeong-Sook Seo, Seong-Mi Park, Hak Jin Kim, Ju-Hee Lee, Eun Kyoung Kim, Ho-Joong Youn
    Journal of Cardiovascular Ultrasound.2018; 26(1): 1.     CrossRef
  • Venous thromboembolic events in patients with lung cancer treated with cisplatin-based versus carboplatin/nedaplatin-based chemotherapy
    Akihisa Mitani, Taisuke Jo, Hideo Yasunaga, Yukiyo Sakamoto, Wakae Hasegawa, Hirokazu Urushiyama, Yasuhiro Yamauchi, Hiroki Matsui, Kiyohide Fushimi, Takahide Nagase
    Anti-Cancer Drugs.2018; 29(6): 560.     CrossRef
  • Long-Term Risk of Venous Thromboembolism in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study
    Arin L. Madenci, Brent R. Weil, Qi Liu, Andrew J. Murphy, Todd M. Gibson, Yutaka Yasui, Wendy M. Leisenring, Rebecca M. Howell, Christopher L. Tinkle, Larissa Nekhlyudov, Lisa R. Diller, Gregory T. Armstrong, Kevin C. Oeffinger, Christopher B. Weldon
    Journal of Clinical Oncology.2018; 36(31): 3144.     CrossRef
  • Beneficial effect of additional treatment with�widely�available anticancer agents in advanced small�lung cell carcinoma: A case report
    Piotr Kruk
    Molecular and Clinical Oncology.2018;[Epub]     CrossRef
  • Cancer-associated venous thromboembolism: Burden, mechanisms, and management
    Cihan Ay, Ingrid Pabinger, Alexander T. Cohen
    Thrombosis and Haemostasis.2017; 117(02): 219.     CrossRef
  • Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma
    Elsa Davidsson, Nicola Murgia, Cristian Ortiz-Villalón, Emil Wiklundh, Magnus Sköld, Karl Gustav Kölbeck, Giovanni Ferrara
    Multidisciplinary Respiratory Medicine.2017;[Epub]     CrossRef
  • Validation of a Machine Learning Approach for Venous Thromboembolism Risk Prediction in Oncology
    Patrizia Ferroni, Fabio M. Zanzotto, Noemi Scarpato, Silvia Riondino, Fiorella Guadagni, Mario Roselli
    Disease Markers.2017; 2017: 1.     CrossRef
  • Severe Intestinal Ischemia During Chemotherapy for Small Cell Lung Cancer
    Barbara Legius, Kristiaan Nackaerts
    Lung Cancer Management.2017; 6(3): 87.     CrossRef
  • Epidemiology and risk factors for venous thromboembolism in lung cancer
    Cihan Ay, Umut Kaan Ünal
    Current Opinion in Oncology.2016; 28(2): 145.     CrossRef
  • A systematic review of biomarkers for the prediction of thromboembolism in lung cancer — Results, practical issues and proposed strategies for future risk prediction models
    Marliese Alexander, Kate Burbury
    Thrombosis Research.2016; 148: 63.     CrossRef
  • 11,555 View
  • 137 Download
  • 30 Web of Science
  • 23 Crossref
Close layer
Interstitial Lung Change in Pre-radiation Therapy Computed Tomography Is a Risk Factor for Severe Radiation Pneumonitis
Yun Hee Lee, Yeon Sil Kim, Sang Nam Lee, Hyo Chun Lee, Se Jin Oh, Seoung Joon Kim, Young Kyoon Kim, Dae Hee Han, Ie Ryung Yoo, Jin Hyung Kang, Suk Hee Hong
Cancer Res Treat. 2015;47(4):676-686.   Published online February 13, 2015
DOI: https://doi.org/10.4143/crt.2014.180
AbstractAbstract PDFPubReaderePub
Purpose
We examined clinical and dosimetric factors as predictors of symptomatic radiation pneumonitis (RP) in lung cancer patients and evaluated the relationship between interstitial lung changes in the pre-radiotherapy (RT) computed tomography (CT) and symptomatic RP. Materials and Methods Medical records and dose volume histogram data of 60 lung cancer patients from August 2005 to July 2006 were analyzed. All patients were treated with three dimensional (3D) conformal RT of median 56.9 Gy. We assessed the association of symptomatic RP with clinical and dosimetric factors.
Results
With a median follow-up of 15.5 months (range, 6.1 to 40.9 months), Radiation Therapy Oncology Group grade ≥ 2 RP was observed in 14 patients (23.3%). Five patients (8.3%) died from RP. The interstitial changes in the pre-RT chest CT, mean lung dose (MLD), and V30 significantly predicted RP in multivariable analysis (p=0.009, p < 0.001, and p < 0.001, respectively). MLD, V20, V30, and normal tissue complication probability normal tissue complication probability (NTCP) were associated with the RP grade but less so for grade 5 RP. The risk of RP grade ≥ 2, ≥ 3, or ≥ 4 was higher in the patients with interstitial lung change (grade 2, 15.6% to 46.7%, p=0.03; grade 3, 4.4% to 40%, p=0.002; grade 4, 4.4% to 33.3%, p=0.008). Four of the grade 5 RP patients had diffuse interstitial change in pre-RT CT and received chemoradiotherapy. Conclusion Our study identified diffuse interstitial disease as a significant clinical risk for RP, particularly fatal RP. We showed the usefulness of MLD, V20, V30, and NTCP in predicting the incidence and severity of RP.

Citations

Citations to this article as recorded by  
  • Safety and Efficacy of Single-Fraction Carbon-Ion Radiotherapy for Early-Stage Lung Cancer with Interstitial Pneumonia
    Shuri Aoki, Hitoshi Ishikawa, Mio Nakajima, Naoyoshi Yamamoto, Shinichiro Mori, Tokuhiko Omatsu, Yuji Tada, Teruaki Mizobuchi, Satoshi Ikeda, Ichiro Yoshino, Shigeru Yamada
    Cancers.2024; 16(3): 562.     CrossRef
  • Research Progress of Idiopathic Pulmonary Fibrosis Complicated with Lung Cancer
    Hao Ruan, Zihui Zhang, Jiao Tian, Mingjiang Li, Ting Xiao
    International Journal of Cancer Management.2024;[Epub]     CrossRef
  • Drug change from nintedanib to pirfenidone for the perioperative management of lung cancer with idiopathic pulmonary fibrosis: A case report
    Yukiko Matsui, Mitsuhiro Abe, Yasufumi Uematsu, Yuki Onozato, Takayoshi Yamamoto, Takekazu Iwata
    The Journal of the Japanese Association for Chest Surgery.2024; 38(5): 446.     CrossRef
  • Preliminary Results of Developing Imaging Complexity Biomarkers for the Incidence of Severe Radiation Pneumonitis Following Radiotherapy in Non-Small Cell Lung Cancer Patients with Underlying Idiopathic Pulmonary Fibrosis
    Jeongeun Hwang, Hakyoung Kim, Sun Myung Kim, Dae Sik Yang
    Life.2024; 14(7): 897.     CrossRef
  • CT-based different regions of interest radiomics analysis for acute radiation pneumonitis in patients with locally advanced NSCLC after chemoradiotherapy
    Liqiao Hou, Kuifei Chen, Chao Zhou, Xingni Tang, Changhui Yu, Haijian Jia, Qianyi Xu, Suna Zhou, Haihua Yang
    Clinical and Translational Radiation Oncology.2024; 48: 100828.     CrossRef
  • Computed tomography patterns and clinical outcomes of radiation pneumonitis in non–small-cell lung cancer patients
    Ji Hoon Choi, Hee Kang, Ji Su Lim, Ki-Nam Lee
    Acta Radiologica Open.2024;[Epub]     CrossRef
  • Populations particulières : impact de l’état général et des principales comorbidités et de leurs traitements sur la prise en charge thérapeutique locale des patients présentant un Cancer Bronchique Non à Petites Cellules
    V. Gounant, R. Ezzedine, B. Duchemann, T. Pierret, S. Brosseau, Y. Castier, G. Zalcman, P. Mordant
    Revue des Maladies Respiratoires Actualités.2024; 16(2): 2S290.     CrossRef
  • Stereotactic body radiation therapy (SBRT) as salvage treatment for early stage lung cancer with interstitial lung disease (ILD): An observational and exploratory case series of non-asian patients
    J. Pluvy, A. Zaccariotto, P. Habert, J. Bermudez, A. Mogenet, J.Y. Gaubert, P. Tomasini, L. Padovani, L. Greillier
    Respiratory Medicine and Research.2023; 83: 100984.     CrossRef
  • Predictors of high-grade radiation pneumonitis following radiochemotherapy for locally advanced non-small cell lung cancer: analysis of clinical, radiographic and radiotherapy-related factors
    Elisabeth Weiss, Anthony Ricco, Nitai Mukhopadhyay, Leila Rezai Gharai, Xiaoyan Deng, Nuzhat Jan, Christopher Guy
    Journal of Radiotherapy in Practice.2023;[Epub]     CrossRef
  • Impact of palliative radiotherapy with or without lung irradiation in patients with interstitial lung disease
    Kenji Makita, Yasushi Hamamoto, Hiromitsu Kanzaki, Kei Nagasaki, Yoshifumi Sugawara, Toshiyuki Kozuki
    Radiotherapy and Oncology.2023; 183: 109636.     CrossRef
  • Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis – The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging
    Nika Guberina, Florian Wirsdörfer, Martin Stuschke, Verena Jendrossek
    Neoplasia.2023; 39: 100892.     CrossRef
  • Immunotherapy-related pneumonitis and the synergic impact of thoracic radiation and preexisting interstitial lung disease
    Maria Azhar, Rodeo Abrencillo, Saumil Gandhi, Mehmet Altan, Ajay Sheshadri
    Current Opinion in Pulmonary Medicine.2023; 29(4): 248.     CrossRef
  • Cancers pulmonaires associés à une pathologie interstitielle pulmonaire fibrosante
    B. Duchemann, J. Cadranel, A. Paix, L. Matton, M. Didier, D. Radu, M. Kambouchner, O. Freynet, K. Chouanhia, P.Y. Brillet, H. Nunes
    Revue des Maladies Respiratoires Actualités.2023; 15(2): 2S214.     CrossRef
  • Risk factor analysis of the development of severe radiation pneumonitis in patients with non-small cell lung cancer treated with curative radiotherapy, with focus on underlying pulmonary disease
    Hakyoung Kim, Jeongeun Hwang, Sun Myung Kim, Juwhan Choi, Dae Sik Yang
    BMC Cancer.2023;[Epub]     CrossRef
  • Quantification of diffuse parenchymal lung disease in non‐small cell lung cancer patients with definitive concurrent chemoradiation therapy for predicting radiation pneumonitis
    Ye Chan An, Jong Hoon Kim, Jae Myung Noh, Kyung Mi Yang, You Jin Oh, Sung Goo Park, Hong Ryul Pyo, Ho Yun Lee
    Thoracic Cancer.2023; 14(36): 3530.     CrossRef
  • Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
    Hiroshi Mayahara, Kazuyuki Uehara, Aya Harada, Keiji Kitatani, Tomonori Yabuuchi, Shuichirou Miyazaki, Takeaki Ishihara, Hiroki Kawaguchi, Hikaru Kubota, Hideaki Okada, Taira Ninomaru, Chihiro Shindo, Akito Hata
    Radiation Oncology.2022;[Epub]     CrossRef
  • Palliative radiotherapy for cancer patients with interstitial lung disease: A physician's perspective
    Satoshi Ikeda
    Radiotherapy and Oncology.2022; 169: 155.     CrossRef
  • Is Thoracic Radiotherapy an Absolute Contraindication for Treatment of Lung Cancer Patients With Interstitial Lung Disease? A Systematic Review
    A. Saha, P. Dickinson, R.K. Shrimali, A. Salem, S. Agarwal
    Clinical Oncology.2022; 34(12): e493.     CrossRef
  • Prospective Study of Proton Therapy for Lung Cancer Patients with Poor Lung Function or Pulmonary Fibrosis
    Jae Myoung Noh, Hongseok Yoo, Woojin Lee, Hye Yun Park, Sun Hye Shin, Hongryull Pyo
    Cancers.2022; 14(6): 1445.     CrossRef
  • Outcomes of proton therapy for non-small cell lung cancer in patients with interstitial pneumonia
    Shingo Hashimoto, Hiromitsu Iwata, Yukiko Hattori, Koichiro Nakajima, Kento Nomura, Kensuke Hayashi, Toshiyuki Toshito, Eiko Yamamori, Kenji Akita, Jun-etsu Mizoe, Hiroyuki Ogino, Yuta Shibamoto
    Radiation Oncology.2022;[Epub]     CrossRef
  • Cancers pulmonaires associés à une pathologie interstitielle pulmonaire fibrosante
    B. Duchemann, A. Paix, L. Matton, M. Didier, D. Radu, M. Kambouchner, O. Freynet, K. Chouahnia, P.-Y. Brillet, H. Nunes
    Revue des Maladies Respiratoires Actualités.2022; 14(2): 2S378.     CrossRef
  • Quantitative Assessment and Comparative Analysis of Longitudinal Lung CT Scans of Chest-Irradiated Nonhuman Primates
    Priyanka Thakur, John D. Olson, Gregory O Dugan, J. Daniel Bourland, Nancy D. Kock, J. Mark Cline
    Radiation Research.2022;[Epub]     CrossRef
  • An Evaluation of Potent Radioprotective Effect of Dimethyl Sulfoxide for Acute Radiation-Induced Lung Injury: Tc99m-DTPA Transalveolar Clearance Scintigraphy Correlated by Histopathologic Findings
    Bengu DEPBOYLU
    Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi.2022; 9(3): 266.     CrossRef
  • Usefulness of Simple Original Interstitial Lung Abnormality Scores for Predicting Radiation Pneumonitis Requiring Steroidal Treatment After Definitive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer
    Tairo Kashihara, Yuko Nakayama, Kimiteru Ito, Yuko Kubo, Kae Okuma, Satoshi Shima, Satoshi Nakamura, Kana Takahashi, Koji Inaba, Naoya Murakami, Hiroshi Igaki, Yuichiro Ohe, Masahiko Kusumoto, Jun Itami
    Advances in Radiation Oncology.2021; 6(1): 100606.     CrossRef
  • Idiopathic pulmonary fibrosis: Current knowledge, future perspectives and its importance in radiation oncology
    Görkem Türkkan, Yves Willems, Lizza E.L. Hendriks, Rémy Mostard, Lennart Conemans, Hester A Gietema, Cristina Mitea, Stéphanie Peeters, Dirk De Ruysscher
    Radiotherapy and Oncology.2021; 155: 269.     CrossRef
  • Radiation-induced lung injury: current evidence
    Marisol Arroyo-Hernández, Federico Maldonado, Francisco Lozano-Ruiz, Wendy Muñoz-Montaño, Mónica Nuñez-Baez, Oscar Arrieta
    BMC Pulmonary Medicine.2021;[Epub]     CrossRef
  • Clinical and Dosimetric Predictors of Radiation Pneumonitis in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation Therapy
    Annemarie F. Shepherd, Michelle Iocolano, Jonathan Leeman, Brandon S. Imber, Aaron T. Wild, Michael Offin, Jamie E. Chaft, James Huang, Andreas Rimner, Abraham J. Wu, Daphna Y. Gelblum, Narek Shaverdian, Charles B. Simone, Daniel R. Gomez, Ellen D. Yorke,
    Practical Radiation Oncology.2021; 11(1): e52.     CrossRef
  • Scarred Lung. An Update on Radiation-Induced Pulmonary Fibrosis
    Natalia Jarzebska, Ekaterina S. Karetnikova, Alexander G. Markov, Michael Kasper, Roman N. Rodionov, Peter M. Spieth
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients
    Ho Cheol Kim, Seonjeong Lee, Jin Woo Song
    Scientific Reports.2021;[Epub]     CrossRef
  • Risk factors for radiation pneumonitis in lung cancer patients with subclinical interstitial lung disease after thoracic radiation therapy
    Fangjuan Li, Hui Liu, Hongyu Wu, Shixiong Liang, Yaping Xu
    Radiation Oncology.2021;[Epub]     CrossRef
  • Radiation pneumonitis after palliative radiotherapy in cancer patients with interstitial lung disease
    Masayuki Okumura, Hidehiro Hojo, Masaki Nakamura, Takashi Hiyama, Naoki Nakamura, Sadamoto Zenda, Atsushi Motegi, Yasuhiro Hirano, Shun-Ichiro Kageyama, Raturi Vijay Parshuram, Takeshi Fujisawa, Hirofumi Kuno, Tetsuo Akimoto
    Radiotherapy and Oncology.2021; 161: 47.     CrossRef
  • Clinical Outcomes of Pencil Beam Scanning Proton Therapy in Locally Advanced Non-Small Cell Lung Cancer: Propensity Score Analysis
    Nalee Kim, Jae Myoung Noh, Woojin Lee, Byoungsuk Park, Hongryull Pyo
    Cancers.2021; 13(14): 3497.     CrossRef
  • Survival analysis in lung cancer patients with interstitial lung disease
    Hassan Alomaish, Yee Ung, Stella Wang, Pascal N. Tyrrell, Saly Abo Zahra, Anastasia Oikonomou, Claudia Staab-Weijnitz
    PLOS ONE.2021; 16(9): e0255375.     CrossRef
  • Fatal Radiation Pneumonitis: Literature Review and Case Series
    Stephen Keffer, Christopher L. Guy, Elisabeth Weiss
    Advances in Radiation Oncology.2020; 5(2): 238.     CrossRef
  • Nationwide survey of radiation therapy in Japan for lung cancer complicated with interstitial lung disease
    Yasuhito Hagiwara, Yuko Nakayama, Shigehiro Kudo, Toyokazu Hayakawa, Naoki Nakamura, Yoshizumi Kitamoto, Shigeo Takahashi, Kayoko Tsujino, Nobuteru Kubo, Yukihisa Tamaki, Yasushi Nagata
    Journal of Radiation Research.2020; 61(4): 563.     CrossRef
  • Clinicopathological characteristics of lung cancer in patients with systemic sclerosis
    Minjiang Chen, Xiaoyan Liu, Yan Xu, Qing Zhou, Yuequan Shi, Dongming Zhang, Hongge Liang, Jing Zhao, Wei Zhong, Mengzhao Wang
    The Clinical Respiratory Journal.2020; 14(12): 1131.     CrossRef
  • Stereotactic Body Radiation Therapy versus Thermal Ablation for Early Stage Non–Small Cell Lung Cancer
    Melissa A. L. Vyfhuis, Pranshu Mohindra, Charles B. Simone
    Radiology.2019; 290(2): 574.     CrossRef
  • Preliminary result of definitive radiotherapy in patients with non-small cell lung cancer who have underlying idiopathic pulmonary fibrosis: comparison between X-ray and proton therapy
    Hakyoung Kim, Hongryull Pyo, Jae Myoung Noh, Woojin Lee, Byoungsuk Park, Hye Yun Park, Hongseok Yoo
    Radiation Oncology.2019;[Epub]     CrossRef
  • Neutrophil‐lymphocyte ratio and a dosimetric factor for predicting symptomatic radiation pneumonitis in non‐small‐cell lung cancer patients treated with concurrent chemoradiotherapy
    Yun Hee Lee, Hoon‐Sik Choi, Hojin Jeong, Ki Mun Kang, Jin Ho Song, Won Sup Lee, Gyeong‐Won Lee, Haa‐Na Song, Hoon‐Gu Kim, Myoung Hee Kang, Dong Yoon Rhee, Bae Kwon Jeong
    The Clinical Respiratory Journal.2018; 12(3): 1264.     CrossRef
  • Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT)
    Daniel Glick, Stephen Lyen, Sonja Kandel, Shane Shapera, Lisa W. Le, Patricia Lindsay, Olive Wong, Andrea Bezjak, Anthony Brade, B.C. John Cho, Andrew Hope, Alexander Sun, Meredith Giuliani
    Clinical Lung Cancer.2018; 19(2): e219.     CrossRef
  • The Association Between the Serum KL-6 Level and the Risk of Radiation Pneumonitis
    Minehiko Inomata, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toru Yamada, Toshiro Miwa, Kentaro Yamagishi, Kuninori Nomura, Ryuji Hayashi, Kazuyuki Tobe
    Haigan.2018; 58(1): 19.     CrossRef
  • Stereotactic body radiotherapy for second primary lung cancer and intra-parenchymal lung metastasis in patients previously treated with surgery: evaluation of indications and predictors of decreased respiratory function
    Takeaki Ishihara, Kazunari Yamada, Aya Harada, Haruhiro Yukiue, Masayuki Tanahashi, Hiroshi Niwa, Takashi Matsui, Koshi Yokomura, Yasuo Ejima, Ryohei Sasaki
    Acta Oncologica.2018; 57(9): 1232.     CrossRef
  • Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non–Small-cell Lung Cancer
    Dwight H. Owen, Lai Wei, Erin M. Bertino, Thomas Edd, Miguel A. Villalona-Calero, Kai He, Peter G. Shields, David P. Carbone, Gregory A. Otterson
    Clinical Lung Cancer.2018; 19(6): e893.     CrossRef
  • Managing the oncologic patient with suspected pneumonia in the intensive care unit
    D. Leoni, B. Encina, J. Rello
    Expert Review of Anti-infective Therapy.2016; 14(10): 943.     CrossRef
  • 13,558 View
  • 199 Download
  • 48 Web of Science
  • 44 Crossref
Close layer
Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer
Do-Youn Oh, Toshihiko Doi, Kuniaki Shirao, Keun-Wook Lee, Sook Ryun Park, Ying Chen, Liqiang Yang, Olga Valota, Yung-Jue Bang
Cancer Res Treat. 2015;47(4):687-696.   Published online February 12, 2015
DOI: https://doi.org/10.4143/crt.2014.225
AbstractAbstract PDFPubReaderePub
Purpose
This phase I trial evaluated the question of whether the standard starting dose of axitinib could be administered in combination with therapeutic doses of cisplatin/capecitabine in patients with previously untreated advanced gastric cancer, and assessed overall safety, pharmacokinetics, and preliminary antitumor activity of this combination.
Materials and Methods
Patients in dose level (DL) 1 received axitinib 5 mg twice a day (days 1 to 21) with cisplatin 80 mg/m2 (day 1) and capecitabine 1,000 mg/m2 twice a day (days 1 to 14) in 21-day cycles. Maximum tolerated dose (MTD) was the highest dose at which ≤ 30% of the first 12 patients experienced a dose-limiting toxicity (DLT) during cycle 1. Ten additional patients were enrolled and treated at the MTD in order to obtain additional safety and pharmacokinetic data.
Results
Three DLTs occurred during cycle 1 in three (25%) of the first 12 patients: ruptured abdominal aortic aneurysm, acute renal failure, and > 5 consecutive days of missed axitinib due to thrombocytopenia. DL1 was established as the MTD, since higher DL cohorts were not planned. Common grade 3/4 non-hematologic adverse events in 22 patients treated at DL1 included hypertension (36.4%) and decreased appetite and stomatitis (18.2% each). Cisplatin/capecitabine slightly increased axitinib exposure; axitinib decreased capecitabine and 5-fluorouracil exposure. Eight patients (36.4%) each had partial response or stable disease. Median response duration was 9.1 months; median progression-free survival was 3.8 months.
Conclusion
In patients with advanced gastric cancer, standard doses of axitinib plus therapeutic doses of cisplatin and capecitabine could be administered in combination. Adverse events were manageable.

Citations

Citations to this article as recorded by  
  • Construction of a hypoxia-immune-related prognostic panel based on integrated single-cell and bulk RNA sequencing analyses in gastric cancer
    Cuncan Deng, Guofei Deng, Hongwu Chu, Songyao Chen, Xiancong Chen, Xing Li, Yulong He, Chunhui Sun, Changhua Zhang
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Early TP53 Alterations Shape Gastric and Esophageal Cancer Development
    Pranshu Sahgal, Brandon M. Huffman, Deepa T. Patil, Walid K. Chatila, Rona Yaeger, James M. Cleary, Nilay S. Sethi
    Cancers.2021; 13(23): 5915.     CrossRef
  • High ELK3 Expression is Associated with the VEGF-C/VEGFR-3 Axis and Gastric Tumorigenesis and Enhances Infiltration of M2 Macrophages
    Wang Dazhi, Jiao Zheng, Ren Chunling
    Future Medicinal Chemistry.2020; 12(24): 2209.     CrossRef
  • RETRACTED: Long non-coding RNA LINC00978 promotes cell proliferation and tumorigenesis via regulating microRNA-497/NTRK3 axis in gastric cancer
    Ju-Yuan Bu, Wei-Ze Lv, Yi-Feng Liao, Xiao-Yu Xiao, Bao-Jun Lv
    International Journal of Biological Macromolecules.2019; 123: 1106.     CrossRef
  • RETRACTED ARTICLE: Anti-gastric cancer effect of Salidroside through elevating miR-99a expression
    Lin Yang, Yanan Yu, Qi Zhang, Xiaoyu Li, Cuiping Zhang, Tao Mao, Siliang Liu, Zibin Tian
    Artificial Cells, Nanomedicine, and Biotechnology.2019; 47(1): 3500.     CrossRef
  • Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients
    Claudia Arena, Giuseppe Troiano, Alfredo De Lillo, Nunzio F. Testa, Lorenzo Lo Muzio
    BioMed Research International.2018; 2018: 1.     CrossRef
  • Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review
    Li-Tzong Chen, Do-Youn Oh, Min-Hee Ryu, Kun-Huei Yeh, Winnie Yeo, Roberto Carlesi, Rebecca Cheng, Jongseok Kim, Mauro Orlando, Yoon-Koo Kang
    Cancer Research and Treatment.2017; 49(4): 851.     CrossRef
  • Angiogenesis inhibitors in early development for gastric cancer
    Mauricio P. Pinto, Gareth I. Owen, Ignacio Retamal, Marcelo Garrido
    Expert Opinion on Investigational Drugs.2017; 26(9): 1007.     CrossRef
  • HER2-induced metastasis is mediated by AKT/JNK/EMT signaling pathway in gastric cancer
    Yiseul Choi, Young San Ko, Jin Ju Park, Youngsun Choi, Younghoon Kim, Jung-Soo Pyo, Bo Gun Jang, Douk Ho Hwang, Woo Ho Kim, Byung Lan Lee
    World Journal of Gastroenterology.2016; 22(41): 9141.     CrossRef
  • 14,989 View
  • 108 Download
  • 11 Web of Science
  • 9 Crossref
Close layer
Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor
Jang Ho Cho, Jae Yun Lim, Ah Ran Choi, Sung Min Choi, Jong Won Kim, Seung Ho Choi, Jae Yong Cho
Cancer Res Treat. 2015;47(4):697-705.   Published online November 27, 2014
DOI: https://doi.org/10.4143/crt.2013.175
Correction in: Cancer Res Treat 2018;50(1):302
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted to validate the survival benefit of metastasectomy plus chemotherapy over chemotherapy alone for treatment of Krukenberg tumors from gastric cancer and to identify prognostic factors for survival. Materials and Methods Clinical data from 216 patients with Krukenberg tumors from gastric cancer were collected. Patients were divided into two arms according to treatment modality: arm A, metastasectomy plus chemotherapy and arm B, chemotherapy alone. Results Overall survival (OS) was significantly increased in arm A relative to arm B for patients initially diagnosed with stage IV gastric cancer (18.0 months vs. 8.0 months; p < 0.001) and those with recurrent Krukenberg tumors (19.0 months vs. 9.0 months; p=0.002), respectively. Metastasectomy (hazard ratio [HR], 0.458; 95% confidence interval [CI], 0.287 to 0.732; p=0.001), signet-ring cell pathology (HR, 1.583; 95% CI, 1.057 to 2.371; p=0.026), and peritoneal carcinomatosis (HR, 3.081; 95% CI, 1.610 to 5.895; p=0.001) were significant prognostic factors for survival. Conclusion Metastasectomy plus chemotherapy offers superior OS when compared to palliative chemotherapy alone in gastric cancer with Krukenberg tumor. Prolonged survival applies to all patients, regardless of gastric cancer stage. Metastasectomy, signet-ring cell pathology, and peritoneal carcinomatosis were prognostic factors for survival. Future prospective randomized trials are needed to confirm the optimal treatment strategy for Krukenberg tumors from gastric cancer.

Citations

Citations to this article as recorded by  
  • The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
    Feng‐Hua Wang, Xiao‐Tian Zhang, Lei Tang, Qi Wu, Mu‐Yan Cai, Yuan‐Fang Li, Xiu‐Juan Qu, Hong Qiu, Yu‐Jing Zhang, Jie‐Er Ying, Jun Zhang, Ling‐Yu Sun, Rong‐Bo Lin, Chang Wang, Hao Liu, Miao‐Zhen Qiu, Wen‐Long Guan, Sheng‐Xiang Rao, Jia‐Fu Ji, Yan Xin, Wei‐
    Cancer Communications.2024; 44(1): 127.     CrossRef
  • Oligometastasis of Gastric Cancer: A Review
    Itaru Yasufuku, Hiroshi Tsuchiya, Seito Fujibayashi, Naoki Okumura, Yuki Sengoku, Masahiro Fukada, Ryuichi Asai, Yuta Sato, Jesse Yu Tajima, Shigeru Kiyama, Takazumi Kato, Yoshihiro Tanaka, Katsutoshi Murase, Nobuhisa Matsuhashi
    Cancers.2024; 16(3): 673.     CrossRef
  • Colorectal Origin: A Marker of Favorable Outcome in Krukenberg Tumor? Results from Clinical and Prognostic Analysis
    Purnima Thakur, Mukesh Sharma, Ashish Chauhan, Kapil M. Pal, Shabnam Thakur, Manish Gupta, Shilpa Kaushal
    South Asian Journal of Cancer.2024; 13(02): 099.     CrossRef
  • Surgical resection and neoadjuvant therapy in patients with gastric cancer and ovarian metastasis: A real-world study
    Hui-Ping Yan, Hong-Rui Lu, Yu-Xia Zhang, Liu Yang, Zhe-Ling Chen
    World Journal of Gastrointestinal Surgery.2024; 16(8): 2426.     CrossRef
  • Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
    Tae-Han Kim, In-Ho Kim, Seung Joo Kang, Miyoung Choi, Baek-Hui Kim, Bang Wool Eom, Bum Jun Kim, Byung-Hoon Min, Chang In Choi, Cheol Min Shin, Chung Hyun Tae, Chung sik Gong, Dong Jin Kim, Arthur Eung-Hyuck Cho, Eun Jeong Gong, Geum Jong Song, Hyeon-Su Im
    Journal of Gastric Cancer.2023; 23(1): 3.     CrossRef
  • Efficacy of chemotherapy combined with surgical resection for gastric cancer with synchronous ovarian metastasis: A propensity score matching analysis
    Jingquan Fang, Xingmao Huang, Xiangliu Chen, Qi Xu, Tengjiao Chai, Ling Huang, Han Chen, Hang Chen, Zeyao Ye, Yian Du, Pengfei Yu
    Cancer Medicine.2023; 12(16): 17126.     CrossRef
  • Clinical Features of Gastric Signet Ring Cell Cancer: Results from a Systematic Review and Meta-Analysis
    Mariagiulia Dal Cero, Maria Bencivenga, Drolaiz H. W. Liu, Michele Sacco, Mariella Alloggio, Kelly G. P. Kerckhoffs, Federica Filippini, Luca Saragoni, Mar Iglesias, Anna Tomezzoli, Fátima Carneiro, Heike I. Grabsch, Giuseppe Verlato, Lorena Torroni, Guil
    Cancers.2023; 15(21): 5191.     CrossRef
  • Frequency and therapeutic strategy for patients with ovarian metastasis from gastric cancer
    Tsutomu Namikawa, Akira Marui, Keiichiro Yokota, Yasuhiro Kawanishi, Masaya Munekage, Sunao Uemura, Hiromichi Maeda, Hiroyuki Kitagawa, Michiya Kobayashi, Kazuhiro Hanazaki
    Langenbeck's Archives of Surgery.2022; 407(6): 2301.     CrossRef
  • Clinics and pathology of Krukenberg tumor: a systematic review and meta-analysis
    Ruggero LIONETTI, Marcello DE LUCA, Antonio RAFFONE, Antonio TRAVAGLINO, Alberto COPPELLOTTI, Roberto PELTRINI, Umberto BRACALE, Michele D’AMBRA, Luigi INSABATO, Fulvio ZULLO, Maria D’ARMIENTO, Francesco CORCIONE
    Minerva Obstetrics and Gynecology.2022;[Epub]     CrossRef
  • Seventeen-year Survival of a Case of Advanced Gastric Cancer with Krukenberg Tumor Treated by Oophorectomies, Subsequent Gastrectomy, and Chemotherapy
    Yoshiro NISHIWAKI, Hideto OCHIAI, Toshikazu KANAI, Hiroaki TAMURA, Tadataka HAYASHI, Shinichiro MIYAZAKI, Shinichi HASEGAWA, Takeshi BABA
    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2022; 83(4): 675.     CrossRef
  • Gastric linitis plastica due to signet-ring cell carcinoma with Krukenberg tumors diagnosed by endoscopic ultrasound-guided fine-needle aspiration
    Takeshi Okamoto, Hidekazu Suzuki, Katsuyuki Fukuda
    Clinical Journal of Gastroenterology.2021; 14(4): 994.     CrossRef
  • The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
    Feng‐Hua Wang, Xiao‐Tian Zhang, Yuan‐Fang Li, Lei Tang, Xiu‐Juan Qu, Jie‐Er Ying, Jun Zhang, Ling‐Yu Sun, Rong‐Bo Lin, Hong Qiu, Chang Wang, Miao‐Zhen Qiu, Mu‐Yan Cai, Qi Wu, Hao Liu, Wen‐Long Guan, Ai‐Ping Zhou, Yu‐Jing Zhang, Tian‐Shu Liu, Feng Bi, Xian
    Cancer Communications.2021; 41(8): 747.     CrossRef
  • Is Routine Gastroscopy/Colonoscopy Reasonable in Patients With Suspected Ovarian Cancer: A Retrospective Study
    Guochen Liu, Junping Yan, Shanshan Long, Zhimin Liu, Haifeng Gu, Hua Tu, Jundong Li
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Surgical management of oligometastatic disease in gastric cancer
    Peng Jin, Xiaoyan Ji, Yantao Tian
    Clinics and Research in Hepatology and Gastroenterology.2020; 44(5): 638.     CrossRef
  • The role of surgical resection before palliative chemotherapy in advanced gastric cancer
    Yong Won Choi, Mi Sun Ahn, Geum Sook Jeong, Hyun Woo Lee, Seong Hyun Jeong, Seok Yun Kang, Joon Seong Park, Jin-Hyuk Choi, Sang-Yong Son, Hoon Hur, Sang-Uk Han, Seung Soo Sheen
    Scientific Reports.2019;[Epub]     CrossRef
  • The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer
    Feng‐Hua Wang, Lin Shen, Jin Li, Zhi‐Wei Zhou, Han Liang, Xiao‐Tian Zhang, Lei Tang, Yan Xin, Jing Jin, Yu‐Jing Zhang, Xiang‐Lin Yuan, Tian‐Shu Liu, Guo‐Xin Li, Qi Wu, Hui‐Mian Xu, Jia‐Fu Ji, Yuan‐Fang Li, Xin Wang, Shan Yu, Hao Liu, Wen‐Long Guan, Rui‐Hu
    Cancer Communications.2019; 39(1): 1.     CrossRef
  • Treatments and overall survival in patients with Krukenberg tumor
    Ruggero Lionetti, Marcello De Luca, Antonio Travaglino, Antonio Raffone, Luigi Insabato, Gabriele Saccone, Massimo Mascolo, Maria D’armiento, Fulvio Zullo, Francesco Corcione
    Archives of Gynecology and Obstetrics.2019; 300(1): 15.     CrossRef
  • Effects of metastasectomy and other factors on survival of patients with ovarian metastases from gastric cancer: a systematic review and meta‐analysis
    Chao Zhang, Wenbin Hou, Jinyu Huang, Songcheng Yin, Pengliang Wang, Zhe Zhang, Yuen Tan, Huimian Xu
    Journal of Cellular Biochemistry.2019; 120(9): 14486.     CrossRef
  • Multi-Modality Treatment for Patients With Metastatic Gastric Cancer: A Real-World Study in China
    Lin Zhao, Jiarui Li, Chunmei Bai, Yongdu Nie, Guole Lin
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Prognostic factors in Krukenberg tumor
    Ruggero Lionetti, Marcello De Luca, Antonio Travaglino, Antonio Raffone, Gabriele Saccone, Antonietta Di Cicco, Luigi Insabato, Massimo Mascolo, Maria D’Armiento, Fulvio Zullo, Francesco Corcione
    Archives of Gynecology and Obstetrics.2019; 300(5): 1155.     CrossRef
  • Palliative surgery for Krukenberg tumors – 12-year experience and review of the literature
    Isaac Seow-En, Gwen Hwarng, Grace Hwei Ching Tan, Leonard Ming Li Ho, Melissa Ching Ching Teo
    World Journal of Clinical Oncology.2018; 9(1): 13.     CrossRef
  • Pressurized intraperitoneal aerosol chemotheprapy after misdiagnosed gastric cancer: Case report and review of the literature
    Maciej Nowacki, Dariusz Grzanka, Wojciech Zegarski
    World Journal of Gastroenterology.2018; 24(19): 2130.     CrossRef
  • Is a Surgical Approach Justified in Metachronous Krukenberg Tumor from Gastric Cancer? A Systematic Review
    Paolo Aurello, Giammauro Berardi, Laura Antolino, Giulio Antonelli, Alessia Rampini, Giovanni Moschetta, Giovanni Ramacciato
    Oncology Research and Treatment.2018; 41(10): 644.     CrossRef
  • An Unusual Cause of Acute Perforation
    Najib Nassani, Liliane Deeb, Sherif Andrawes
    Gastroenterology.2017; 152(5): 956.     CrossRef
  • Krukenberg tumors: Seed, route and soil
    Annamaria Agnes, Alberto Biondi, Riccardo Ricci, Valerio Gallotta, Domenico D'Ugo, Roberto Persiani
    Surgical Oncology.2017; 26(4): 438.     CrossRef
  • Comparison of a Panel of Biomarkers Between Gastric Primary Cancer and the Paired Krukenberg Tumor
    Bo Wang, Ke Sun, Yinying Zou
    Applied Immunohistochemistry & Molecular Morphology.2017; 25(9): 639.     CrossRef
  • Treatment strategy and prognostic factors for Krukenberg tumors of gastric origin: report of a 10-year single-center experience from China
    Pengfei Yu, Ling Huang, Guoping Cheng, Litao Yang, Gaiguo Dai, Jieer Ying, Yian Du
    Oncotarget.2017; 8(47): 82558.     CrossRef
  • Surgical treatment of gastric carcinoma with ovarian metastases
    Tomasz Olesinski
    Current Issues in Pharmacy and Medical Sciences.2017; 30(4): 195.     CrossRef
  • Krukenberg Tumors of Gastric Origin: The Rationale of Surgical Resection and Perioperative Treatments in a Multicenter Western Experience
    Fausto Rosa, Daniele Marrelli, Paolo Morgagni, Chiara Cipollari, Giovanni Vittimberga, Massimo Framarini, Luca Cozzaglio, Corrado Pedrazzani, Stefano Berardi, Gian Luca Baiocchi, Franco Roviello, Nazario Portolani, Giovanni de Manzoni, Guido Costamagna, G
    World Journal of Surgery.2016; 40(4): 921.     CrossRef
  • 21,191 View
  • 392 Download
  • 33 Web of Science
  • 29 Crossref
Close layer
Palliative Radiotherapy in the Presence of Well-Controlled Metastatic Disease after Initial Chemotherapy May Prolong Survival in Patients with Metastatic Esophageal and Gastric Cancer
Mohan Hingorani, Sanjay Dixit, Miriam Johnson, Victoria Plested, Kevin Alty, Peter Colley, Andrew W. Beavis, Rajarshi Roy, Anthony Maraveyas
Cancer Res Treat. 2015;47(4):706-717.   Published online February 16, 2015
DOI: https://doi.org/10.4143/crt.2014.174
AbstractAbstract PDFPubReaderePub
Purpose
We report the outcomes of patients treated with palliative radiotherapy (pRT) to the primary tumour in the context of well-controlled metastatic disease after initial chemotherapy. Materials and Methods Clinical records of 132 patients with metastatic esophago-gastric (OG) cancer treated with palliative chemotherapy (pCT) between January 2009 and June 2013 were reviewed. Ninetyseven patients had responding or stable disease after 3 months of chemotherapy, of whom 53 patients received pRT to the primary tumour after initial chemotherapy in the presence of well-controlled metastatic disease (group A, pCT-RT). The remaining 44 patients were treated with pCT alone (group B, pCT). Treatment-related outcomes were assessed in above groups including time to local progression (TTLP), progression-free and overall survival.
Results
The median overall survival for patients treated with pRT after initial chemotherapy (group A) was 23.3 months (95% confidence interval [CI], 17.70 to 28.89 months) and significantly higher than the 14 months (95% CI, 10.91 to 17.08 months) in patients treated with pCT alone (group B) (p < 0.001). The use of pCT-RT was an independent predictor of OS in multivariate analysis. Local recurrence was observed in 12/53 of patients (23%) in group A compared to 16/44 (36%) in group B. The median TTLP was significantly higher in patients after pCT-RT at 17.3 months (5.23 months to 44.50 months) compared to 8.3 months (range, 4.10 to 25.23 months) in patients treated with pCT alone (p=0.006). Conclusion The possibility of pRT influencing systemic disease in advanced OG cancer has not been reported, and results from the present study present strong arguments for investigation of this therapeutic strategy in a randomized trial.

Citations

Citations to this article as recorded by  
  • Comparison of Efficacy and Safety of Combined Chemoimmunotherapy With or Without Radiation Therapy for Stage IVB Esophageal Squamous Cell Carcinoma: A Multicenter Propensity Score Matching Analysis
    Biqi Chen, Wenyan Chen, Qi Cheng, Hao Zhang, Bingyi Wang, Yujin Xu, Chen Yang, Xingyuan Cheng, Ruixi Wang, Sifen Wang, Peiying Cen, Lin Wang, Mihnea P. Dragomir, Yujia Zhu, Shiliang Liu, Mian Xi, Qiaoqiao Li, Baoqing Chen
    International Journal of Radiation Oncology*Biology*Physics.2024;[Epub]     CrossRef
  • The value of intervention with radiotherapy after first-line chemo-immunotherapy in locally advanced or metastatic esophageal squamous cell carcinoma: A multi-center retrospective study
    Hui-Hui Hu, Xin Xu, Xiao-Yang Li, Ya Zeng, Yue Li, Xin-Yun Song, Xiao-Long Fu, Xiu-Mei Ma, Wen Yu
    Clinical and Translational Radiation Oncology.2024; 48: 100818.     CrossRef
  • Oligometastatic esophageal cancer cured by systemic therapy combined with radiotherapy to primary tumor and metastasis (metastasis-directed therapy)—small case series
    Mohan Hingorani, Hannah Stubley
    Exploration of Targeted Anti-tumor Therapy.2024; 5(4): 921.     CrossRef
  • The Contribution of Curative Dose Radiotherapy to Primary Disease with Concurrent Chemotherapy on Survival in Patients with Metastatic Esophageal Cancer
    Menekşe Turna, Meltem Kırlı, Okan Özdemir, Hamit Başaran, Kadriye Ayşenur Arlı Karaçam
    European Archives of Medical Research.2023; 39(2): 74.     CrossRef
  • Induction immunochemotherapy followed by radiotherapy for patients with unresectable locally advanced or metastatic esophageal cancer: A propensity score-matched analysis
    Wei Deng, Xiao Chang, Xin Dong, Yuting Zhao, Dan Yang, Leilei Jiang, Anhui Shi, Huiming Yu, Rong Yu, Zefen Xiao, Weihu Wang
    International Immunopharmacology.2023; 124: 110955.     CrossRef
  • Combine radiotherapy and immunotherapy in esophageal squamous cell carcinoma
    Yicong Chen, Ruixuan Yu, Yongmei Liu
    Critical Reviews in Oncology/Hematology.2023; 190: 104115.     CrossRef
  • Metastasis pattern and prognosis in men with esophageal cancer patients
    Shengqiang Zhang, Jida Guo, Hongyan Zhang, Huawei Li, Mohamed Osman Omar Hassan, Linyou Zhang
    Medicine.2021; 100(25): e26496.     CrossRef
  • A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Patients with Initially Diagnosed Metastatic Esophageal Cancer: A SEER-Based Study
    Xin Tang, Xiaojuan Zhou, Yanying Li, Xue Tian, Yongsheng Wang, Meijuan Huang, Li Ren, Lin Zhou, Zhenyu Ding, Jiang Zhu, Yong Xu, Feng Peng, Jin Wang, You Lu, Youling Gong
    Annals of Surgical Oncology.2019; 26(2): 321.     CrossRef
  • Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach

    Journal of Gastric Cancer.2019; 19(1): 1.     CrossRef
  • A clinical analysis of systemic chemotherapy combined with radiotherapy for advanced gastric cancer
    Hong-Min Dong, Qin Wang, Wen-Ling Wang, Gang Wang, Xiao-Kai Li, Guo-Dong Li, Juan Chen
    Medicine.2018; 97(23): e10786.     CrossRef
  • Palliative radiotherapy and chemoradiotherapy in stage IVA/B esophageal cancer patients with dysphagia
    Terufumi Kawamoto, Keiji Nihei, Keisuke Sasai, Katsuyuki Karasawa
    International Journal of Clinical Oncology.2018; 23(6): 1076.     CrossRef
  • Improved Overall Survival with Aggressive Primary Tumor Radiotherapy for Patients with Metastatic Esophageal Cancer
    David M. Guttmann, Nandita Mitra, Justin Bekelman, James M. Metz, John Plastaras, Weiwei Feng, Samuel Swisher-McClure
    Journal of Thoracic Oncology.2017; 12(7): 1131.     CrossRef
  • Lymph node dissection improved survival in patients with metastatic thoracic esophageal cancer: An analysis of 220 patients from the SEER database
    San-Gang Wu, Zhen-Yu He, Yan Wang, Jia-Yuan Sun, Huan-Xin Lin, Guo-Qiang Su, Qun Li
    International Journal of Surgery.2016; 35: 13.     CrossRef
  • Expression of microtubule-associated protein TPX2 in human gastric carcinoma and its prognostic significance
    Cuijie Shao, Changsheng Duan, Jiani Wang, Shunlian Luan, Yong Gao, Dan Jin, Deqiang Wang, Yuming Li, Lihua Xu
    Cancer Cell International.2016;[Epub]     CrossRef
  • 11,870 View
  • 84 Download
  • 14 Web of Science
  • 14 Crossref
Close layer
Overexpression of Plasminogen Activator Inhibitor-1 in Advanced Gastric Cancer with Aggressive Lymph Node Metastasis
Yun-Suhk Suh, Jieun Yu, Byung Chul Kim, Boram Choi, Tae-Su Han, Hye Seong Ahn, Seong-Ho Kong, Hyuk-Joon Lee, Woo Ho Kim, Han-Kwang Yang
Cancer Res Treat. 2015;47(4):718-726.   Published online February 2, 2015
DOI: https://doi.org/10.4143/crt.2014.064
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to investigate differentially expressed genes using DNA microarray between advanced gastric cancer (AGC) with aggressive lymph node (LN) metastasis and that with a more advanced tumor stage but without LN metastasis.
Materials and Methods
Five sample pairs of gastric cancer tissue and normal gastric mucosa were taken from three patients with T3N3 stage (highN) and two with T4N0 stage (lowN). Data from triplicate DNA microarray experiments were analyzed, and candidate genes were identified using a volcano plot that showed ≥ 2-fold differential expression and were significant by Welch's t test (p < 0.05) between highN and lowN. Those selected genes were validated independently by reverse- transcriptase–polymerase chain reaction (RT-PCR) using five AGC patients, and tissue- microarray (TMA) comprising 47 AGC patients.
Results
CFTR, LAMC2, SERPINE2, F2R, MMP7, FN1, TIMP1, plasminogen activator inhibitor-1 (PAI- 1), ITGB8, SDS, and TMPRSS4 were commonly up-regulated over 2-fold in highN. REG3A, CD24, ITLN1, and WBP5 were commonly down-regulated over 2-fold in lowN. Among these genes, overexpression of PAI-1 was validated by RT-PCR, and TMA showed 16.7% (7/42) PAI-1 expression in T3N3, but none (0/5) in T4N0 (p=0.393).
Conclusion
DNA microarray analysis and validation by RT-PCR and TMA showed that overexpression of PAI-1 is related to aggressive LN metastasis in AGC.

Citations

Citations to this article as recorded by  
  • Expression of Serpin Family E Member 1 (SERPINE1) Is Associated with Poor Prognosis of Gastric Adenocarcinoma
    Jie Lv, Chunyang Yu, Hanhan Tian, Tao Li, Changhua Yu
    Biomedicines.2023; 11(12): 3346.     CrossRef
  • Helicobacter pylori-induced fibroblast-derived Serpin E1 promotes gastric cancer growth and peritoneal dissemination through p38 MAPK/VEGFA-mediated angiogenesis
    Wei Cheng, Yonghui Liao, Yuan Xie, Qinrong Wang, Leilei Li, Yuanjia Chen, Yan Zhao, Jianjiang Zhou
    Cancer Cell International.2023;[Epub]     CrossRef
  • Analysis of CFTR gene expression as an immunological and prognostic biomarker in pan-cancers
    Qi Wang, Shubing Jia, Jie Zheng, Rongwu Xiang, Yong Cui, Jinghai Zhang, Yijia Xu, Mingyi Zhao
    Computers in Biology and Medicine.2022; 146: 105614.     CrossRef
  • Interplay of Helicobacter pylori, fibroblasts, and cancer cells induces fibroblast activation and serpin E1 expression by cancer cells to promote gastric tumorigenesis
    Xueshu Chen, Wei Chen, Yan Zhao, Qinrong Wang, Wenling Wang, Yining Xiang, Hang Yuan, Yuan Xie, Jianjiang Zhou
    Journal of Translational Medicine.2022;[Epub]     CrossRef
  • SERBP1 affects the apoptotic level by regulating the expression and alternative splicing of cellular and metabolic process genes in HeLa cells
    Junjie Zhou, Wenhao Chen, Qianwen He, Dong Chen, Chunguang Li, Congqing Jiang, Zhao Ding, Qun Qian
    PeerJ.2022; 10: e14084.     CrossRef
  • A qualitative transcriptional signature of recurrence risk for stages II–III gastric cancer patients after surgical resection
    Huarong Zhang, Xiangyu Li, Junling Wu, Jiahui Zhang, Haiyan Huang, Yawei Li, Meifeng Li, Shanshan Wang, Jie Xia, Lishuang Qi, Ting Chen, Lu Ao
    Journal of Gastroenterology and Hepatology.2021; 36(9): 2501.     CrossRef
  • Weighted correlation network analysis identifies FN1, COL1A1 and SERPINE1 associated with the progression and prognosis of gastric cancer
    Qiaoyun Zhao, Jun Xie, Jinliang Xie, Rulin Zhao, Conghua Song, Huan Wang, Jianfang Rong, Lili Yan, Yanping Song, Fangfei Wang, Yong Xie
    Cancer Biomarkers.2021; 31(1): 59.     CrossRef
  • Current therapeutic options for gastric adenocarcinoma
    C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
    Saudi Journal of Biological Sciences.2021; 28(9): 5371.     CrossRef
  • Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma
    Gary Tincknell, Ann-Katrin Piper, Morteza Aghmesheh, Therese Becker, Kara Lea Vine, Daniel Brungs, Marie Ranson
    Cancers.2021; 13(16): 4097.     CrossRef
  • Sustained postoperative plasma elevations of plasminogen activator inhibitor‑1 following minimally invasive colorectal cancer resection
    H.M.C. Kumara, Addison Poppy, Dasuni Gamage, Erica Pettke, Abhinit Shah, Xiaohong Yan, Vesna Cekic, Richard Whelan
    Molecular and Clinical Oncology.2021;[Epub]     CrossRef
  • High WBP5 expression correlates with elevation of HOX genes levels and is associated with inferior survival in patients with acute myeloid leukaemia
    C. Ward, P. Cauchy, P. Garcia, J. Frampton, M. A. Esteban, G. Volpe
    Scientific Reports.2020;[Epub]     CrossRef
  • microRNA‐501‐5p promotes cell proliferation and migration in gastric cancer by downregulating LPAR1
    Xiang Ma, Jiaxi Feng, Ming Lu, Wenjuan Tang, Jianbo Han, XiaGang Luo, Qinghong Zhao, Li Yang
    Journal of Cellular Biochemistry.2020; 121(2): 1911.     CrossRef
  • Adipocyte-Derived Leptin Promotes PAI-1-Mediated Breast Cancer Metastasis in a STAT3/miR-34a Dependent Manner
    Si-Jing Li, Xiao-Hui Wei, Xiao-Man Zhan, Jin-Yong He, Yu-Qi Zeng, Xue-Mei Tian, Sheng-Tao Yuan, Li Sun
    Cancers.2020; 12(12): 3864.     CrossRef
  • Global transcriptomic analysis identifiesSERPINE1as a prognostic biomarker associated with epithelial-to-mesenchymal transition in gastric cancer
    Bodong Xu, Zhigang Bai, Jie Yin, Zhongtao Zhang
    PeerJ.2019; 7: e7091.     CrossRef
  • Role of ion channels in gastrointestinal cancer
    Kyle J Anderson, Robert T Cormier, Patricia M Scott
    World Journal of Gastroenterology.2019; 25(38): 5732.     CrossRef
  • Clinicopathological and Prognostic Significance of WW Domain Binding Protein 5 Expression in Papillary Thyroid Carcinoma
    Yangyang Qian, Zongfu Pan, Zhenying Guo, Xinyang Ge, Guowan Zheng, Jun Cao, Ping Huang, Xin Zhu, Xuhang Zhu, Qingliang Wen, Minghua Ge
    BioMed Research International.2019; 2019: 1.     CrossRef
  • Cystic fibrosis transmembrane conductance regulator—emerging regulator of cancer
    Jieting Zhang, Yan Wang, Xiaohua Jiang, Hsiao Chang Chan
    Cellular and Molecular Life Sciences.2018; 75(10): 1737.     CrossRef
  • Identification of Potential Key Genes Associated With the Pathogenesis and Prognosis of Gastric Cancer Based on Integrated Bioinformatics Analysis
    Xinkui Liu, Jiarui Wu, Dan Zhang, Zhitong Bing, Jinhui Tian, Mengwei Ni, Xiaomeng Zhang, Ziqi Meng, Shuyu Liu
    Frontiers in Genetics.2018;[Epub]     CrossRef
  • The Expression and Significance of FAK/PI3K/AKt/mTOR Signaling Pathway Related Proteins in Human Gastric Carcinoma
    波 于
    World Journal of Cancer Research.2018; 08(03): 113.     CrossRef
  • Proteomic analysis of evodiamine-induced cytotoxicity in thyroid cancer cells
    Hui-I Yu, Hsiu-Chuan Chou, Yi-Ching Su, Li-Hsun Lin, Chieh-Hsiang Lu, Hsiang-Hsun Chuang, Yi-Ting Tsai, En-Chi Liao, Yu-Shan Wei, Yi-Ting Yang, Ying-Ray Lee, Hong-Lin Chan
    Journal of Pharmaceutical and Biomedical Analysis.2018; 160: 344.     CrossRef
  • Dynamic matrisome: ECM remodeling factors licensing cancer progression and metastasis
    Arseniy E. Yuzhalin, Su Yin Lim, Anton G. Kutikhin, Alex N. Gordon-Weeks
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2018; 1870(2): 207.     CrossRef
  • MicroRNA-200c binding to FN1 suppresses the proliferation, migration and invasion of gastric cancer cells
    Hengchun Zhang, Zhiguo Sun, Yan Li, Dong Fan, Hao Jiang
    Biomedicine & Pharmacotherapy.2017; 88: 285.     CrossRef
  • Methylation Levels of LINE-1 As a Useful Marker for Venous Invasion in Both FFPE and Frozen Tumor Tissues of Gastric Cancer
    Jimin Min, Boram Choi, Tae-Su Han, Hyuk-Joon Lee, Seong-Ho Kong, Yun-Suhk Suh, Tae-Han Kim, Hwi-Nyeong Choe, Woo Ho Kim, Keun Hur, Han-Kwang Yang
    Molecules and Cells.2017; 40(5): 346.     CrossRef
  • WW domain binding protein 5 induces multidrug resistance of small cell lung cancer under the regulation of miR-335 through the Hippo pathway
    Ruixiang Tang, Yingying Lei, Bingshuang Hu, Jie Yang, Shun Fang, Qiongyao Wang, Man Li, Linlang Guo
    British Journal of Cancer.2016; 115(2): 243.     CrossRef
  • Gastric cancer from operating theatre to bench in Korea
    H-K Yang
    British Journal of Surgery.2016; 103(10): 1251.     CrossRef
  • The embryonic stress response to in vitro culture: insight from genomic analysis
    Gael Cagnone, Marc-André Sirard
    Reproduction.2016; 152(6): R247.     CrossRef
  • 15,140 View
  • 163 Download
  • 27 Web of Science
  • 26 Crossref
Close layer
Dosimetric and Clinical Influence of 3D Versus 2D Planning in Postoperative Radiation Therapy for Gastric Cancer
Jung Ae Lee, Yong Chan Ahn, Do Hoon Lim, Hee Chul Park, Margarita S. Asranbaeva
Cancer Res Treat. 2015;47(4):727-737.   Published online December 2, 2014
DOI: https://doi.org/10.4143/crt.2014.018
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to investigate the dosimetric and clinical influence of computed tomography–based (3-dimensional [3D]) simulation versus conventional 2-dimensional (2D)–based simulation in postoperative chemoradiotherapy (CRT) for patients with advanced gastric cancer in terms of parallel opposed anteroposterior-posteroanterior field arrangement. Materials and Methods A retrospective stage-matched cohort study was conducted in 158 patients treated with adjuvant CRT following curative surgery and D2 dissection from 2006 to 2008 at Samsung Medical Center: 98 patients in the 3D group; and 60 patients in the 2D group. For comparison of the dosimetric parameters between 3D plan and 2D plan, second sets of radiation treatment plans were generated according to the same target delineation method used in the 2D group for each patient in the 3D group (V2D). Acute toxicity, recurrence, and survival were analyzed. The median follow-up period was 28 months (range, 5 to 51 months). Results The 3D group showed better dose-volume histogram (DVH) profiles than the V2D group for all dosimetric parameters, including the kidneys, liver, spinal cord, duodenum, pancreas, and bowel. However, no difference in acute gastrointestinal toxicity and survival outcomes was observed between the 3D group and the 2D group. Conclusion The 3D plan enabled precise delineation of the target volume and organs at risk by visualization of geometric changes in the internal organs after surgery. The DVH of normal tissues in the 3D plan was superior to that of the V2D plan, but similar clinical features were observed between the 3D group and the 2D group.

Citations

Citations to this article as recorded by  
  • Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer
    Ya-Kun Jiang, Wei Li, Ying-Yang Qiu, Meng Yue
    World Journal of Gastrointestinal Oncology.2024; 16(6): 2318.     CrossRef
  • Evaluation the benefits of additional radiotherapy for gastric cancer patients after D2 resection using CT based radiomics
    Haoze Zheng, Qiao Zheng, Mengmeng Jiang, Didi Chen, Ce Han, Jinling Yi, Yao Ai, Jingyi Yan, Xiance Jin
    La radiologia medica.2023; 128(6): 679.     CrossRef
  • The impact of radiation treatment planning technique on unplanned hospital admissions
    Sanders Chang, Meng Ru, Erin L. Moshier, Madhu Mazumdar, Doran Ricks, Nathan E. Goldstein, Juan P. Wisnivesky, Kavita V. Dharmarajan
    Advances in Radiation Oncology.2018; 3(4): 647.     CrossRef
  • Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist’s view of the ARTIST randomized phase III trial
    Jeong Il Yu, Do Hoon Lim, Yong Chan Ahn, Jeeyun Lee, Won Ki Kang, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Seung Tae Kim, Sung Kim, Tae Sung Sohn, Min Gew Choi, Jae Moon Bae, Heerim Nam
    Radiotherapy and Oncology.2015; 117(1): 171.     CrossRef
  • 16,337 View
  • 124 Download
  • 6 Web of Science
  • 4 Crossref
Close layer
Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute
Yooju Shin, Sang Yun Ha, Jiyeon Hyeon, Boram Lee, Jeeyun Lee, Kee-Taek Jang, Kyoung-Mee Kim, Young Suk Park, Cheol-Keun Park
Cancer Res Treat. 2015;47(4):738-746.   Published online February 16, 2015
DOI: https://doi.org/10.4143/crt.2014.224
AbstractAbstract PDFPubReaderePub
Purpose
Management of gastroenteropancreatic (GEP) neuroendocrine tumors with liver metastases (NETLM) presents many clinical challenges. Assessment of the extent of disease and primary tumor site is crucial for management. In this study, we investigated the primary tumor sites and prognostic factors in GEP NETLM among Korean patients. Materials and Methods We reviewed the medical records of 72 Korean patients diagnosed with GEP NETLM between January 1999 and May 2013, focusing on their clinical and pathologic characteristics.
Results
The most frequently encountered primary tumor sites were the pancreas (n=25, 35%), stomach (n=8, 11%), gall bladder (n=4, 6%) and rectum (n=3, 4%). Twenty-five patients (35%) had occult primary tumor. Twelve patients (17%) had histological grade G1 tumors, 30 patients (42%) had G2 tumors, and 30 patients (42%) had G3 tumors. The mean follow-up period after histological confirmation of hepatic metastases was 11.30±2.44 months for G3 tumors, 19.67±4.09 months for G2 tumors, and 30.67±6.51 months for G1 tumors. Multivariate analyses revealed that an unknown primary tumor site (p=0.001) and higher histological grade (p < 0.001) were independent prognostic indicators for shorter overall survival (OS). Most long-term survivors (OS > 24 months) had received antitumor treatment. Conclusion The primary tumor site most frequently associated with GEP NETLM was the pancreas. Unknown primary tumor and higher histological grade were independent prognostic indicators for shorter OS. Patients identified as being at a risk of shorter OS should be followed up closely.

Citations

Citations to this article as recorded by  
  • Clinicopathological Characteristics of Nonfunctional Pancreatic Neuroendocrine Neoplasms and the Effect of Surgical Treatment on the Prognosis of Patients with Liver Metastases: A Study Based on the SEER Database
    Abuduhaibaier Sadula, Gang Li, Dianrong Xiu, Chen Ye, Siqian Ren, Xin Guo, Chunhui Yuan, Min Tang
    Computational and Mathematical Methods in Medicine.2022; 2022: 1.     CrossRef
  • Effects of tumor origins and therapeutic options on the prognosis of hepatic neuroendocrine tumors
    Xiaoxiao Jiao, Wenqing Luan, Xiaoqian Peng, Lu Liu, Lianfeng Zhang, Lin Zhou
    Medicine.2020; 99(51): e23655.     CrossRef
  • Analysis of B-ultrasound and contrast-enhanced ultrasound characteristics of different hepatic neuroendocrine neoplasm
    Xiao-Ning Kang, Xiao-Yu Zhang, Jie Bai, Zun-Yi Wang, Wen-Jie Yin, Li Li
    World Journal of Gastrointestinal Oncology.2019; 11(5): 436.     CrossRef
  • Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies
    Lingaku Lee, Tetsuhide Ito, Robert T Jensen
    Expert Review of Anticancer Therapy.2019; 19(12): 1029.     CrossRef
  • A Case Report: Gastric Mixed Neuroendocrine-Nonneuroendocrine Neoplasm with Aggressive Neuroendocrine Component
    Quang Duy Pham, Ichiro Mori, Robert Y. Osamura
    Case Reports in Pathology.2017; 2017: 1.     CrossRef
  • Pancreatic neuroendocrine tumor Grade 1 patients followed up without surgery: Case series
    Mitsuru Sugimoto, Tadayuki Takagi, Rei Suzuki, Naoki Konno, Hiroyuki Asama, Ko Watanabe, Jun Nakamura, Hitomi Kikuchi, Yuichi Waragai, Mika Takasumi, Satoshi Kawana, Yuko Hashimoto, Takuto Hikichi, Hiromasa Ohira
    World Journal of Clinical Oncology.2017; 8(3): 293.     CrossRef
  • Gastroenteropancreatic—origin neuroendocrine carcinomas
    Yong Gyun Won, Kyung-Jin Seo, Jiyeon Hyeon, Ok Ran Shin, Eundeok Chang, Der Sheng Sun, Hae Sung Won, Yoon Ho Ko, Sae Jung Na, Su Lim Lee, Young Mi Ku, Dong Soo Lee
    Medicine.2017; 96(49): e9009.     CrossRef
  • A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases
    Liangtao Ye, Huilin Ye, Quanbo Zhou, Zhihua Li, Qing Lin, Langping Tan, Wenchao Gao, Zhiqiang Fu, Shangyou Zheng, Rufu Chen
    International Journal of Surgery.2016; 29: 108.     CrossRef
  • Liver Metastasis of Gastrointestinal Neuroendocrine Tumors: A Single Center Experience
    Bita Geramizadeh, Ali Kashkooe, Seyed Ali Malekhosseini
    Hepatitis Monthly.2016;[Epub]     CrossRef
  • Neuroendocrine neoplasms of liver - A 5-year retrospective clinico-pathological study applying World Health Organization 2010 classification
    Deepak Kalyansingh Burad, Thomas Alex Kodiatte, Sayd Mohamed Rajeeb, Ashish Goel, Chundamannil Eapen Eapen, Banumathi Ramakrishna
    World Journal of Gastroenterology.2016; 22(40): 8956.     CrossRef
  • Unusual endoscopic findings of gastric neuroendocrine tumor
    Kazuhiro Kishi, Akihiko Fujisawa, Minoru Horikita, Yoshihiro Nakai, Kazushi Ooshimo, Fumiko Kishi, Masako Kimura, Chun-che Lin, Tetsuji Takayama
    The Journal of Medical Investigation.2015; 62(3.4): 251.     CrossRef
  • 11,833 View
  • 77 Download
  • 11 Web of Science
  • 11 Crossref
Close layer
The Frequency of and Risk Factors for the Use of Bisphosphonates in the Adjuvant Setting of Primary Breast Cancer in Germany
Eva-Maria Fick, Alexander Katalinic, Annika Waldmann
Cancer Res Treat. 2015;47(4):747-756.   Published online January 5, 2015
DOI: https://doi.org/10.4143/crt.2014.099
AbstractAbstract PDFPubReaderePub
Purpose
The aim of this cross-sectional health care study (use of bisphosphonates in primary tumors of the mammae, EBisMa) is to determine how often bisphosphonate medication is used in patients with non-metastatic primary breast cancer treatment, but who do not suffer from osteoporosis. Furthermore, we describe patients’ characteristics and the most frequently used type of bisphosphonate in adjuvant therapy.
Materials and Methods
The study population included primary breast cancer patients of four breast centers in northern Germany. Data on bisphosphonate therapy were collected by use of patient questionnaires; clinical data were extracted from the registers. Patients with and without prescribed bisphosphonate adjuvant treatment were tested for statistically significant differences regarding their characteristics.
Results
Four hundred seventy-four of 663 contacted patients participated in the study. Thirty-nine out of 474 patients (9.6%) were on adjuvant bisphosphonate therapy. Zoledronic acid was the most frequently reported bisphosphonate used for prevention of bone metastases. Compared to patients who did not report bisphosphonate medication, women who did report bisphosphonate therapy had a significantly higher advanced tumor stage (p < 0.001). Both the T2-T4 stage and N+ stage remained significant predictors in multivariate-adjusted regression models.
Conclusion
Bisphosphonates are rarely used in the adjuvant treatment of primary breast cancer. Patients with advanced tumor stage were more likely to use bisphosphonates in the adjuvant treatment of primary breast cancer. Further research is needed to identify patients who may benefit most from adjuvant bisphosphonate treatment.

Citations

Citations to this article as recorded by  
  • Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark
    Priscila Corraini, Uffe Heide‐Jørgensen, Morten Schiødt, Sven Erik Nørholt, John Acquavella, Henrik Toft Sørensen, Vera Ehrenstein
    Cancer Medicine.2017; 6(10): 2271.     CrossRef
  • 10,456 View
  • 72 Download
  • 2 Web of Science
  • 1 Crossref
Close layer
Using the Lymph Node Ratio to Evaluate the Prognosis of Stage II/III Breast Cancer Patients Who Received Neoadjuvant Chemotherapy and Mastectomy
San-Gang Wu, Qun Li, Juan Zhou, Jia-Yuan Sun, Feng-Yan Li, Qin Lin, Huan-Xin Lin, Xun-Xing Gaun, Zhen-Yu He
Cancer Res Treat. 2015;47(4):757-764.   Published online December 8, 2014
DOI: https://doi.org/10.4143/crt.2014.039
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted to investigate the prognostic value of lymph node ratio (LNR) in stage II/III breast cancer patients who undergo mastectomy after neoadjuvant chemotherapy.
Materials and Methods
Clinical and pathological data describing stage II/III breast cancer patients were included in this retrospective study. The primary outcomes were locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS).
Results
Among 277 patients, there were 43 ypN0, 64 ypN1, 89 ypN2, and 81 ypN3 cases. Additionally, there were 43, 57, 92 and 85 cases in the LNR 0, 0.01-0.20, 0.21-0.65, and > 0.65 groups, respectively. The median follow-up was 49.5 months. Univariate analysis showed that both ypN stage and LNR were prognostic factors of LRFS, DMFS, DFS, and OS (p < 0.05). Multivariate analysis showed that LNR was an independent prognostic factor of LRFS, DMFS, DFS, and OS (p < 0.05), while ypN stage had no effect on prognosis (p > 0.05).
Conclusion
The integrated use of LNR and ypN may be suitable for evaluation the prognosis of stage II/III breast cancer patients who undergo mastectomy after neoadjuvant chemotherapy.

Citations

Citations to this article as recorded by  
  • Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study
    Lingfeng Tang, Linshan Jiang, Xiujie Shu, Yudi Jin, Haochen Yu, Shengchun Liu
    Scientific Reports.2024;[Epub]     CrossRef
  • Prognostic disparities in young patients based on breast cancer subtype: A population-based study from the SEER database
    Bing Chen, Xiaojuan Zhang, Yi Liu, Chuandong Wang
    Medicine.2023; 102(13): e33416.     CrossRef
  • The Effect of Lymph Node Harvest on Prognosis in Locally Advanced Middle-Low Rectal Cancer After Neoadjuvant Chemoradiotherapy
    Zhuangbin Lin, Xiaobo Li, Jianyuan Song, Rong Zheng, Cheng Chen, Anchuan Li, Benhua Xu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Breast Cancer Patients With Positive Apical or Infraclavicular/Ipsilateral Supraclavicular Lymph Nodes Should Be Excluded in the Application of the Lymph Node Ratio System
    Zhe Wang, Wei Chong, Huikun Zhang, Xiaoli Liu, Yawen Zhao, Zhifang Guo, Li Fu, Yongjie Ma, Feng Gu
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • Is Pathologic Axillary Staging Valid If Lymph Nodes Are Less than 10 with Axillary Lymph Node Dissection after Neoadjuvant Chemotherapy?
    Hee Jun Choi, Jai Min Ryu, Jun Ho Lee, Yoonju Bang, Jongwook Oh, Byung-Joo Chae, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Se Kyung Lee, Jonghan Yu
    Journal of Clinical Medicine.2022; 11(21): 6564.     CrossRef
  • A novel nomogram for predicting locoregional recurrence risk in breast cancer patients treated with neoadjuvant chemotherapy and mastectomy
    Zhou Huang, Mei Shi, Wei-Hu Wang, Liang-Fang Shen, Yu Tang, Qing-Lin Rong, Li Zhu, Xiao-Bo Huang, Jian Tie, Jia-Yi Chen, Jun Zhang, Hong-Fen Wu, Jing Cheng, Min Liu, Chang-Ying Ma, Shu-Lian Wang, Ye-Xiong Li
    Radiotherapy and Oncology.2021; 161: 191.     CrossRef
  • Lymph node ratio as best prognostic factor in triple‐negative breast cancer patients with residual disease after neoadjuvant chemotherapy
    Gabriel A. De la Cruz‐Ku, Diego Chambergo‐Michilot, Bryan Valcarcel, Pamela Rebaza, Mecker Möller, Jhajaira M. Araujo, Daniel Enriquez, Zaida Morante, Cesar Razuri, Renato Luque, Antonella Saavedra, Eduardo Eyzaguirre, Maria Lujan, Naysha Noel, Joseph Pin
    The Breast Journal.2020; 26(9): 1659.     CrossRef
  • Development and validation of a nomogram incorporating axillary lymph node ratio to predict survival in node-positive breast cancer patients after neoadjuvant chemotherapy
    Jianguo Lai, Zihao Pan, Peixian Chen, Guolin Ye, Kai Chen, Fengxi Su
    Japanese Journal of Clinical Oncology.2019; 49(1): 22.     CrossRef
  • Lymph node ratio as an alternative to pN staging for predicting prognosis after neoadjuvant chemotherapy in breast cancer
    Dong Hui Cho, Soo Youn Bae, Ji Young You, Hong Kyu Kim, Young Woo Chang, Yoo Jin Choi, Sang Uk Woo, Gil Soo Son, Jae Bok Lee, Jeoung Won Bae, Seung Pil Jung
    The Kaohsiung Journal of Medical Sciences.2018; 34(6): 341.     CrossRef
  • Ganglio secundario como indicador de linfadenectomía axilar en pacientes afectas de cáncer de mama
    Manel Cremades, Mireia Torres, Montse Solà, Jordi Navinés, Icíar Pascual, Antonio Mariscal, Albert Caballero, Eva Castellà, Miguel Ángel Luna, Joan Francesc Julián
    Cirugía Española.2017; 95(9): 536.     CrossRef
  • Secondary Node Analysis as an Indicator for Axillary Lymphadenectomy in Breast Cancer Patients
    Manel Cremades, Mireia Torres, Montse Solà, Jordi Navinés, Icíar Pascual, Antonio Mariscal, Albert Caballero, Eva Castellà, Miguel Ángel Luna, Joan Francesc Julián
    Cirugía Española (English Edition).2017; 95(9): 536.     CrossRef
  • Risk factors of locoregional relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy following mastectomy and radiotherapy
    Liang Huang, Sheng Chen, Wentao T. Yang, Zhiming Shao
    Oncotarget.2017; 8(24): 39703.     CrossRef
  • Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer
    Jacqueline Tsai, Danielle Bertoni, Tina Hernandez-Boussard, Melinda L. Telli, Irene L. Wapnir
    Annals of Surgical Oncology.2016; 23(10): 3310.     CrossRef
  • Number of negative lymph nodes as a prognostic factor for ypN0-N1 breast cancer patients undergoing neoadjuvant chemotherapy
    Fei Xin, Yue Yu, Zheng-Jun Yang, Li-Kun Hou, Jie-Fei Mao, Li Xia, Xin Wang, Xu-Chen Cao
    Tumor Biology.2016; 37(6): 8445.     CrossRef
  • 11,699 View
  • 86 Download
  • 18 Web of Science
  • 14 Crossref
Close layer
Impact on Survival of Regular Postoperative Surveillance for Patients with Early Breast Cancer
Ji Yun Lee, Sung Hee Lim, Min-Young Lee, Haesu Kim, Moonjin Kim, Sungmin Kim, Hyun Ae Jung, Insuk Sohn, Won Ho Gil, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Cancer Res Treat. 2015;47(4):765-773.   Published online January 13, 2015
DOI: https://doi.org/10.4143/crt.2014.168
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to evaluate the role of regular postoperative surveillance to improve the prognosis of patients with breast cancer after curative surgery. Materials and Methods We retrospectively analyzed the medical records of 4,119 patients who received curative surgery for breast cancer at Samsung Medical Center between January 2000 and September 2008. Patients were divided into two groups (group I, regular postoperative surveillance; group II, control group) according to their post-therapy follow-up status for the first 5 years after surgery. Results Among the 3,770 patients selected for inclusion, groups I and II contained 3,300 (87%) and 470 (13%) patients, respectively. The recurrence rates at 5 years for groups I and II were 10.6% and 16.4%, respectively (hazard ratio, 0.85; 95% confidence interval [CI], 0.67 to 1.09; p=0.197). The 10-year mortality cumulative rates were 8.8% for group I and 25.4% for group II (hazard ratio, 0.28; 95% CI, 0.22 to 0.35; p < 0.001). In multivariate analysis for recurrence-free survival (RFS), age over 40 years (p < 0.001), histologic grade 1 (p < 0.001), and pathologic stage I (p < 0.001) were associated with longer RFS but not with follow- up status. Multivariate analysis for overall survival (OS) revealed that patients in group I showed significantly improved OS (hazard ratio, 0.29; 95% CI, 0.23 to 0.37; p < 0.001). Additionally, age over 40 years, histologic grade I, and pathologic stage I were independent prognostic factors for OS. Conclusion Regular follow-up for patients with breast cancer after primary surgery resulted in clinically significant improvements in patient OS.

Citations

Citations to this article as recorded by  
  • Follow-up strategy and survival for five common cancers: A meta-analysis
    Boris Galjart, Diederik J. Höppener, Joachim G.J.V. Aerts, Christiaan H. Bangma, Cornelis Verhoef, Dirk J. Grünhagen
    European Journal of Cancer.2022; 174: 185.     CrossRef
  • Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry
    Ji-Yeon Kim, Danbee Kang, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jong Han Yu, Se Kyung Lee, Young-Hyuck Im, Jin Seok Ahn, Eliseo Guallar, Juhee Cho, Yeon Hee Park
    Journal of Global Oncology.2019; (5): 1.     CrossRef
  • Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice
    Angela Lamarca, Hamish Clouston, Jorge Barriuso, Mairéad G McNamara, Melissa Frizziero, Was Mansoor, Richard A Hubner, Prakash Manoharan, Sarah O’Dwyer, Juan W Valle
    Journal of Clinical Medicine.2019; 8(10): 1630.     CrossRef
  • Analysis of patient-detected breast cancer recurrence
    Trishul Kapoor, Sean Wrenn, Peter Callas, Ted A. James
    Breast Disease.2017; 37(2): 77.     CrossRef
  • 11,880 View
  • 89 Download
  • 3 Web of Science
  • 4 Crossref
Close layer
Setup Error and Effectiveness of Weekly Image-Guided Radiation Therapy of TomoDirect for Early Breast Cancer
Mi Joo Chung, Guk Jin Lee, Young Jin Suh, Hyo Chun Lee, Sea-Won Lee, Songmi Jeong, Jeong Won Lee, Sung Hwan Kim, Dae Gyu Kang, Jong Hoon Lee
Cancer Res Treat. 2015;47(4):774-780.   Published online February 13, 2015
DOI: https://doi.org/10.4143/crt.2014.189
AbstractAbstract PDFPubReaderePub
Purpose
This study investigated setup error and effectiveness of weekly image-guided radiotherapy (IGRT) of TomoDirect for early breast cancer. Materials and Methods One hundred and fifty-one breasts of 147 consecutive patients who underwent breast conserving surgery followed by whole breast irradiation using TomoDirect in 2012 and 2013 were evaluated. All patients received weekly IGRT. The weekly setup errors from simulation to each treatment in reference to chest wall and surgical clips were measured. Random, systemic, and 3-dimensional setup errors were assessed. Extensive setup error was defined as 5 mm above the margin in any directions.
Results
All mean errors were within 3 mm of all directions. The mean angle of gantry shifts was 0.6°. The mean value of absolute 3-dimensional setup error was 4.67 mm. In multivariate analysis, breast size (odds ratio, 2.82; 95% confidence interval, 1.00 to 7.90) was a significant factor for extensive error. The largest significant deviation of setup error was observed in the first week of radiotherapy (p < 0.001) and the deviations gradually decreased with time. The deviation of setup error was 5.68 mm in the first week and within 5 mm after the second week. Conclusion In this study, there was a significant association between breast size and significant setup error in breast cancer patients who received TomoDirect. The largest deviation occurred in the first week of treatment. Therefore, patients with large breasts should be closely observed on every fraction and fastidious attention is required in the first fraction of IGRT.

Citations

Citations to this article as recorded by  
  • AAPM Task Group Report 306: Quality control and assurance for tomotherapy: An update to Task Group Report 148
    Quan Chen, Yi Rong, Jay W. Burmeister, Edward H. Chao, Nathan A. Corradini, David S. Followill, X. Allen Li, An Liu, X. Sharon Qi, Hairong Shi, Jennifer B. Smilowitz
    Medical Physics.2023;[Epub]     CrossRef
  • Robustness of VMAT to setup errors in postmastectomy radiotherapy of left-sided breast cancer: Impact of bolus thickness
    Yipeng He, Sijia Chen, Xiang Gao, Lirong Fu, Zheng Kang, Jun Liu, Liwan Shi, Yimin Li, Akif Enes Arikan
    PLOS ONE.2023; 18(1): e0280456.     CrossRef
  • ESTRO-ACROP guideline for positioning, immobilisation and setup verification for local and loco-regional photon breast cancer irradiation
    M.E. Mast, A. Leong, S.S. Korreman, G. Lee, H. Probst, P. Scherer, Y. Tsang
    Technical Innovations & Patient Support in Radiation Oncology.2023; 28: 100219.     CrossRef
  • Critical Factors of Dose Distribution in Breast Cancer Tomotherapy With Metallic Port Breast Tissue Expander: Image Correction, Delivery Mode, and Volume Impact
    Hsing-Yi Lee, Yu-Hsiu Yen, Yu-Lun Tsai, Pei-Chih Tu, Chi-Ming Pu, Chia-Hong Lin, Louis Tak Lui, Suzun Shaw, Ching-Jung Wu, Hsin-Hua Nien
    Technology in Cancer Research & Treatment.2022;[Epub]     CrossRef
  • Factors impacting on patient setup analysis and error management during breast cancer radiotherapy
    Ioana-Claudia Costin, Loredana G. Marcu
    Critical Reviews in Oncology/Hematology.2022; 178: 103798.     CrossRef
  • Postoperative radiotherapy with intensity-modulated radiation therapy versus 3-dimensional conformal radiotherapy in early breast cancer: A randomized clinical trial of KROG 15-03
    Kyu Hye Choi, Sung Ja Ahn, Jae Uk Jeong, Mina Yu, Jin Hee Kim, Bae Kwon Jeong, Joo Hwan Lee, Sung Hwan Kim, Jong Hoon Lee
    Radiotherapy and Oncology.2021; 154: 179.     CrossRef
  • Analysis of local setup errors of sub-regions in cone-beam CT-guided post-mastectomy radiation therapy
    Jidan Zhou, Shuai Li, Chengwei Ye, Konglong Shen, An Li, Gang Chen, Xiaoyu Li, Sen Bai, Weifeng Wang, Renming Zhong
    Journal of Radiation Research.2020; 61(3): 457.     CrossRef
  • A Prospective Study to Investigate the Placement of Setup Skin Markings for Larger Breasted Women Undergoing External Beam Radiotherapy (RT) for Breast Cancer
    Chris Osam Doudoo, Neill Roberts, Emmanuel Amankwaa Frempong, Clement Edusa, Kwamena Beecham, Kofi Agyiri, Promise Ahiagbenyo, George Felix Acquah, Dominic Gadeka Eric Abakuri, Michael Mordey, Anna Maria Anim, Bismark Djan
    International Journal of Scientific Research in Science and Technology.2019; : 99.     CrossRef
  • Dosimetric Comparison of Setup Errors in Intensity Modulated Radiation Therapy with Deep Inspiration Breath Holding in Breast Cancer Radiation Therapy
    Ham Il-Sik, Cho Pyong-Kon, Jung Kang-Kyo
    Journal of Radiological Science and Technology.2019; 42(2): 137.     CrossRef
  • Setup Error Assessment and Correction in Planar kV Image- Versus Cone Beam CT Image-Guided Radiation Therapy: A Clinical Study of Early Breast Cancer Treated With External Beam Partial Breast Irradiation
    Wei Wang, Ting Yu, Min Xu, Qian Shao, Yingjie Zhang, Jianbin Li
    Technology in Cancer Research & Treatment.2019;[Epub]     CrossRef
  • A Potential Anti-Tumor Herb Bred in a Tropical Fruit: Insight into the Chemical Components and Pharmacological Effects of Momordicae Semen
    Xiao-Rong Xu, Chuan-Hong Luo, Bo Cao, Run-Chun Xu, Fang Wang, Xi-Chuan Wei, Ting Zhang, Li Han, Ding-Kun Zhang
    Molecules.2019; 24(21): 3949.     CrossRef
  • Xihuang pill promotes apoptosis of Treg cells in the tumor microenvironment in 4T1 mouse breast cancer by upregulating MEKK1/SEK1/JNK1/AP-1 pathway
    Liang Su, Yiming Jiang, Yu Xu, Xinye Li, Wenbin Gao, Chunwei Xu, Changqian Zeng, Jie Song, Wencai Weng, Wenbo Liang
    Biomedicine & Pharmacotherapy.2018; 102: 1111.     CrossRef
  • The Antitumor Effect of Xihuang Pill on Treg Cells Decreased in Tumor Microenvironment of 4T1 Breast Tumor‐Bearing Mice by PI3K/AKT~AP‐1 Signaling Pathway
    Xin-ye Li, Liang Su, Yi-ming Jiang, Wen-bin Gao, Chun-wei Xu, Chang-qian Zeng, Jie Song, Yu Xu, Wen-cai Weng, Wen-bo Liang, Jian-Li Gao
    Evidence-Based Complementary and Alternative Medicine.2018;[Epub]     CrossRef
  • Setup errors and effectiveness of Optical Laser 3D Surface imaging system (Sentinel) in postoperative radiotherapy of breast cancer
    Xiaobo Wei, Mengjiao Liu, Yun Ding, Qilin Li, Changhai Cheng, Xian Zong, Wenming Yin, Jie Chen, Wendong Gu
    Scientific Reports.2018;[Epub]     CrossRef
  • Applying human factors engineering methods for hazard identification and mitigation in the radiotherapy process
    Mariana Bernardes, Clarissa Trzesniak, Patricia Trbovich, Carlos Henrique Pereira Mello
    Safety Science.2018; 109: 270.     CrossRef
  • Compared with intensity‐modulated radiotherapy, image‐guided radiotherapy reduces severity of acute radiation‐induced skin toxicity during radiotherapy in patients with breast cancer
    Jang‐Chun Lin, Jo‐Ting Tsai, Yu‐Ching Chou, Ming‐Hsien Li, Wei‐Hsiu Liu
    Cancer Medicine.2018; 7(8): 3622.     CrossRef
  • A topology-based method to mitigate the dosimetric uncertainty caused by the positional variation of the boost volume in breast conservative radiotherapy
    Peng-Yi Lee, Chih-Yuan Lin, Shang-Wen Chen, Chun-Ru Chien, Chun-Nan Chu, Hsiu-Ting Hsu, Ji-An Liang, Ying-Jun Lin, An-Cheng Shiau
    Radiation Oncology.2017;[Epub]     CrossRef
  • Setup deviations for whole-breast radiotherapy with TomoDirect: A comparison of weekly and biweekly image-guided protocols
    Jae Hong Jung, Joo-Young Jung, Sun Hyun Bae, Seong Kwon Moon, Kwang Hwan Cho
    Journal of the Korean Physical Society.2016; 69(7): 1247.     CrossRef
  • Displacement of Surgical Clips during Postoperative Radiotherapy in Breast Cancer Patients Who Received Breast-Conserving Surgery
    SooYoon Sung, Joo Hwan Lee, Jong Hoon Lee, Sung Hwan Kim, Yoo-Kang Kwak, Sea-Won Lee, Ye Won Jeon, Young Jin Suh
    Journal of Breast Cancer.2016; 19(4): 417.     CrossRef
  • Review on the Applications and Molecular Mechanisms ofXihuangPill in Tumor Treatment
    Qiujun Guo, Jinyin Lin, Rui Liu, Yebo Gao, Shulin He, Xinyao Xu, Baojin Hua, Conghuang Li, Wei Hou, Honggang Zheng, Yanju Bao
    Evidence-Based Complementary and Alternative Medicine.2015; 2015: 1.     CrossRef
  • 14,639 View
  • 178 Download
  • 20 Web of Science
  • 20 Crossref
Close layer
Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine
Choong-kun Lee, Minkyu Jung, Hye Jin Choi, Hye Ryun Kim, Hyo Song Kim, Mi Ryung Roh, Joong Bae Ahn, Hyun Cheol Chung, Su Jin Heo, Sun Young Rha, Sang Joon Shin
Cancer Res Treat. 2015;47(4):781-789.   Published online February 16, 2015
DOI: https://doi.org/10.4143/crt.2014.261
AbstractAbstract PDFPubReaderePub
Purpose
There is no standard second-line regimen for malignant melanoma patients with disease progression after first-line chemotherapy, and platinum-alkylating agents combined with paclitaxel have shown modest efficacy. Materials and Methods We conducted a phase II, open-label, single-arm study to test the efficacy of docetaxel combined with carboplatin for malignant melanoma patients who failed previous treatment with dacarbazine. Intravenous docetaxel (35 mg/m2 on days 1 and 8 of each cycle) and carboplatin (area under the curve 3 on days 1 and 8 of each cycle) was administered every 21 days. Primary end point was objective response rate (ORR).
Results
Thirty patients were enrolled in the study, and the median follow-up duration was 19.8 months. Among 25 per-protocol patients, there were three responders (1 with complete response and 2 with partial response) and 17 stable disease patients (ORR, 12.0%). Among the per-protocol population, the median progression-free survival (PFS) was 4.3 months and the median overall survival (OS) was 9.6 months. Uveal melanoma patients (n=9) showed the best prognosis compared to other subtypes (median PFS, 7.6 months; OS, 9.9 months). The most common grade 3 or 4 adverse event was neutropenia (n=15, 50.0%). Conclusion Docetaxel combined with carboplatin showed association with an acceptable safety profile and overall efficacy for patients with malignant melanoma who had progressed on chemotherapy containing dacarbazine.

Citations

Citations to this article as recorded by  
  • Signaling pathways driving ocular malignancies and their targeting by bioactive phytochemicals
    Courtney R. Croley, Joshua Pumarol, Blake E. Delgadillo, Andrew C. Cook, Faith Day, Tea Kaceli, Caroline C. Ward, Imran Husain, Ali Husain, Sabyasachi Banerjee, Anupam Bishayee
    Pharmacology & Therapeutics.2023; 248: 108479.     CrossRef
  • A Phase 1 study of ADI‐PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1‐negative metastatic uveal melanoma
    Pui Ying Chan, Melissa M. Phillips, Stephen Ellis, Amanda Johnston, Xiaoxing Feng, Amit Arora, Gordon Hay, Victoria M. L. Cohen, Mandeep S. Sagoo, John S. Bomalaski, Michael T. Sheaff, Peter W. Szlosarek
    Pigment Cell & Melanoma Research.2022; 35(4): 461.     CrossRef
  • iUMRG: multi-layered network-guided propagation modeling for the inference of susceptibility genes and potential drugs against uveal melanoma
    Yueping Ren, Congcong Yan, Lili Wu, Jingting Zhao, Mingwei Chen, Meng Zhou, Xiaoyan Wang, Tonghua Liu, Quanyong Yi, Jie Sun
    npj Systems Biology and Applications.2022;[Epub]     CrossRef
  • Systemic and Liver-Directed Therapies in Metastatic Uveal Melanoma: State-of-the-Art and Novel Perspectives
    Francesca Comito, Paola Valeria Marchese, Angela Dalia Ricci, Nastassja Tober, Chiara Peterle, Francesca Sperandi, Barbara Melotti
    Future Oncology.2021; 17(33): 4583.     CrossRef
  • New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review
    Mario Damiano Toro, Lucia Gozzo, Luciano Tracia, Marco Cicciù, Filippo Drago, Claudio Bucolo, Teresio Avitabile, Robert Rejdak, Katarzyna Nowomiejska, Sandrine Zweifel, Yacoub A. Yousef, Rashed Nazzal, Giovanni Luca Romano
    Biomedicines.2021; 9(10): 1311.     CrossRef
  • Interferon-α versus interleukin-2 in Chinese patients with malignant melanoma
    Shenglong Li, Xixi Wu, Peng Chen, Yi Pei, Ke Zheng, Wei Wang, Enduo Qiu, Xiaojing Zhang
    Anti-Cancer Drugs.2019; 30(4): 402.     CrossRef
  • Mechanism of HN‑3 cell apoptosis induced by carboplatin: Combination of mitochondrial pathway associated with Ca2+ and the nucleus pathways
    Bo Shen, Wenjing Mao, Jin‑Chul Ahn, Phil‑Sang Chung, Peijie He
    Molecular Medicine Reports.2018;[Epub]     CrossRef
  • Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: Significance for melanoma treatment
    Mohamed Hassan
    World Journal of Experimental Medicine.2015; 5(4): 206.     CrossRef
  • 13,287 View
  • 105 Download
  • 7 Web of Science
  • 8 Crossref
Close layer
Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
Seung Tae Kim, Tae Won Kim, Kyu-pyo Kim, Tae-You Kim, Sae-Won Han, Ji Yun Lee, Sung Hee Lim, Min-Young Lee, Haesu Kim, Young Suk Park
Cancer Res Treat. 2015;47(4):790-795.   Published online December 2, 2014
DOI: https://doi.org/10.4143/crt.2014.126
AbstractAbstract PDFPubReaderePub
Purpose
Regorafenib, an oral multi-targeted tyrosine kinase inhibitor, is considered the new standard of care in patients with chemotherapy-refractory colorectal cancers (CRCs). However, there are no data on this drug in Korean patients.
Materials and Methods
We evaluated patients who received oral regorafenib 160 mg once daily during the first 3 weeks of each 4-week cycle between August 2013 and September 2013. All patients had previously progressed fluorouracil, irinotecan, and oxaliplatin with or without biologic agents such as cetuximab or bevacizumab.
Results
Thirty-two patients were enrolled (median age, 57 years; male:female ratio, 20:12; Eastern Cooperative Oncology Group performance status [0-1:2], 31:1; colon:rectum, 21:11). The overall response rate was 3.1% and the disease control rate was 50.0% (95% confidence interval [CI]) with one partial response and 15 patients with stable disease. The median progression-free survival was 4.2 months (95% CI, 3.1 to 5.2 months) and the median overall survival has not yet been reached. The most common adverse events of grade two or higher related to regorafenib were hand-foot skin reaction (25%), mucositis (19%), abdominal pain (9%), and liver function test (LFT) abnormalities (9%). Grade 3 or 4 toxicities included LFT abnormalities (9%), abdominal pain (9%), rash (6%), anemia (3%), leukopenia (3%), neutropenic fever (3%), and fatigue (3%). There was no treatment-related death.
Conclusion
Regorafenib appears to have promising activity and tolerable toxicity profiles in Korean patients with refractory CRC, consistent with the CORRECT trial findings.

Citations

Citations to this article as recorded by  
  • Salvage Treatment Option for Metastatic Colorectal Cancer:Regorafenib
    Havva YESİL CİNKİR
    SDÜ Tıp Fakültesi Dergisi.2020; 27(4): 471.     CrossRef
  • Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review
    Maria Røed Skårderud, Anne Polk, Kirsten Kjeldgaard Vistisen, Finn Ole Larsen, Dorte Lisbet Nielsen
    Cancer Treatment Reviews.2018; 62: 61.     CrossRef
  • The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong
    Ka-On Lam, Kin-Chung Lee, Joanne Chiu, Victor Ho-Fun Lee, Roland Leung, T S Choy, Thomas Yau
    Postgraduate Medical Journal.2017; 93(1101): 395.     CrossRef
  • Pseudocirrhosis caused by regorafenib in an advanced rectal cancer patient with multiple liver metastases
    Kensuke Kumamoto, Shungo Endo, Noriyuki Isohata, Azuma Nirei, Daiki Nemoto, Kenichi Utano, Takuro Saito, Kazutomo Togashi
    Molecular and Clinical Oncology.2017; 6(1): 63.     CrossRef
  • Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib
    Bin Zhao, Hong Zhao
    Oncotarget.2017; 8(55): 93813.     CrossRef
  • Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice
    Fabien Calcagno, Sabrina Lenoble, Zaher Lakkis, Thierry Nguyen, Samuel Limat, Christophe Borg, Marine Jary, Stefano Kim, Virginie Nerich
    Clinical Medicine Insights: Oncology.2016; 10: CMO.S38335.     CrossRef
  • 12,211 View
  • 146 Download
  • 13 Web of Science
  • 6 Crossref
Close layer
Can Serum be Used for Analyzing the KRAS Mutation Status in Patients with Advanced Colorectal Cancer?
Seung Tae Kim, Won Jin Chang, Lihua Jin, Jae Sook Sung, Yun Ji Choi, Yeul Hong Kim
Cancer Res Treat. 2015;47(4):796-803.   Published online January 30, 2015
DOI: https://doi.org/10.4143/crt.2014.106
AbstractAbstract PDFPubReaderePub
Purpose
KRAS mutations have been used widely as prognostic or predictive marker in patients with advanced colorectal cancer (CRC). However, it may be difficult to obtain a tumor tissue for analyzing the status of KRAS mutation in large proportion of patients with advanced disease.
Materials and Methods
We obtained pairs of tumor and serum samples from 65 patients with advanced CRC, between March 2008 and July 2011. KRAS mutation status from the tumor samples was analyzed by genomic polymerase chain reaction and direct sequence, and KRASmutation status from the serum samples was determined by a genomic polymerase chain reaction– restriction fragment length polymorphism assay.
Results
KRAS mutations were detected in the serum samples of 26 patients and in the tumor samples of 31 patients. KRAS mutation status in the serum and tumor samples was consistent in 44 of the 65 pairs (67.7%). There was a significant correlation between the mutations detected in the serum sample and the mutations detected in the matched tumor sample (correlation index, 0.35; p < 0.004). Twenty-two of the 57 patients (38.5%) received anti-epidermal growth factor receptor therapy as any line therapy. There was no significant difference in the overall survival (OS) in accordance to the status of KRASmutations in both the serum and tumor samples (p > 0.05). In a multivariate analysis, liver metastasis and no cytoreductive operation were independent prognostic factors for decreased OS.
Conclusion
The serum sample might alternatively be used when it is difficult to obtain tumor tissues for analyzing the status of KRAS mutation in patients with advanced CRC.

Citations

Citations to this article as recorded by  
  • The Prognostic Utility of KRAS Mutations in Tissue and Circulating Tumour DNA in Colorectal Cancer Patients
    Joel Petit, Georgia Carroll, Jie Zhao, Peter Pockney, Rodney J. Scott
    Gastroenterology Insights.2024; 15(1): 107.     CrossRef
  • Effect of CIP2A and its mechanism of action in the malignant biological behavior of colorectal cancer
    Wei Chen, Jing-Lin Liang, Kai Zhou, Qing-Li Zeng, Jun-Wen Ye, Mei-Jin Huang
    Cell Communication and Signaling.2020;[Epub]     CrossRef
  • The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta‐analysis
    Wenli Xie, Li Xie, Xianrang Song
    Cancer Medicine.2019; 8(3): 1218.     CrossRef
  • Prognostic value of circulating cell-free DNA in patients with pancreatic cancer: A systemic review and meta-analysis
    Linyan Chen, Yi Zhang, Yuan Cheng, Dan Zhang, Sha Zhu, Xuelei Ma
    Gene.2018; 679: 328.     CrossRef
  • The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis
    Rongyuan Zhuang, Song Li, Qian Li, Xi Guo, Feng Shen, Hong Sun, Tianshu Liu, Alvaro Galli
    PLOS ONE.2017; 12(8): e0182562.     CrossRef
  • 11,653 View
  • 85 Download
  • 6 Web of Science
  • 5 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP